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Role of soluble interleukin-2 receptor in idiopathic IgA nephropathy. F.
Rivera, M. Parera, M. Perdiguero, and A. Campos, Hospital de
Alicante y Elda (SVS), Centro de Transfusiones, Facultad Medicina
(Departamento M. Interna), Alicante, Spain. Lnterleukin-2 (IL-2) is
involved in T cell activation in idiopathic IgA nephropathy (IgAN). The
soluble form of the IL-2 receptor (sIL-2R) is released into the medium
after antigenic stimulation, and its role in idiopathic IgA nephropathy
(IgAN) is unknown. We have studied 24 patients with inactive IgAN
and 11 healthy controls in which we have measured serum levels of
sIL-2R (ELISA, CellFreeR), and we have investigated clinical and
immunobiological correlations. Serum levels of sIL-2R were higher in
patients than in controls (1348 271.32 vs. 590 36.24 U/mI,
respectively; P = 0.0003). There was no correlation between renal
function, serum levels of IgA, proteinuria, percentages of CD4+,
CD8+, CD25+ cells, levels of IL-2 (in serum and supernatants from
PBMC cultures) and serum concentration of sIL-2R. However, there
was a close correlationship between microhematuria and serum levels
of sIL-2R (r = 0.73, P = 00001). Moreover, these levels were higher in
the subgroup of patients with recurrent macrohematuna (N = 11) than
in patients with urinary asymptomatic findings or hypertension (N = 13)
(1781 446 vs. 784 72 U/mI, respectively; P = 0.019). We conclude
that sIL-2R plays a role in cellular immune response with regard to T
cell activation in patients with IgAN even in stages of apparent clinical
inactivity. The correlation with microhematuria and its association with
clinical form suggests that sIL-2R is related with the mechanism that
produces glomerular inflamation and could possibly be a marker of
clinical activity.
Treatment of hyperkalemia with fenoterol by inhalation. M. de Ia
Torre, V. Peral, .4. Rogada, C. Rodriguez, V. Cuesta, and J. Herrera,
Servicio de Nefrologia, Hospital General de Asturias, Oviedo, Spain.
Intravenous /32-adrenergic-agonists has been shown to be effective in
treating hyperkalemia. However, its effect by inhalation is not well
known. The aim of this study was to assess the effectiveness of
Fenoterol by inhalation in lowering the plasmatic potassium (K)
concentration. Eighteen hemodialysis (HD) patients (II women and 7
men; mean age 52.6 years; range: 23—76 years) with an initial K
concentration of 6.13 1.09 mmol/liter were treated. Each patient
received 7.5 mg of Fenoterol by nebulizador 60 minutes prior to an
(HD) session. Blood was taken for K, Na, and in 9 patients blood
specimens were taken for pH, pCO2, and bicarbonate at time 0 baseline,
and at 30 and 60 minutes after the Fenoterol inhalation. Blood pressure
and pulse rate were recorded every 15 minutes. The results were
analyzed by paired student's T test. Plasmatic K concentration after
the Fenoterol inhalation, expressed as mean + SD, decreased from 6.13
1.09 to 5.77 1.22 mmol/liter(P <0.01) and from 6.13 1.09 to 5.57
1.17 (P < 0.001) at 30 and 60 minutes respectively. A reduction in
plasmatic Na from 138 2.32 to 138.8 2.32 (P < 0.01) mmol/Iiter
was found at 60 mm. The other parameters were unchanged. No
complications, specifically tachyarrhythmias, occurred. No changes in
blood pressure and pulse were found. We conclude that hyperkalemia
can be effectively reduced with the administration of Fenoterol by
inhalation. The treatment is easy and safe, and can be used as the only
therapeutic method or in combination with other therapeutic tools.
High prevalence of overt autoimmune hypothyroidism in CAPD pa-
tients. A. Ortiz, A. Reyero, ML. Alberola, E. Glez Parra, M.P. GarrOn,
G. Blum, C. Caramelo, and S. Casado, Fundación Jiménez DIaz, 28040
Madrid, Spain. Thyroid function tests may be altered by uremia.
Moreover, some CAPD patients have mildly elevated serum TSH
levels. However, overt hypothyroidism has been considered excep-
tional, and it has been attributed to peritoneal losses of thyroid
hormones and/or to therapy with iodinated antiseptics. We have studied
the levels of T4, free T4, TSH and the presence of antithyroid
antibodies in the sera of 26 CAPD patients with a mean age of 60 years
(range 32—78). Group I: 22 clinically euthyroid patients had normal
values of free T4, and only 2 had mildly raised TSH levels (>5
U/mliter): 8.5 and 12 U/mliter. Antithyroid antibodies were negative.
Group 11: 4 male patients, all aged over 60, had Overt hypothyroidism,
defined by hormonal (free T4 < 0.7 ng/dl, TSH > 100 U/mliter),
analytical and clinical abnormalities. The prevalence of overt hypothy-
roidism in patients over 60 was 21% (4/19). Hypothyroidism was
autoimmune in three patients, and secondary to amiodarone in one.
Eight patients from both groups had elevated serum creatin kinase (CK)
levels: 4 had overt hypothyroidism, 3 were treated with fibrates, and in
one no cause was found. Hormonal replacement therapy resulted in a
subjective sense of improvement and normalization of serum choles-
terol and CK. Conclusions: (1) In contrast to other authors, we have
found a high prevalence of overt hypothyroidism in CAPD patients. (2)
The etiology was autoimmune in 3/4 cases, probably because of the
increased prevalence of autoimmune hypothyroidism in the aged,
coupled with peritoneal losses of thyroid hormone, (3) Elevated serum
CK levels in the absence of drug-induced rhabdomyolysis is highly
suggestive of hypothyroidism in CAPD patients.
Changes in the ventricular function of patients treated with vitamin D-3
i.v. C. Sanz-Moreno, J. Segovia, E. Baamonde, M. Gonzalez, J.
Fdez-Fdez, D. Sanz-Guajardo, and J. Botella, Hospital Puerta de
Hierro, Madrid, Spain. Patients with hyperparathyroidism, secondary
to chronic renal failure, may also have an inadequate myocardial
hypertrophy, that is, the increase in the left ventricular mass is lower
than expected. Consequently, there is an increase in the end-systolic
stress produced by the blood pressure. In 11 patients treated with
Calcitrol i.v. over a period of six months, the levels if iPTH dropped
from 562.3 293.8 pg/mI to 96.3 77.4 (P < 0.0001). At the same time,
the echocardiography indicated a significant increase in the interven-
tricular septal thickness, in the left ventricular mass, and in the
mass/volume ratio (P < 0.001); the latter because there is no increase in
the ventricular volume, The end-systolic stress resisted by the left
ventricle decreased from 252.7 54.6 dynes/cm2 to 211.3 29.6 (P <
0.001). At the same time, the heart rate decreased from 85.1 7.3
beats/mm to 62.5 3.1 (P < 0.01), with no modification in the blood
pressure. In conclusion, the control of hyperparathyroidism transforms
the inadequate myocardial hypertrophy into one more appropriate to
the hemodynamic condition.
Acquired cystic renal disease (ACRD): The value of radiological images
of the tumors. A. Covarsi, N. Marigliano, R. Novillo, 0. Sanchez, A.
Rodriguez, J. Garin, and J.R. Gonzalez, Hospital General del Insalud
San Pedro de Alcántara, COceres, Spain. ACRD is a new entity
encountered in patients undergoing dialysis, characterized by the
progressive substitution of the renal parenchima by multiple cysts. Its
principal complication is neo-plastic degeneration. Sixty-six patients
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undergoing dialysis, 59 on hemodialysis and 7 on CAPD, were studied
with actual time echographs and computerized axial tomographs.
Twenty-two (37.9%) fulfilled the ACRD criteria and 36 (61.2%) did not.
Lesions were defined as being simple cysts, atypical cysts or solid
tumors according to universally-accepted criteria. Atypical cysts and
solid tumors were considered to be tumoral images. In the ACRD
group, two patients presented solid tumor lesions which were contrast-
enhanced, and another patient had an intracystic nodule (an atypical
cyst). In the non-ACRD group, one patient had an intracystic nodule
(an atypical cyst). Histological study of the ACRD patient with an
intracystic nodule revealed papillar carcinoma. In the other three
patients, the "tumoral image" corresponded to a residual fibrotic
lesion, a vascular protrusion in the interior of the cyst, and to a
solidified cyst; in this latter patient renal cell carcinoma was found, the
size of which (0—5 centimetres) made it impossible to detect in a
radiological exploration. A fifth patient who had undergone a nephrec-
tomy, due to recurrent hematurias, revealed an increase in the size of
the left kidney and a cyst with irregularities in the wall (an atypical cyst)
in the radiological exploration; in the anatomological/pathological
study, adenomas and carcinomas were found throughout the kidney. It
can be concluded that modern radiological equipment is not sufficiently
sensitive for the diagnosis of the tumors associated with the cystic
disease.
Influence of membranes on generation of interleukin-2 during hemodi-
alysis. A. Mendiluce, J. Bustamante, F. Robina, R. Bustamante, F. de
Alvaro, M.A. Macia, and F. Dapena, Servicio de Nefrologla, Hospital
Clinico Valladolid, Espanã. The levels of the interleukin-2 (IL-2) were
measured in the serum of 22 patients in chronic hemodialysis (13 males,
9 females, mean age 52.7 14.2 years), and 9 normal subjects used as
time controls. Patients with renal diseases secondary to inmunologic
diseases, those receiving some type of immunosuppressor treatment, or
those having intercurrent infections were excluded from the study. All
of the study subjects were Ag. Hbs— and HIV—. The different
membranes used for treatment were cuprophan, polysulfon (PS), poly-
acrylonitrile (AN69) and ethylene vinyl alcohol (EVAL). Blind sam-
plings were taken from the arterial line during, one dialysis session for
each membrane at the time 0, 5, 30, 120, and 240 minutes, at 6 and 12
months after stabilization with the membranes. The concentration of
IL-2 was determined by immunoenzymatic assay (ELISA). Plasma
levels of IL-2 were high in all hemodialyzed as compared with normal
controls (53.3 17.1 pM). Pre- and post-dialysis with the different
membranes:
Cuprophan 252.0 104 and 295.0 118 M
Polysulfon 270.8 169 and 301.0 225 M
Polyacrylonitnle 247.5 118 and 302.1 136 M
Ethylene vinyl alcohol 227.0 117 and 264.0 150 M
We conclude that in hemodialysis there is an increase in the IL-2
compared with the controls (P <0.005). This increase is independent of
the type of membrane used and does not significantly vary between pre-
and postdialysis.
Interleukin-2 and renal disease. A. Mendiluce, F. Robina, R. Busta-
mante, F. de Alvaro, J.M. Briso-Montiano, F. Dapena, MA. Macia,
and J. Bustamante, Servicio de NefrologIa, Hospital Clinico, Vallad-
olid, Spain. The production of interleukin-2 (IL-2) was evaluated in
uremic patients: 41 subjects were selected (25 on hemodialysis, 8 under
continued out-patient peritoneal dialysis (COPPD), 4 with chronic renal
disease (C.R.D.), and 4 transplants). The basic renal diseases were: 6
patients with chronic glomerulonephritis, 10 with renal polycystic
kidney disease, 8 with chronic interstitial nephritis, 3 with nephroscle-
rosis and 8 non-filiated. The blood creatinine levels in the C.R.I. cases
were 6.4 mg/dl (5.7—7.4 mg/dl), and 1.16 mg!dl (1.1—1.3 mg!dl) in the
transplants. The membranes used in hemodialysis were cuprophan in 12
cases, polyacrylonitrile in 5, polysulfon in 4 and ethylene vinyl alcohol
(EVAL) in 4. The average stay on hemodialysis was 90 months (1—144
months), and 39 months on CAPD (6—76 months). Individuals with renal
disease secondary to immunogical disease were excluded from the
study. All patients were Ag Hbs— and HIV—. IL-2 concentration was
determined by immunoenzymatic assay (ELISA), expressed in M (I
= 42 pg/mI). The IL-2 values in healthy subjects were 53.3 17.1
PM; 134 25 M in transplants; 307 68 M in CAPD; 243 106 M
in hemodialysis patients; and 183 17 pM in C.R.D. individuals, the
IL-2 levels in dialyzed patients being significantly elevated in relation to
the control group (P < 0.01). The elevations in the transplant group
were not significant. Neither the duration of dialysis nor the type of
membrane utilized effected the IL-2 levels, while patients with poly-
cystosis presented lower IL-2 levels than the rest of the patients (P <
0.01).
Histological analysis of rapidly progressive glomerulonephritis (RPGN)
using monoclonal antibodies (MA). P. Arrizabalaga, A. Torras, E.
Mirapeix, L. Dame/I, and L. Revert, Servicio Nefrologla, Hospital
ClInico, Barcelona, Spain. Local interactions between macrophages
and T lymphocytes have been shown both in experimental anti-
glomerular basement membrane antibody and immune complex-in-
duced GN. We have identified immunocompetent cell intraglomerular
infiltration by avidin-biotin-immunoperoxidase technique, using MA for
common leukocyte antigen (CD45), all T lymphocytes (CD3), helper!
inducer T cells (CD4), cytotoxic/suppressor T cells (CD8) and mono-
cytes-macrophages (CD 14), in 14 renal biopsies from patients with
RPGN (3 type I, 6 type II and 5 type III). Positive cells identified with
each MA were counted within all glomeruli. The number of positive
cells: Number of glomeruli ratio was expressed. The leukocyte ratio
was 14 5 (x SE), 13 5, 1.5 0.6, 2.7 1.6; the macrophage ratio
was 5.3 2,6.8 5.3, 2.8 0.4, 1.4. 1.4; and the Tlymphocyte was
3.6 1.4, 1 0.7, 0.4 0.3, 1.5 0.7 for respectively: type I, primary
type II, secondary type II, and type III RPGN. No intraglomerular
CD8 cells were present in any of the type III biopsies. In conclusion,
monocytes-macrophages clearly predominated over T-cells on intraglo-
merular cell infiltration. Intraglomerular leukocytes, particularly mac-
rophages, were more numerous in type I and primary type II GNRP
than in the remaining types. The finding of macrophages as well as
T-cells bearing CD4 phenotype, without immune deposit evidence
(type III), suggests that cellular immunity may play a role in RPGN.
Purification of a kidney growth factor present in plasma of uninephrec-
tomized human subjects. A. GarcIa-Ocana, J. Ortega, and P. Esbrit,
Metabolic Unit Research Laboratory, Fundación Jiménez DIaz,
Madrid, Spain. A kidney growth factor activity was partially purified by
chromatographic techniques from plasma of human kidney transplan-
tation donors and a renal cancer patient after uninephrectomy (UNX).
Purification involved, firstly, gel filtration on an Ultrogel AcA 54
column (2.5 '< 90cm),eluted with 50 m sodium phosphate, pH 7.5: the
fraction pool corresponding to an apparent Mr of 17—22 KDa was
further purified on a Mono Q column (0.5 >< 5 cm) in a dual HPLC
system, eluting with a gradient of 0—0.5 M NaCl. The renotropic activity
of plasma extracts was assessed by measuring the rate of (3H)thymidine
incorporation into DNA of rat cortical tubules. The isolated activity
was dose-dependent, with a maximal stimulation (140—180% over
control) at 100—150 ng/ml, decreasing at higher concentrations. This
activity was detected between 7 and 12 days post-UNX and, at least in
one case, decreased thereafter. The renotropic activity from plasma of
a human donor, when further purified on an alkyl-Superose column (0.5
)< 5 cm) by HPLC, progressively increased tubule DNA synthesis in the
range 5—20 ng!ml. The potency of this renotropic activity and its elution
by gel filtration are similar to those displayed by a renal growth factor
isolated from rat plasma after UNX (Nephrol Dial Transplant 4:334—
338, 1989).
Effect of bezafibrate on lipoprotein Lp (a) and triglyceride-rich lipo-
proteins, including intermediate density lipoproteins (IDL), in patients
with chronic renal failure receiving hemodialysis. A. PelegrI, M. SentI,
R. Romero, J. Pedro-Botet, X. Nogues, A. Foraster, and J. Rubies-
Prat, Hospital Germans Trias i Pujol, Hospital del Mar, Universidad
Autónoma de Barcelona, Barcelona, Spain. The effect of fibric acid
derivates on VLDL and HDL in patients with chronic renal failure on
hemodialysis is well known. Nevertheless, there are no studies con-
cerning the effect of bezafibrate on lipoprotein (a) concentration and
gross abnormalities in IDL composition in these patients. The aim of
the present study was to investigate the effect of bezafibrate at doses of
200 mg three times weekly throughout a period of 10 weeks, on
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lipoprotein (a), and triglyceride-rich lipoproteins in 12 patients receiving
hemodialysis. The results were as follows:
Mean SEM (mgldl)
Before treatment After treatment P
Serum cholesterol 199 10 163 8 <0.01
Serum triglycerides 246 15 168 14 <0.005
Serum apoprotein A-i 115 5 126 4 <0.05
Serum apoprotein B 91 5 72 4 <0.01
Serum lipoprotein (a) 35 7 25 6 NS
VLDL-cholesterol 36 5 21 3 <0.05
VLDL-triglycerides 133 15 81 9 <0.01
IDL-cholesterol 17 4 8 2 NS
IDL-triglycerides 41 9 15 3 <0.05
LDL-cholesterol 103 9 92 8 NS
LDL-triglycerides 40 7 36 4 NS
HDL-cholesterol 27 2 30 3 NS
HDL-triglycerides 10 2 10 I NS
No side-effects were observed and serum creatine kinase values stayed
within normal limits throughout the study. In conclusion, the improve-
ment of the lipoprotein profile in patients with chronic renal failure on
hemodialysis under bezafibrate therapy suggests a decrease in the
coronary heart disease risk.
Study of the profile lipidic and nutritional status according to the
dialytic treatment utilized in uremic patients. 3. Bonet, M. Borr4s, J.
Bonal, J. Teixido, F. Cofan, R, Romero, and A. Caralps, Renal Unit,
Universitary Hospital "GERMANS TRIAS I PUJOL," BADALONA,
SPAIN. Coronary heart disease (C.H.D.), is the primary cause of death
in dialyzed patients. Is is known that hyperlipemia accelerates athero-
sclerosis, and this has a trend towards C.H.D. The objective of this
study has been to compare the dialytic treatments, and to see whether
these can influence the lipid abnormality and nutritional status of the
uremic patients. Included in the study were 18 patients on hemodialysis
(H.D.), and 18 on continuous ambulatory peritoneal dialysis
(C.A.P.D.), affected by diverse chronic nephropathies (with the excep-
tion of the diabetics). The following parameters were studied: Sex, age,
time in dialysis, body mass index (B.M.I.), bicipital arm circumference
(B.A.C.), tricipital skinfold, triglycerides, total-cholesterol and its
fractions, atherogenic index (A.I.), total proteins (T.P.), hematocrit
(Hct), and parathyroidhormone (PTH). The diets were the same for the
patients of HD and CAPD. It has been taken with significant value to
part of one P < 0.05. There were no significant differences between the
following parameters: Age, sex, BMI, BAC, TSF, T-chol, HDL-chol,
triglycerides, and Hct. There were statistically significant differences in
the following parameters:
LDL-chol A.!. PTH
HD
CAPD
2.69
3.63
1.11
1.57
3.93 2.19
5.66 2.07
178,05 150.06 P < 0.05458.05 103.52
Moreover, there were significant positive relationships between the
BMI, triglycerides and Al (r = 0.35P 0.05). Also, there were significant
negative relationships between TP and Hct, and also between the length
of time on treatment and T-chol. In conclusion: (1) In CAPD, a bigger
augment of LDL-chol, AL, and PTH exists in respect to HD. (2)
Independent of the dialytic treatment, a positive and significant rela-
tionship exists between the BMI and AL and triglycerides. (3) Indepen-
dent of the dialytic treatment, the T.P. had a positive relationship with
the Hct. (4) A non-significant relationship exists between the length of
time on treatment and the T-chol.
Serum lipoprotein Lp (a) levels in patients with chronic renal failure
receiving hemodiaysis. R. Romero, M. SentI, X. Nogues, A. PelegrI, J.
Pedro-Botet, A. Forester, J, Rubiés-Prat, Hospital Germans TrIas i
Pujol, Hospital del Mar, Universidad Autónoma de Barcelona, Barce-
lona, Spain. Lipoprotein disturbances in patients with chronic renal
failure (CRF) receiving hemodialysis consist of a derangement of the
metabolism of triglyceride-rich lipoproteins, with a decrease in the
plasma concentration of high density lipoproteins. However, there are
no extensive studies concerning serum Lp (a) levels in these patients.
Serum cholesterol, triglycerides, low density lipoprotein (LDL)-choles-
terol, HDL-cholesterol, and Lp (a) levels, have been measured in 71
men with CRF receiving hemodialysis, and in 64 healthy control men.
Mean (sD) mg/dl
PPatients Controls
Cholesterol 161 (41) 202 (36) <0.005
Triglycerides 144 (78) 111(56) <0.005
LDL-cholesterol 90 (27) 124 (30) <0.005
HDL-cholesterol 32 (13) 41(10) <0.005
Lp (a) 21(18) 13 (13) <0.05
The increased serum Lp (a) levels, together with abnormalities in other
lipoproteins, are consistent with a higher cardiovascular risk in patients
with CRF receiving hemodialysis.
Effects of angiotensin converting enzyme inhibitor (ACE i) in nor-
motensive type 2 diabetic patients (DM II) with microalbumlnuria
(MAL): A randomized controlled trial. R. Romero, I. Salinas, M.
Borrds, A. Lucas, J. Teixido, J.L, Reverter, E. Abat, and A. Sanmarti,
Nephrology, Endocrinology and Immunology Services, Hospital Ger-
mans Trias i Pujol, Badalona, Barcelona, Spain. The normotensive
type I diabetic patients with incipient nephropathy ACEi decreases
MAL excretion, but this effect is less studied in type 2 normotensive
diabetic patients. The aim of present work was to study the effect of
captopril (C) in normotensive type 2 diabetic patients with MAL.
Subjects and methods: Twenty six-normotensive type 2 diabetic pa-
tients with MAL (10 women and 16 men), age: 53, 27 11, 44, years
were randomized in 2 matched groups of 13 patients. During 6 months,
group A did not receive treatment, and group B was treated with
increasing doses of C. BP, renal function by isotopic techniques (FC,
RPF, FF) metabolic parameters and MAL were monitorized at 0, 3 and
6 months. Analysis of variance, paired and unpaired student's T test
and linear regression analysis were used for statistical analysis. The
results were as follows: Diastolic BP (75.61 967 vs. 69.61 8.65 mm
Hg) am Mean BP (94.56 9.8 vs. 88.92 5.08 mm Hg) decreases only
in group C (P < 0.05). Difference in mean percentage variation in MAL
excretion between two groups was significant (P < 0.05) and FF (P <
0.05). No significant differences were observed in metabolic parame-
ters. In conclusion, type II diabetic patients prevented increases in
MAL in relation to control group.
Fungal peritonitis in continuous ambulatory peritoneal dialysis: Results
with fiuconazole. L. Palomares, J.A. Sobrado, A.J. Perez, M. Moreiras,
M. Courel, and L. Gonzalez, Nephrology Section, Complexo Hospi-
zalario Xeral CIes, Pizarro, 22. 36204 Vigo, Spain. During the last 5
years, there were 27 patients undergoing continuous ambulatory pen-
toneal dialysis (CAPD) in our center. The mean incidence of peritonitis
was 1.1 episodes/patient/year. Fungal peritonitis (FP) accounted for 6%
of episodes of peritonitis. The antifungal therapy and the outcome of 3
episodes of FP in 3 CAPD patients (2 men and 1 woman), who were
treated with fluconazole used as a single antifungal agent, are discussed
here. The fungi isolated were Candida parapsiosis in 2 cases and
Hansenula anomalous in the other case. Prior to the onset of FP, all the
patients had had one or more episodes of bacterial infections which had
been treated with antibiotics, The Tenckhoff catheter was removed in
all the patients and they were transferred to interim hemodialysis (HD),
Treatment with oral fluconazole was started after a mean time of 5 days
after the onset of the FP episode. An oral loading dose of 200 mg was
followed by a single daily dose of 100 mg for 42 days. After the
completion of therapy, a correct peritoneal fluid flow could be proved
with a temporary peritoneal access in the 3 patients, and the cultures of
the peritoneal effluent were negative for fungi in all the cases. After the
insertion of a new Tenckhoff catheter, two of the patients successfully
resumed CAPD. Nevertheless, the remaining patient continued on HD
at her own request. Fluconazole's pharmacokinetic profile makes this
agent an advantageous drug over other antifungal agents. We note
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favorable results with the use of this antifungal drug, associated with
the resolution of fungal peritonitis and with the possibility to resume
CAPD in the three reported patients.
Systemic amyloidosis of dialysis: Study of 25 autopsies. J. Fort, M. T.
Vidal, J. Camps, A. Segarra, R. Roca, A. Olmos, and L. Piera,
Nephrology and Pathological Anatomy Departments, Hospital General
VaIID'Hebron, Barcelona, Spain. To investigate the systemic involve-
ment of dialysis related amyloidosis, we studied visceral material from
autopsies of 25 patients (18 males and 7 females), who had been
dialyzed with Cuprophan membranes for more than five years. The
average age of the patients was 54.6 years, and they had been on
dialysis an average of 9.8 years. Patients suffering from primary and
secondary amyloidosis were rejected. Samples of different organs
including articular synovia were studied using a red-Congo stain
method and peroxidase with anti-beta 2 human microglobulin serum to
make the immunohistochemical study. The lack of reaction against
other antisera (anti-AA, anti pre-albumina) was used as a control.
Visceral beta-2 microglobulin amyloid deposits were found in 11 of the
25 autopsies (44%). The deposits were scarce, small, segmentary, and
were found in the muscularis of the vessel walls, and in some samples
a giant-cellular reaction was seen. In all the patients except three—in
whom no joint symptoms were detected—a close correlation between
the finding of systemic amyloid deposits and large amyloid deposits at
the articular synovia were observed. In two patients, one suffering from
articular symptoms, synovia articular deposits of amyloid were found,
without showing any systemic involvement. The mean age of the
patients with visceral deposits of amyloid was 62.3 years; significantly
higher (P = 0.02) than that of the patients in whom we did not find
systemic involvement, whose mean age was 48.2 years. Neither signif-
icant differences in the mean duration of dialysis nor in the levels of beta
2 microglobulin were found. We conclude that the incidence of systemic
amyloid involvement in our study is high and seems to be related to a
higher average age of the patients, the heart and bowel being the most
commonly involved organs. Although in the majority of patients, a
close correlation between systemic involvement and articular deposits
of amyloid were seen, the lack of articular symptomatology does not
exclude the presence of visceral involvement. On the other hand, the
finding of articular deposits does not necessary imply systemic involve-
ment.
Gastrointestinal bleeding (GB) in patients undergoing periodic hemo-
dialysis. R. Roca, M. Ramirez de Arellano, A. Segarra, J. Fort, J.
Camps, A. Olmos, and L. Piera, Department of Nephrology, Hospital
General Vail d'Hebrón, Barcelona, Spain. A retrospective study was
undertaken to determine the prevalence, etiology and prognosis of GB
in chronic renal failure patients on hemodialysis. From January 1976 to
December 1990, 824 patients started on hemodialysis in related centers
of our hospital; 66 of whom (8%) suffered from 125 bleeding episodes of
hematemesis, melena or rectal bleeding. Esophagogastroduodenoscopy
(98), colonoscopy (28) and scintigraphy with technetium-labeled eryth-
rocytes (3) were the explorations carried out. The factors analyzed
which could be dialysis-related were: age, sex, primary nephropathy,
average time on dialysis, drugs and hepatopathy. Results: There were
66 patients, 68.2% were males and 31.8% were females. The mean age
of the patients who suffered from the first or only episode of GB was 54
years (range, 20 to 77 years). They had been on dialysis an average of
4 years (range, 0 to 13 years). We found more than one bleeding episode
in 36.3% of patients. We observed a greater prevalence of GB in
patients with interstitial nephropathy (24.2%). The most frequent
causes of upper GB were duodenal ulcer (21.4%), erosive gastritis
(21.4%), esophageal varices (11.9%) and Mallory-Weiss tear (10.7%).
The most frequent causes of lower GB were hemorrhoids (35.7%),
colonic cancer (17.8%), colonic polyps (17.8%) and ischemic colitis
(10.7%). The diagnostic yield of explorations was the following: 84.6%
for the esophagogastroduodenoscopy, 85.7% for the colonoscopy and
33.3% for the scintigraphy with technetium-labelled erythrocytes. In
10.4% of episodes we didn't reach any etiologic diagnostic. 16.6% of
patients had one episode of GB before starting hemodialysis. There was
a previous drug intake in 12.8% of GB episodes. The overall mortality
was 1.5%, 66.6% of episodes resolved with medical treatment (antiac-
ids, U2-receptor antagonists and/or estrogens), 16.6% with measures of
endoscopic hemostasia and 16.6% with surgery.
Assessment of nutritional status of hemodialysis patients by anthropom-
etry, plasmatic proteins and urea kinetic model. f.M. Osorio, A. Osuna,
P. Galindo, A. Montes, M. Benitez, M.M. Biechy, F. Feud, A. Perez de
Ia Cruz and C. Asensio, C.S. "Virgen de las Nieves," 18014 Granada,
Spain. Protein-calorie malnutrition is a main risk factor in hemodialysis
patients, and the assessment of their nutritional status is essential in the
treatment scheme. The purpose of this study is to evaluate the nutri-
tional status of a stable hemodialysis population and the influence of
diverse therapy characteristics upon it. We studied 106 patients (65
male, 41 female) aged from 20 to 80 years (x = 56.2 13.3) who were
hemodialyzed with acetate (70%), bicarbonate (30%), cellulosic mem-
branes (64.3%) and non-cellulosic membranes (35.7%). Seventeen
patients were treated with rHuEPO (16%). In all the patients we
measured albumin, prealbumin, transferrin and colinesterase as well as
per and KT/V following the urea kinetic model. In 65 patients we
measured post-hemodialysis dry weight (DW), triceps skinfold thick-
ness (TST) and mid-arm muscle circumference (AMC); in all cases it
was considered the 15th percentile as normality criterion. Results are as
follows:
x so <normal <normal <normal
Albumin
Prealbumin
Transferrin
Cohn-
esterase
3537 662.67
26 6.78
242.9 63.5
6859.5 1975
57%
14.76%
21.9%
19.8%
DW
TST
AMC
21.8%
44.61%
37.7%
per
KT/V
58%
35.7%
No correlation between the studied proteins, per and anthropometric
paramçters was found. Prealbumin was significantly lower (P < 0.01) in
patients with subnormal DW and TST. We found no significant differ-
ences in any nutritional parameter when considering the influence of
dialysate buffer, type of membrane, r-HuEPO treatment, daily protein
intake and KT/V. Per was significantly lower (P < 0.001) in patients
with KT/V <0.9. Per and KT/V were found to be weakly, (r = 0.365)
but significantly (P < 0.05) correlated. Our conclusions were as follows:
(1) Among stable patients undergoing hemodialysis there is a consider-
able percentage (15—60%) with some data pointing to malnutrition. (2)
Our study seems to confirm that protein intake estimated by per
depends on KT/V. (3) The obtained data suggest that per alone is not
enough to assess the nutritional status of hemodialysis patients. (4) The
biochemical and anthropometric parameters are not related (except for
pralbumin), and they are not influenced by the different types of
hemodialysis.
Continuous doppler (CD) in the diagnosis of renal artery stenosis (RAS)
in the renal transplant (RT). M. Cabello, M. Gonzalez-Molina, G.
Alvarez, A. Gomez-Pardai, M.A. Frutos, C. Calvar, and E. Lopez de
Novales, Nephrology and Radiology Services, Hospital Regional,
Malaga, Spain. We studied 28 RT patients with RAS diagnosed by CD.
The patients (22 male and 6 female) were being treated with cyclospo-
rine plus prednisone in 25 cases (89.2%), and with azathioprine plus
prednisone in 3 (10.7%). The type of anastomosis was end-to-side, with
Carrel patch in 20 cases (71.4%), and end-to-end in the other 8 (28.6%).
In 3 cases (10.7%), there were vascular abnormalities (more than one
artery). Indications for the Doppler study were arterial hypertension in
17 cases (60.7%), deterioration in the renal function in 10 (35.7%), and
incidental discovery during Doppler control in 1 (3.5%). The intrarenal
pulsed wave Doppler curve was normal in 13 cases (46.4%), and low
frequency in 15 (53.6%). CD scanning at 3 MHz over the renal artery in
the cases of stenosis showed a systole greater than 7.5 KHz (range:
7.5—19.8; mean: 9.7). Confirmation by arteriography showed 25 cases of
RAS and 3 kinking. We conclude that CD is useful for the diagnosis of
RAS and the demonstration of systole with frequencies greater than 7.5
KHz is indicative of RAS. Nevertheless, it is not possible with CD to
differentiate between RAS and kinking.
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Embolization of the non-functioning renal graft (RG) with alcohol as an
alternative to nephrectomy. M. Cabello, M. Gonzalez-Mo/ma, A. Es-
caño, D. Burgos, and F. Lopez de Novales, Nephrology and Radiology
Services, Hospital Regional, Malaga, Spain. The definitive loss of the
RG and the suspension of immunosuppression are not always well
tolerated, and there are patients who present symptomatology and
complications necessitating a transplantectomy. One alternative to this
technique is the embolization with alcohol of the graft by means of
catheterization of the renal artery. From 1987 to 1991, we carried out 11
embolizations in patients whose ages ranged from 20 to 60 years (men
48.8 years). These patients lost their grafts between 1 and 90 months
after transplant from immunological causes in 6 cases (54.5%), recur-
rence of the primitive disease in 2 (18.1%), and 3 (27.2%) for unrelated
causes, but compatible with chronic rejection. The mean time interval
between loss of graft and embolization was 3 months (0.5—8 months),
and the indication was made by maintained fever in 8 cases (72.8%), and
in 3 (27.2%) as a common practice in our service. The complications
were: Renal infection with the formation of abscess and transplan-
tectomy in 1 (in this case as well as the alcohol a coil was used in the
embolization) and in all the others fever and tolerable pain over the area
of the graft for Ito 2 days. In all cases Doppler was used to confirm the
absence of blood flow in the graft 24 to 48 hours later. We conclude that
embolization with alcohol of non-functioning grafts is a valid alternative
to surgery and avoids the associated risks.
Idiopathic renal lithiasis (IRL) and idiopathic hypercalciuria (IAH): A
metabolic study. M. VOzquez Martul, P. Arnaiz, J. Baeza, and J.L.
EcUa, Renal and Biochemical Units, Hospital Niño JesOs, Madrid,
Spain, The aim of this study was to explore the role of some promoters
and inhibitors in the formation of calcium stones. Twenty-five children
diagnosed with IRL, and 20 children with idiopathic absorptive hyper-
calciuria (lAM), were compared to a control group (CG) of normal
children (sex and age matched). Biochemical studies ruled out hyper-
parathyroidism, tubulopathies, and urinary tract infections. Dietary
intakes of calcium, oxalate and vitamin D were done in all. Below is a
comparative study on urine excretion of calcium (Ua), uric acid (1tA)'
oxalate (Uo), citrate (U1), and magnesium (UMe) (expressed as mean
SD)
CG
(N = 59)
Lithiasis(N = 25)
IAH
(N = 20)
Signifi-
cance
Age 10.1 2.35 10.36 3.79 10.68 2.98 NS
Uca 2.47 1.29 3.73 2.16a 5.60 284b p < 0.05
mg/K!
day
UcaiCr 0.12 0.66 0.18 0.lla 0.26 013b P < 0.05
mgi
mg
UA 594.88 256.21 755 359.37 777.82 260.01 NS
mgi
1.73!
day
U0 0.63 0.30 0.45 0.23a 0.77 0.56 P < 0.05
mgi
kg!
day
U0iCr 0.03 0.01 0.05 0.02a 0.05 o.4 P < 0.05
mgi
mgU 11.47 7.78 9.96 5,54a 16.90 10.54" P < 0.05
mgi
kg!
day
Uc,iCr 0.54 0.34 0.45 0.23 0.77 056b P < 0.05
mgi
mg
UMg!Cr 0.12 0.09 0.09 0.04 0.11 0.05 NS
mgi
mg
a Means significant to CB
b Significant to other group
In conclusion, IRL and IAH showed increased urinary calcium and
oxalate. Increased urinary citrate in IAH, an inhibitor of crystallization,
may explain the absence of stones in our group. The urinary Mg/Cr ratio
was not a useful inhibitor index.
The diagnostic use of ambulatory monitoring of blood pressure in
"white coat" hypertension. J. Mora-Macia and J. Ocon-Pujadas,
Unidad de HTA, Servicio de Nefrologla, FundaciOn Puigvert, Barce-
lona, Spain. The introduction of the concept of "white coat" hyper-
tension implies a new approach in the study and treatment of hyper-
tension. We studied the incidence and characteristics of "white coat"
hypertension in subjects with essential mild hypertension (EMH). We
chose at random 95 subjects with EMH whose casual diastolic blood
pressure (clinical reading by doctor) was between 90 and 104 mm Hg.
We performed 24 four-hour ambulatory blood pressure monitoring
(ABMP) with a non-invasive automatic device (Spacelabs 5300). We
considered "white coat" hypertension present when the daytime aver-
age (8 to 22 hours) of the diastolic blood pressure was lower than 90 mm
Hg: group I (GI); and subjects to be without "white coat" hypertension
when the daytime average of diastolic blood pressure was higher than
90mm Hg: group 2 (G2). Group I was made up of 36(38%) subjects, 22
women and 14 men of 48 17 years; and G2 was made up of 59 (62%),
34 women and 15 men of 48 13 years. The casual levels of systolic
blood pressure (SBP), diastolic blood pressure (DBP) and heart rate
(HR) in GI versus G2 were: 146 14/95 4 mm Hg, 86 14 bpm vs.
152 15/98 4 mm Hg, 83 14 ppm (P < 0.05!NS, NS). The average
values of 24 four-hour ABMP in 01 versus G2 were: 126 15/80 S
mm Hg, 74 9 bpm vs. 137 13/93 7 mm Hg, 79 10 bpm (P <
0.001/P < 0.001, P < 0.01). The day-night differences of SBP, DBP
and HR in GI versus G2 were: 11 9/Il 8mm Hg, 10 9 bpm vs.
17 10/15 7 mm Hg, 11 8 bpm (P < 0.01/P < 0.01, NS). The
prevalence of WCH in EMH was 38%. These subjects, false hyperten-
sives, showed a significantly smaller day-night blood pressure differ-
ence than the subjects that did not have WCH. This suggests that the
subjects who did not show WCH may have a higher alert level in the
diurnal period, so we can separate "white coat" phenomenon from
"white coat" hypertension. In this way, 24 four-hour blood pressure
monitoring may be a useful method in detecting false hypertensive
subjects.
Genetic-ultrasonographic and clinical study on families with autosomal
dominant polycystic kidney disease (AI)PKD): Early diagnosis. I. Rod-
riguez Villarreal, B. Peral, J.L. San-Mi/lan, C. Hernandez , D. Mora,
F. Fdez-Mora, and C. Suarez, Nephrology Unit, H. General de
Huelva, Molecular Genetics Department, H. RamOn y Cajal, Madrid,
Spain. This study was carried out on the families of 32 ADPKD
diagnosed patients. The study consisted of 18 families totaling 177
people, of which 28 are not consanguineous, and 117 are first, second,
and third generation relatives of the 32 affected patients. The genetic
study is based on the detection of polymorphisms of DNA (RFLP). In
the majority of families we used 6 DNA probes for screening on the
short arm of chromosome 16 close to the polycystic kidney disease gene
(PKDI). During the study we classified the families as follows: PKDI 13
(72%), No-PKD1 2(11%) and not genetically classifiable 3(17%). Of the
57 people of the PKDI families at risk, we diagnosed 23 cases of
ADPKD and discarded the illness in 34. Of the 23 genetically diagnosed,
11 were diagnosed by ultrasound, 7 were classified as suspicious, and 2
had no renal involvement detected by ultrasound. An ultrasound study
wasn't carried out on three of the patients. The patients who had
negative and suspicious results from the ultrasound study were under
twenty years old. At the time of the study, 8 patients (35%) had
symptoms compatible with ADPKD. The number of patients with
alterations in sediment and proteinuria isn't significant with respect to
the healthy members of the PKDI families with these alterations. From
our study we conclude: (1) Evidence of heterogeneity in our population.
(2) The genetic study is more exact than the ultrasonographic and
clinical study in the I and II decade of life. (3) During the genetic study
we discarded the illness in individuals at risk (24 under 30 years old), an
interesting factor in a hereditary illness. (4) The presence of a cyst in a
individual at risk of the PKD1 families is indicative of a positive
diagnosis in 70% of our cases.
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Beneficial effect of PAF antagonist, RN 52021, in preventing renal
damage induced by warm ischemia. J. Torras, J.R. Bordalba, M.
Carrera, D. Serón, A.M. Castelao, R. Poveda, J. Alsina, and f.M.
Grino, Unitat de Recerca Experimental and Nephrology, Urology and
Pathology Servs, Hospital of Bellvitge, Barcelona, Spain. Prolonged
warm ischemia time (WIT) during renal allograft reperfusion is associ-
ated with increased incidence of posttransplant acute tubular necrosis.
An experimental model of unilateral renal flush solution perfusion, 60
minute WIT, and contralateral nephrectomy, was used to study the
ability of endovenous BN 52021, a potent PAF antagonist, to prevent
renal damage. Fifty male adult Wistar rats weighing 250 to 350 g were
included and divided in four groups according to treatment: Gr 1: Saline
isotonic solution (N = 13), Gr 2: Eurocollins solution (N 13), Gr 3: 5
mg/kg of endovenous BN 52021 plus Eurocollins solution (N 14), Gr
4: 10 mg/kg of endovenous BN 52021 plus Eurocollins solution (N
10). On days 0, 1, 2, 3, and 8, plasma urea (PU) and creatinine (P.)
were determined. On days 0, 2, and 8, 24-hour diuresis and creatinine
clearance (Car) were determined. Rats were sacrificed on day 8 and
renal tissue was removed and processed for conventional histology.
Tubular necrosis, dilation, vacuolization and interstitial edema were
measured with a semiquantitative scale graded from 0—3+. Comparison
between groups was performed with an ANOVA. Three rats from group
1 died of uremia. Results are summarized in the next table.
Day Group I Group 2
Cr .tmol/ 0 32.0 2.2 32.2 3.5
liter 1
2
3
8
237.7 18.5
314.1 43.3
232.6 46.6
68.7 2.7
285.2 33.9
265.7 57.1
224.2 64.4
69.1 4.2
C. 0 0.45 0.02 0.40 0.05
mI/mm 2
8
0.08 0.02
0.23 0.03
0.11 0.02
0.31 0.03
Day Group 3 Group 4 P
'Cr 0 29.0 0.9 32.4 4.9 NS
p,noll 1 176.6 23.5 132.3 18.9 0.0008
liter 2
3
8
162.6 38.0 98.6 20.3
104.4 18.5 61.9 8.8
55.5 0.1 52.7 6.9
0.0063
0.0203
0.002
Cc. 0 0.47 0.09 0.40 0.04 NS
mI/mm 2
8
0.22 0.03 0.29 0.03
0.34 0.03 0.44 0.04
0.0001
0.0117
Conclusions are as follows: (1) Eurocollins loses its ability to renal
preserve during WIT. (2) Administration of endovenous BN 52021
before warm ischemia offers a renal protector effect. (3) This protector
effect is more evident at higher doses.
Comparative study between double and triple therapy in 190 cadaver
renal transplants. M. Cao, A. Alonso, F. Arrojo, C. Fernandez Rivera,
J. Oliver, M. Adeva, J. Moncalian, and F. Valdes, Servicio de
Nefrologla, Hospital Juan Canalejo, La Coruña, Spain. Low doses of
cyclosporine (CsA), azathioprine (AZA) and prednisone (PD), have
been used for their immunosuppressor synergic effect, reducing neph-
rotoxicity and economic costs in renal transplantation (R.T.). We
reviewed 190 consecutive renal transplants (1.986—1.990). Group A
consisted of 138 RT (19 retransplants) immunosuppressed with CsA at
doses of 14mg/kg/day and 20mg/day of PD. Group B consisted of 52 RT
(7 retransplants) receiving CsA 8 mg/kg/day, AZA 2 mg/kg and PD 20
mg/day. Trough levels of CsA were 200—700 ng/ml (polyclonal RIA in
whole blood), in both groups. There were no statistically significant
differences between the two groups in: Sex, original terminal-stage
renal disease, cold ischemia time, duration of dialysis, sensitization
(more or less 75%), HLA mismatches at B + DR loci, previous RT or
receptor age. Group B patients had received fewer transfusions 9.7 vs.
13.3 than Group A (P < 0.05). In this group, donors were younger with
an average age of 26 vs. 35 (P < 0.001). Results were as follows:
Group A Group B P
Patient survival at 97% 94.3% NS
1st year
Graft survival at 80.15% 79.3% NS
1st year
Initial graft function 54% 72% <0.05
Primary non-functioning 10% 9% NS
Post-transplant renal 7.7 11.9 4.9 10.1 NS
failure
Hospitalization time 26.7 20.4 20.9 27.6 NS
days
One month rejection 0.31 0.49 0.39 0.53
Six month rejection 0.36 0.55 0.41 0.56 NS
Patients without rejection 58% 61%
First day rejection 11.5 9.01 7.8 5.86 NS
Average CsA level 1st week 730 457 664 493 NS
ng/ml
Average CsA level 1st month 751 389 746 249 NS
ng/ml
Average CsA level 6th month 402 181 566 163 <0.01
ng/ml
Total infections 54% 65% NS
Mean creatinine level 3rd month 1.82 1.40 1.72 0.64 NS
mg/dl
Mean creatinine level 6th 1.82 1.13 1.85 0.94 NS
mg/dl
We conclude that: (1) The appearance of acute rejection is the most
important factor in the creatinine increase after 12 months in our series,
both in patients treated with AZA plus PRED and CsA plus PRED. (2)
The appearance of rejection is correlated to the degree of incompati-
bility DR, and is more frequent among patients treated with AZA plus
PRED. (3) The use of CsA is associated with a greater rate of initial
non-functioning grafts, which determines the differences in the creati-
nine after 12 months among the patients without rejection.
Early determinants of the renal graft function: Analysis and identifi-
cation. M. Cao, F. Arrojo, A. Alonso, C. Fernandez-Rivera, T.C.
Falcon, M. Adeva, J. Oliver, J. Moncalian, A. Carmona, M.P. Fontan,
and F. Valdes, Servicio de Nefrologla, Hospital Juan Canalejo, La
Coruña, Spain. The benefits obtained with care improvement and the
use of CsA are obvious, especially in the short term. However, the
average lifespan of the grafts hasn't increased in the same measure as
survival over 1 to 2 years. Early secondary injuries in immunological
and/or toxic factors are likely to condition the graft prognostic, and the
creatinine (Crs) gained over the year can be an indication of that later
evolution. To assess these circumstances, we have revised the influence
of histocompatibility, incidence of acute rejection, initial graft function,
and use of CsA over the creatinine after 12 months in our series of
cadaver donor transplants, with evolution over more than one year,
divided into 2 groups: Group A 122, RT [immunosuppressed (IS) with
prednisone (PD) + azthioprine (AZA)1 and Group B, 96 RT [IS with
cyclosporine (CsA) + prednisone]. There were no differences in the
age, time on dialysis, transfusions or hyperimmunization, but they did
appear in the case of incompatibility DR: AZA + PD (10%) vs. CsA +
PD (2%) P < 0.001. Previous transplants AZA + PD (1) vs. CsA + PD
(1.1) P <0.001 number of rejections AZA + PD (0.81) vs. CsA + PD
(0.43) P < 0.001 and the rate of initial non-functioning grafts AZA + PD
19.83% vs. CsA + PD 39.58% (P < 0.01). Our results were as follows:
The levels of Crs after 12 months were higher in both groups among the
patients with previous rejections over those who didn't experience
rejection: AZA + PD (2.31 1.83 vs. 1.24 0.61 (P < 0.001), CsA +
PD: (2.55 1.22 vs. 1.63 0.65 (P < 0.001). A significant difference
was also found among the patients without rejection: CsA + PD: 1.63
0.65 vs. AZA -1- PD: 1.24 0.61 (P < 0.01). Within the group of patients
with rejection there were no differences, regardless of the therapy used
and the initial or non-initial graft function. However, among patients
without rejection, the creatinine was higher in patients with initial
non-functioning graft than in those which functioned initially, but only
in the group of patients treated with CsA + PD: 1.84 0.65 vs. 1.50
0.03 (P < 0.001). The rejection rate per patient was higher in the group
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AZA + PRED than in that of CsA + PRED, and they were significantly
correlated with the DR incompatibility for the whole series. Our
conclusions were as follows: (1) No significant differences were ob-
served between patients and graft survival in both groups. (2) Patients
with triple drug therapy have a lesser incidence of posttransplant renal
failure and a similar incidence of acute rejections and infections. (3)
There exists a similar rate of acute rejections and infections. (4) The
advantage of triple drug therapy and the value of the GA levels in this
group are still to be determined in further studies and long-term
follow-up.
Correlation between serum 1,25(OH)2 D3 and fractional rate of intes-
tinal calcium absorption in hypercalciuric renal lithiasis: Role of phos-
phate. M. V. Alvarez-A rroyo, A. Rapado, ML. Traba, C. de Ia Piedra,
and M. Torralbo, Laboratorio de Ia Unidad Metabólica. Fundación
.Jiménez Diaz, Madrid 28040, Spain. I ,25(OH),D3, the active vitamin D3
metabolite, regulates intestinal calcium absorption and its pathology
must be involved in calcium metabolism. Hypercalciuric renal lithiasis
(HRL) is the main known cause of renal stone formation. There are
several mechanisms to explain its pathogenesis: Renal, absorptive and
resorptive. Intracellular phosphate, a modulator of la hydroxylase,
when decreased could induce an increase in I ,25(OH)2D3, with conse-
quent elevation in intestinal calcium absorption and hypercalciuria. The
correction of this phosphate defect could lead to an improvement in
calciuria and in the presence of HRL. Fifty-eight HRL patients (36 men
and 22 women) were studied. Patients with renal tubular acidosis,
chronic urinary infection, chronic renal disease and/or primary hyper-
parathyroidism were excluded. Ten patients with high calcium intesti-
nal absorption rate and normal l,25(OH)2 D3 serum levels, and 10
patients with high calcium intestinal absorption rate and high
1 ,25(OH)2D3 serum levels were randomly chosen for a treatment with
oral phosphate (1,5 g/day) for at least 6 months. Methods included a
standard renal lithiasis study in blood and in 24-hour urine. 1 ,25(OH)2D3
was assessed by a radioreceptor assay (normal range: 18—50 pg/mI), and
net calcium absorption fraction (a) was measured by a radioisotopic
Ca47 method (normal values: 0.4—0.8 h). A positive linear correlation
between a and I ,25(OH)2D3 was found (r = 0.42; P < 0.05). Patients
were divided in three groups: I (N = 20) with normal a (h :0.6 0.11)
and normal l,25(OH)2 D3 serum levels (34.7 7.84 pg/mI); group II (N
= 19) with elevated a (h:l.02 0.13) and normal 1,25 (OH)2 D3
values (36.2 6.64 pg/mI) andgroup II1(N = 19) with high a(h':l.04
0.16) and high 1 ,25(OH)2 D3 serum levels (67.87 12.8 pg/mI). Oral
phosphate administration produced a normalization in 1 ,25(OH)2D3
values (pg/ml:74.16 16 vs. 44 12; P <0.01), a significant decrease
ofa(h1:l.l 0.3;P< 0.01), andadecreaseinurinary
calcium excretion (CaJCr: 0.26 0.05 vs. 0.15 0.05; P < 0.01) in
Group III. These biochemical values did not change significantly in
group II. Absorptive HRL is divided in two groups according to
I,25(OH)2D3 serum levels. In patients with high active vitamin D serum
levels, oral phosphate treatment could prevent hypercalciuria, possibly
due to increased intracellular renal phosphate concentration.These
results confirm the effectiveness of' oral phosphate treatment in this
group of HRL patients (FISss 89/0799).
Acute overload of iron and blood aluminum levels. C. Sanz-Moreno, T.
Gea, F. Fdez-Giron, J. Fdez-Fdez, E. Armada, D. Sanz-Guajardo, J.
Naranjo, J. Botella, Hospital Puerta de Hierro, Madrid, Spain. It is
now known that there is mutual interference of iron (Fe) and aluminum
(Al) in the organism; the overload of one may increase the blood levels
of the other. Therefore, treatment with Fe may cause an increase in the
levels of Al in the blood. This increase may secondarily reduce the
levels of ionic Ca, since Al increases the binding of Ca to the albumin.
Eighty-four patients on RDT were treated with an acute overload of Fe
i.v. (3 consecutive doses of 50 mg of Fe-Dextrane at the end of the HD
sessions). Using the DFO test, the patients were divided into two
groups: +DFO (N 33) and —DFO (N 51), according to whether the Al
increase in the blood was greater or less than 200 meg/mI. In both
groups the Fe overload significantly increased the Al in blood (48.6
38.8 sg/ml in the +DFO and 20.4 21 in the —DFO), and reduced the
ionicCa(1.07 0.9mg/dlinthe +DFOandO.93 0.72inthe —DFO).
There were no significant changes in the total Ca levels, PTH, Fe,
ferritin, albumin, phosphorous or P. alkaline. The lack of change is
perhaps due to the briefness of the experiment. In conclusion, the acute
Fe overload increases the Al in the blood, and this occurs more
intensely in patients with aluminum intoxication.
Long-term effect of medical treatment on renal function in patients with
primary hyperparathyroidism. E. Gonzalez Parra, B. Peramo, A.
Rapado, Unidad Metabólica, Fundación Jimenez Diaz, Madrid, Spain.
It is known that primary hyperparathyroidism (PH) is associated with a
high prevalence of impaired renal function that usually improves
following parathyroidectomy. We have reviewed the glomerular filtra-
tion rate in 128 patients with verified PH (persistent hypercalcemia and
elevated serum IPTH). Fifty-four were followed with medical treatment
(M) during 8.74 3.4 years (5—19 years) and their renal function
compared with 74 patients followed for 8,52 3.5 (5—18 years) after
successful parathyroidectomy (S). Mean age (years): M = 51.38
14.54; S = 44.1 13.9. Gender: M = 17 m137 f; S = 25 m/49 f.
Urolithiasis: M = 35%; S = 43%. High blood pressure: M = 15%; S =
43%. Serum creatinine (mg/dl): M = Initial: 1.01 0.29; follow up: 1.17
0.61. S = Initial: 1.05 0.39; follow up: 1.14 0.91. Creatinine
clearance (mL/min): M = Initial: 86.74 22.25; follow up: 85.26 31.6.S = Initial: 85.17 25.24; follow up: 91.87 29.09. No correlation
could be established between treatment selection and development of
renal failure. In PH patients followed up for more than five years after
medical treatment, we do not recognize changes in renal function. No
significant differences have been detected in the follow up of renal
function between the medical and surgical selected group. We postulate
that renal function is not a critical value in selecting patients for surgical
treatment.
Hepatitis C virus (HCV): Prevalence in a dialysis population at one
center. R. Se/gas, R. Mtnez-Zapico, MA. Bajo, JR. Romero, J.
Muñoz, C. Rinon, and fL. Miguel, Hospital La Paz, Madrid, Spain.
HCV has been recently defined by determination of specificantibodies.
Its prevalence in dialysis populations, under special risk of receiving
blood transfusions, remains to be described. Our aim has been to
explore our dialysis patients by determining plasma C-antibodies
through ELISA test System (ORTHO HCV Antibody) performed twice
for each patient. This cross-sectional study included 61 patients on
hemodialysis and 43 patients on CAPD. Respective mean times: 78 63
and 32 27 months. The influence of previous transplantation and
blood transfusions was also determined. (1) Prevalence of HCV is
markedly higher in HD than in CAPD. (2) Longer periods on hemodi-
alysis, but not in CAPD, are directly related to a higher incidence of
HCV. There is an increased HCV incidence after 5 years on HD, but
not in CAPD. (3) More than 4 blood transfusions increases two-fold the
risk of HCV in lID, but not in CAPD. (4) Previous renal transplantation
increases slightly the risk of HCV in HD, but not in CAPD. (5) Non-B
chronic hepatitis in HD is related to HCV in 71% of patients. Our final
conclusion is that hepatitis C virus is clearly related to hemodialysis
practice, but not to CAPD.
Staphylococcus aureus nasal carrier (SANC) induced by subcutaneous
recombinant human erythropoietin. R. Se/gas, M.J. Castro, M.A. Bajo,
M.J. Fernanadez, K. Lopez-Revuelta, and J.R. Romeo, F. de Alvaro,
C. Riñon, Hospital La Paz, Madrid, Spain. SANC status supposes a
risk for patients on CAPD due to a higher probability of suffering
peritoneal/catheter infections. The subcutaneous (se) use of drugs has
been related with SANC in insulin-dependent diabetics, IVDA, HD
patients, and users of anti-allergic vaccine. On CAPD, rHuEPO is
almost universally used by s.c. route, Our aim was to evaluate the new
appearance of SANC in 85 patients by means of nasal smear. Patients
were divided in four groups according to diabetic status and rHuEPO
treatment (mean dose 2000 U twice a week, during 14 months): 54
non-diabetic control patients, 26 diabetic control patients, 18 non-
diabetic rHuEPO treated and II diabetic treated patients. The influence
of SANC on peritoneal/catheter infections was also evaluated. The
prevalence of SANC on control groups was non-diabetic 30%, and
diabetic 23%. After rHuEPO treatment this prevalence was increased to
39% and 45%, respectively, due to 3 and 3 new SANC patients. SANC
supposed a higher incidence of S. aureus infections affecting both
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catheter and peritoneum: SANC patients (29% of the population)
suffered 45% of peritonitis and 42% of exit-site infections caused by S.
aureus. We conclude that the prevalence of S. aureus nasal carrier is
higher in those CAPD patients who use subcutaneous rHuEPO and this
status confers a higher risk of suffering dialysis-related infections
caused by this germ.
A prospective study of peritoneal function at long-term CAPD. M.J.
Fernandez-Reyes, R. Se/gas, E. Bosque, C. Campo, M.A. Bajo, K.
Lopez-Revuelta, A.C. Jimenez, J.R. Romero, F. De Alvaro, and C.
Riñon, Hospital La Paz, Madrid, Spain. This paper presents our results
of sequential peritoneal kinetic studies and ultrafiltration capacity (UF)
in 56 patients followed at least three years on CAPD. All patients
admitted to this treatment from 1980 until 1988 were included. Mean
observation period was 5 years, with an overall follow-up of 276
patient-years. Kinetic studies were performed by mathematical model-
ing techniques (determining MTCs for urea and creatinine, mi/mm) and
UF was calculated with a standard formula (mi/day). Statistical analysis
was done by ANOVA test. Neither mean values of urea-MTC nor
creatinine-MTC showed significant changes during the study period.
However, UF capacity showed a significant decrease from 1800 530
to 1400 600 mI/day (P < 0.01). This trend was mainly induced by
those patients with a higher number of accumulated days of peritonitis.
These patients also showed an increase in their values of creatinine-
MTC. The long-term pentoneal stability in those patients with low
peritonitis rate was remarkable. Data on peritoneal clearances showed
an overall stability. Diabetes status or drugs did not show any influence
on peritoneal functional data. In conclusion, after 10 years on CAPD,
human peritoneum is able to perform solute and water exchange with
only minimal trouble in those patients affected not by a frequent
peritonitis rate, but the evolution of these episodes measured by the
number of accumulated days of peritoneal inflammation.
Moncrief's technique for implanting peritoneal catheters: the impor-
tance of the external healing phase. R. Se/gas, MA. Bajo, M.J.
Fernandez, K. Lopez-Revuelta, F. Borrego, E. Bosque, C. Jimenez, C.
Riñon, J.R. Romero, and F. Dc Alvaro, Hospital La Paz, Madrid,
Spain. Moncrief's experience with implantation tecnique of peritoneal
catheter access (designated as Moncrief's catheter), suggests that the
rate of catheter-dependent peritonitis is higher than it was thought
before. While in the standard implantation technique, the terminal
segment of the catheter remains external; in Moncrief's catheter, it is
reimplanted under the skin for the initial period of 4 weeks. Moncrief's
clinical trial on 59 patients with a follow-up period of 530 patient-
months, reveals a substantial decrease in the incidence of recurrent
peritonitis, suggesting the importance of the wound healing phase in the
long-term evolution of CAPD patients. It is the aim of this paper to
present the results obtained with this technique in 10 CAPD patients at
our unit. The results were as follows: In three patients the implantation
was frustrated because of bleeding in the abdominal wall in one, and
doubts about the right intraperitoneal position in two. Two other
patients did not reach the last phase due to sudden death and a wound
abscess which required catheter removal. In the other five patients the
process was completed. One of them required a surgical procedure to
release an omental entrapment. Two other catheters suffered traumatic
damage during their exteriorization. The appearance of the exit site of
these five catheters is completely different from those implanted by the
standard method, resembling natural navels. In spite of the high
incidence of complications during our trial with this technique—most of
them due to our inexperience—we strongly believe that the Moncrief
catheter is the very first substantial improvement toward a safer
peritoneal access in CAPD.
Adequacy of dialysis in patients longer than 4 years on CAPD:
Significance of the urea kinetic model (UKM), creatinine kinetics and
their relationship with clinical parameters. M.A. Bajo, R. Se/gas, M.J.
Edez-Reyes, E. Bosque, K. Lopez-Revue/ta, C. Campos, C. Jiinenez,
F. Borrego, C. Riñon, J.R. Romero, and F. de Alvaro, Hospital La
Paz, Madrid, Spain. UKM is a useful tool for evaluating adequacy of
dialysis in HD patients. However, its use on CAPD patients shows
controversial data. Our aim has been to know retrospectively whether
the UKM has any influence on the evolution of CAPD patients. We
studied 56 patients, aged 48.4 15.4, with a minimal follow-up of 3
years (3996 patient-months). At the beginning and yearly thereafter we
evaluated lean body weight, KT/V-UN, EN-CREAT, NPCR, creati-
nine, BUN, and albumin, hospitalization rate, incidence of peritonitis,
morbidity, and mortality. The prescription of dialysis was based on
clinical parameters and peritoneal MTCs. Statistical analysis was done
by ANOVA test and uni- and multivariant methods. The loss of residual
renal function with stability in diffusive peritoneal parameters induced
a decrease in KT/V-UN and EN-Creat at long-term. These two indices
showed as the best in terms of relationship with clinical stability. Values
above 8 for EN-creat, 1.7 for KT/V-UN/week, and 1.2 g/kg/day for
NPCR showed a direct correlation with lesser presence of uremic
symptoms, and lower hospitalization, morbidity and mortality rates.
These data did not show a relationship with technique failure rate.
UKM loses the significance of these relations in patients with high
peritoneal permeability. Probably this fact reflects a decrease in apetite
secondary to the high peritoneal glucose absorption. Low peritoneal
diffusion capacity did not show as a special risk for a long-term bad
prognosis. The stability of NPCR values during the study is remarkable.
According to our results, we propose a prospective study on adequacy
of dialysis based in kinetics of urea or creatinine. Extreme values could
be for KT/V-UN-week >1.7 and <1.2 and for EN-creatinine >8 and
<5.
Can the high prevalence of anti-HVC+ in HD patients be predictive as
a marker of liver disease? G. Barril, M. de Castro, B. RincOn, C. Bernis,
C. Ga Cant6n, J.A. Sanchez Tomero, E. Gruss, J. Motellón, J.A.
Ayala, J.C. DIaz Bailón, R. Moreno Otero, and J.A. Traver, Servicios
de NefrologIa y HepatologIa, Hospital de Ia Princesa, Universidad
Autonóma, Madrid, Spain. There is a high prevalence in HD patients of
antibody to hepatitis C virus having proved worse pronostic of virus C
liver disease in HD and kidney post-transplant. For this study we
selected 228 patients studying the prevalence of anti-HVC in different
HD units, including one unit with patients Ag HBs+: 125 male, 123
female, with a mean age of 53.3 years and mean duration of HD time of
44.8 months. We considered HD time, blood transfusions, hepatic
biochemical parameters, test for HBs Ag, anti-HBs and anti-HBc by
radiomnmunoassay (abbot), serum anti-HVC using an enzyme immu-
noassay (Ortho). A proportion of 30.2% of the total patients were found
anti-HVC+ , finding a signficative correlation with the number of blood
transfusions, HD time, presence of HBsAg and anti-HBC±. At that
moment only in 3.96% of the total patients we find elevated transami-
nases, but this was not valuable as a parameter of liver disease.
Conclusions: (1) There is a high prevalence of anti-HVC+ HD patients
in relation with the number of blood transfusions, HD time, and
association of Ag HBs an anti-HBc+. (2) The usual biochemical
parameters cannot be used as an index of activity in virus C liver
disease. (3) The routinely used methods at present are not sensitive
enough to detect virus C. Therefore, it is necessary to use more exact
methods to know when to practice a liver biopsy to study the possibility
of an Interferon treatment and evaluate the indication of kidney
transplant of these patients in relationship with the severity of their liver
disease.
Conversion of azathioprine (AZA) to cyclosporine (CsA) in renal
transplant patients with azathioprine intolerance. M.C. Cantarell, L.
Capdevila, M. Mann, J. Roselló, M. Ramirez, J. Vila, and L. Piera,
Servicio de NefrologIa y Servicio de Medicina Preventiva y EstadIstica,
Hospital General Va/I d'Hebron, Barcelona, Spain. A total of 207 renal
allograft recipients were on immunosuppressive maintenance therapy
with azathioprine (2.5 mg/kg/day) and prednisone (0.10 mg/kg/day).
Twenty-six underwent conversion to CsA (5 mgrs/kg/day) and pred-
nisone (0.25 mglkg/day) or triple therapy: CsA + AZA + prednisone.
The main reasons for conversion to CsA were: decreased white blood
count, liver dysfunction and chronic rejection (renal graft biopsy)
secondary to inadequate immunosuppresion due to the first two causes
mentioned above. Of the 26 patients: 22 were males and 4 females with
a median age of 40.7 years. Median time from transplantation was 67
22 months. Conversion started 46.8 28 months from transplantation
with a follow-up of 19.6 17 months. Conversion was gradually
established with AZA and CsA overlap for one week, being complete
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after AZA was discontinued. The maintenance prednisone dose re-
mained unchanged. Eight patients were maintained with triple therapy.
Results are reported in the table:
Leukopenia Liver dysfunction
AZA CsA AZA CsA
Creat
WBC
Hct
SGOT
SGPT
GGT
1.9 0.9
3.3 0.6
32.4 13
15 6.5
14 10
42 29
3.2 2.2
6.1 2.l
33.4 8.9
24.1 14
24.2 19
43.8 52
1.2 0.3
5.3 2.4
40 10
66.7 51
75.1 18
143 195
2.1 1.3
6.2 1.7
37.2 10
51.8 28
69.8 46
133 153
Chronic rejection
AZA CsA
Creat.
WBC
Hct
SOOT
SGPT
GGT
1.9 0.5
5.2 1.5
30±8
20.3 16
26.6 20
19 18
3.6 1.8
7.7 1.7a
30±9
15.2 6
14.2 6.8
31,8 28
a P < 0.05 comparing before and after treatment
Our conclusions were as follows: (1) Absence of acute rejection
episodes in the conversion of AZA to CsA. (2) Patients with leukopenia
returned to normal white blood counts value. (3) Alterations in liver
function persisted post conversion. (4) Conversion to CsA showed a
significative increase in serum creatinine in the three groups, although
this change was different for each group (P < 0.05). (5) Changes in renal
function expressed as the inverse of serum creatinine (I/Cr) versus
time, in the chronic rejection group, before and after conversion,
showed a slow rate of decline in renal function.
Enalapril associated anemia in kidney transplants. MC. Cantarell, L.
Capdevila, J. Munne, M. Ramirez, J. Vila, and L. Piera, Servicio de
Nefrologia y Medicina Nuclear, Hospital General Vail d'Hebron,
Barcelona, Spain. A decrease in red blood cells has been reported in
patients with arterial hypertension treated with enalapril, We have
studied 13 kidney allograft recipients, with arterial hypertension treated
with enalapril. None of them had renovascular pathology. Of thirteen
patients, 11 were males and 2 were females, with a median age of 41
8.6 years. Immunosuppresive therapy consisted of cyclosporine and
prednisone. Enalapril therapy was instituted 25.6 18 months from
transplantation with a follow-up of 18.6 10 months. Blood pressure,
renal function, whole blood cyclosporine levels, and anemia studies
were performed before and after enalapril therapy. We observed blood
pressure control, but no significative differences appeared in serum
creatinine (2.4 1 mg/dI vs. 2.6 1.4 mg/dl), proteinuria and
cyclosporine whole blood levels. A significant hematocrit decrease was
observed: From 37.8 5.6% to 32.9 5% (P < 0.05). Similar but
nonsignificant erythropoietin decrease (18.6 13 mU/mI to 16.7 12
mU/mi, RIA) was also detected. Our conclusions were : (I) patients
with arterial hypertension (post-kidney transplant under enalapril ther-
apy) showed a reduction in red blood cells. (2) Enalapril must be
considered in differential diagnosis of the anemia associated with
kidney transplant.
Captopril TC99mDTPA renography as screening test for renal artery
stenosis in kidney transplantation. MC. Cantareil, L. Capdevila, M.
Frajie, J. Castells, J.L. Tovar, M. Ramirez, J. Vila, and L. Piera,
Servicio de Nefrologia y Medicina Nuclear, Hospital General Vail
d'Hebron, Barcelona, Spain. Changes in renal function taking place
after ACEI (angiotensin converting enzyme inhibition) administration is
a known fact detected by radionuclide scanning. We have studied these
modifications in a group of 16 renal allograft hypertensive patients. In
all of them arterial hypertension control was difficult to achieve. Graft
was placed in the right iliac fosa, with anastomosis of the renal artery
end-to-side with the external iliac artery. Immunosuppressive therapy
consisted of cyclosporine and prednisone. Serum creatinine was infe-
rior to 3 mg/dl. Radionuclide scanning was performed after 111 mEq of
TC9SmDTPA was given intravenously. After the initial (basal) scan,
Captopril 50 mg was administered by mouth. Then a second scanning
was performed. Differences between sequential renal images (uptake
and excretion), as well as time-activity curves, were analyzed. All cases
were studied by digital substraction angiography (DSA). Of 16 patients,
three showed renal impairment after ACEI administration, detected in
the renographic curve. These 3 patients had graft arterial stenosis
confirmed by DSA. The remaining thirteen patients with no changes in
isotopic scanning, had a normal DSA as well. Those patients were
treated with ACEL and renal function showed no alterations. Our
conclusions were: (1) Captopril renography was a diagnostic test in all
cases of graft artery stenosis. (2) It is a simple test, and we suggest the
practice in renal graft associated arterial hypertension to detect renal
artery pathology, and also include it before starting ACEI therapy.
Effects of E.V. rHuEPO on bone marrow in patients with renal chronic
insufficiency. J.A. Bravo Soto, MaD. Del Pino Pino, M. Alma gro
Slnchez de Puerta, A. Cabrera Garrido, M. Cenit, J.M. Osorio
Moratalia, M. Benitez Sanchez, A. Monies Puerta, and C. Asensio
Peinado, Nephrology-Hematoiogy, HG y E. Virgen de las Nieves"
Granada, Spain. Ever since rHuEPO has been available, several
studies on its effect on bone marrow (BM) of patients with renal chronic
insufficiency (RCI) have been published. Most of these are in vitro
studies showing an increase in CFU-E. Our aim is to describe morpho-
logical changes taking place in the BM of a group of patients with RCI
who are undergoing hemodialysis and being treated with this protein,
and their relation to the supplied dose and/or its blood levels. We ran a
longitudinal study throughout 24 weeks in 14 patients with severe
anemia who were undergoing hemodialysis for more than 6 months. All
of them received rHuEPO: 50 lU/kg/session, with further modifications
in order to maintain hematocrit = 30%. The BM specimens obtained by
sternum puncture were stained with May-Grunwald and Perls, and
studied by two observers separately. They made a global count over 500
cells and a specific count over 100 red cells, and then they also
considered macrophagic iron, erythroblastic iron and erythroblastic
islets. In blood we measured hemoglobin, hematocrit, absolute number
of reticulocytes, ferritin and EPO (RIA-INCSTAR). All determinations
were taken in the weeks, 0, 3, 9, 16 and 14, and the statistical analysis
was done with the program "R-SIGMA."
Week 0 3rd 9th
rHuEPO lU/kg/week 0 129 14 197 64
% Red cells (BM) 17.6 4.2 28 9 (S) 30 9 (S)
M/E relation 3.6 0.9 2.3 0.8 (S) 2.2 1.1 (S)
% Proerythroblasts 2 2.1 3 2.6 4.3 2 (S)
% Basophilic erythroblasts 13.5 5.3 14.2 6.8 18.7 6.1
% Polichrome erythroblasts 36.4 7.9 35.7 8.8 38.7 5.4
% Orthochro, erythroblasts 48 12.8 46.7 15.5 38.1 8.2
Hematocrit 20.1 1.6 22 1.8 27.5 3.5 (S)
Absolute reticulocytes 25409 40854 (5) 49616 (5)
16th 24th
rHuEPO lU/kg/week 183 126 180 166
% Red cells (BM) 20 7.2 23 11
M/E relation 3.5 1.7 2.9 1.8
% Proerythroblasts 3.6 2.1 3.1 1.8
% Basophilic erythroblasts 17.4 6.3 14.2 5.4
% Polichrome erythroblasts 43.3 7.5 (S) 41.9 8.6
% Orthochro, erythroblasts 35.5 11.3 40.9 10.3
Hernatocrit 30.9 4.5 (S) 29.5 2.9 (S)
Absolute reticulocytes 49949 (S) 56452 (S)
We found a significant increase in erythroblastic islets from 9th week
onwards that was maintained up to the 24th week. No correlation was
found between rHuEPO dose, EPO blood level and percentage of red
cells in BM, and no correlation was found either between the latter ones
and hematocrit and absolute reticulocyte number. Our conclusions
were: (I) rHuEPO produces an increase in red cells on BM of RCI
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patients, mainly of proerythroblasts and erythroblastic islets. (2) The
rHuEPO dose and blood level do not seem to be the only factors in the
response, because they are not globally correlated. Nevertheless, in the
individual case, there's evidence of a better response to a higher dose.
(3) This glycoprotein does not modify the remaining cell series in BM.
Genetic counseling in autosomal-dominant polycystic kidney disease
(ADPKD): Conventional versus genetic linkage diagnoses. S. Aguado, E.
Gómez, E. Ga go, F. Fernández Vega, E. Cob, C. LOpez Larrea, and
J. Alvarez-Grande, Hospital Covadonga, Oviedo, Spain. Genetic coun-
selling implications of ADPKD diagnoses based in conventional or
genetic linkage methods were compared. Genetic studies were offered
to 35 ADPKD families in accordance with international ad hoc commit-
tee recomendations. Clinical and genetic studies included in all cases
sonography and linkage studies with 7 different DNA probes. Families
were required to have at least 6 meiosis and 2 affected members.
Twelve unrelated families with PKDI type disease were found to meet
these criteria. Analysis of these 12 families showed a total number of
101 risk members, 33 of whom were free of disease. Sixty-three (92.7%)
of the 68 affected members had been conventionally diagnosed,
whereas 5/68 can only be diagnosed on a genetic basis. Although 48
(76.2%) of these conventionally diagnosed patients were, due to their
familial history, diagnosed during their presymptomatic ADPKD stage,
their mean age at diagnosis was 32 15 years, whereas the age of the
5/68 genetically diagnosed patients was 16 years (range 8—25). Conven-
tional diagnosis of ADPKD is a late (postreproductive) one when
considering genetic counseling. This defect can be improved with
genetic linkage studies.
Presymptomatic diagnosis of autosomal-dominant polycystic kidney
disease (ADPKD) with DNA probes. S. Aguado, E. GOmez, E. Gago, E.
Cow, C. LOpez Larrea, R. MarIn, and J. Alvarez-Grande, Hospital
Covadonga, Oviedo, Spain. Genetic testing was done in ADPKD
families with the aim of estimating clinical utility of diagnostic DNA
probes. A total of 35 families was reviewed in the last two years.
Genetic studies were done with 7 DNA probes. Clinical and ecograph-
ical studies were done within a maximum period of 15 days. Families
eligible for genetic studies were those who had at least 6 meiosis and 2
affected members in the family. Only 13 (37%) families fulfilled the
aforementioned criteria for doing genetic studies. One (7.7%) of these
families was of the not linked (non PKDI) variety. Of the 12 remaining
PKD1 families, a total of 101 risk members (52 males and 49 females,
mean age 37 17 years, range 9—71) were studied. Each family was
formed by a mean of 8 4 members at risk (range 6—19). Sixty-eight
(67%) of the 101 risk patients were affected by the mutation or had
clinical disease. Sixty-three (93%) of these patients, had been previ-
ously diagnosed by conventional methods, whereas 5 (7%) can only be
diagnosed with DNA probes. A high percentage of ADPKD families are
genetically uninformative. Presymptomatic diagnosis of ADPKD re-
quires extensive family studies.
A prospective study about utility of diagnostic tests in diagnosis of
cytomegalovirus in renal transplant (RT) patients. E. Gomez, S. Aguado,
S. Melon, M. de Ona, R. Cimadevilla, A. MartInez, and J. Alvarez
Grande, S Nefrologia y Microbiologia, H Covadonga, Oviedo, Spain.
From 02/24/87 to 12/31/87, 109 consecutive renal transplants were
prospectively studied with the aim of detecting cytomegalovirus infec-
tion (CMVI) or disease (CMVD). Fifteen patients who lost their grafts
before 3 months were excluded from the analysis. Ninety-four were
valid patients. Blood and urine specimens were examined pretrans-
plant. Post-transplant specimens were examined weekly during the first
two months, and monthly until the 12th month. In each specimen the
following tests were done in blood: (1) antigenemia by inmunofluores-
cence methods with monoclonal antibodies; (2) conventional viral
culture; (3) determination of IgG and 1gM antibodies. On urine; (4)
immunofluoresecence with monoclonal antibodies (5) viral culture.
Since January 1990: (6) shell vial in blood; (7) shell vial in urine; (8)
hybridization with DNA probe in shell vial, both in blood and urine. We
studied 7673 specimens; 33 (35%) patients were free of infection. Of the
remaining 61 patients, 44 (72%) had CMVI and 17 (28%) had CMVD.
Twelve out of 17 patients of the CMVD group did have sero-conversion
and positive tests in blood and urine during their follow-up, while only
16/44 of the CMVI group did (P = 0.016). All patients with CMVD had
viremia and/or antigenemia while only 29/44 of CMVI patients did (P
0.003). Presence of antigenemia or positive shell vial cultures were
detected more frequently in both groups than positive conventional
culture (44 vs. 13 and 17 vs. 10). We concluded that determination of
antigenemia and viremia (by hybridization or shell vial) were the best
diagnostic tests for diagnosing CMVD.
Influence of immunosuppressive therapy on pituitary-testicular func-
tion after renal transplantation. R. Peces, M. Gorostidi, L. Sanchez, P.
Escalada, andJ. Alvarez, Service of Nephrology, Hospital Covadonga,
Oviedo, Spain. After successful renal transplantation, abnormalities of
the pituitary-gonadal axis of hemodialyzed patients are reversed or
improved in those receiving conventional immunosuppressive therapy.
It has been suggested from clinical and experimental studies that
cyclosporine (Cs), induces an inhibitory effect on the pituitary-testicu-
lar axis, manifested by hormonal changes and impairment in spermato-
genesis. To characterize the effect of Cs on the pituitary-testicular axis,
we studied 26 renal transplant recipients, 19 on Cs (Cs group), and 7 on
classic therapy (Aza group). In addition, 8 cases from Cs group were
sequentially studied during maintenance hemodialysis and after trans-
plantation. Basal plasma levels of FSH, LH, prolactin and testosterone
were determined by RIA. There were no significant differences in
hormonal levels between Cs and Aza groups. When hormonal levels in
the 8 patients from the Cs group were evaluated during dialysis and
after renal transplantation, a decrease in LH levels was found (19.6
3.9vs. 6.8 0.8 U/liter, P < 0.01), as was a decrease in prolactin levels
(9.0 1.0 vs. 6.4 0.4 ng/ml, P < 0.02). FSH and testosterone levels
did not change. These results demonstrate that the pituitary-testicular
dysfunction of the hemodialyzed patients is reversed by a successful
renal transplantation, regardless of the type of immunosuppressive
regime. Cs does not impair the pituitary-testicular function, at least with
the dosage now used in clinical practice.
In vitro production of TNFa and 1L6 induced by OKT3. R. Peces,
J.M. Urra, M. Gorostidi, P. Escalada, and C. LOpez-Larrea, Services
of Nephrology and Immunology, Hospital Covadonga, Oviedo, Spain.
The use of OKT3 monoclonal antibody for both prophylaxis and
therapy of acute rejection is frequently accompanied by the so-called
"first-dose" reaction. This reaction is now related to a massive,
although transient, release in the circulation of some cytokines, includ-
ing TNFa and 1L6. We examined in vitro production of TNFs and 1L6
induced by OKT3 in supernatants of peripheral blood mononuclear
cells (PBMC) from 29 renal transplant recipients (RT) during stable
transplant function and 20 normal controls. RT patients were treated
with prednisone, azathioprine and cyclosporine. PBMC were incubated
during 90 mm. in RPMI-1640 in the absence or presence of 1 zg/ml of
OKT3. Identical experiments were performed previous to incubation
with 100 g/ml of methylprednisolone (MP). TNFo was determined
using the TNF-sensitive WEHI 164 cell line. 1L6 was measured using
the 1L6 dependent B9 cell line. PBMC from control subjects showed
higher TNFa release than RT patients after 90 mm. of incubation in
RPMI-l640. Both controls and RT showed significant increase of TNFa
production following OKT3 stimulus. When MP was added before
OKT3, RT (but not controls) showed significant inhibition of TNFa
production. Basal 1L6 release was no different in both groups and did
not change after OKT3 stimulus. These results demonstrate that OKT3
induces in vitro TNFa release. In RT, the release of TNFa is attenu-
ated, but not inhibited by maintenance immunosuppression. TNFa may
be the early mediator of first-dose syndrome and high dose MP, and by
inhibiting its production may be beneficial.
Anti-HCV antibody prevalence: In-center versus home hemodialysis.
M. Gorostidi, S. Aguado, E. Gómez, A. Martinez, L. Otero, E. Gago,
and J. Alvarez-Grande, Services of Nephrology and Microbiology,
Hospital Covadonga, Oviedo, Spain. It has not been well defined if the
presence of anti-HCV positive patients in a hemodialysis unit consti-
tutes a risk factor for anti-HCV negative patients while maintaining the
adequate prophylactic measures. The aim of the study was to charac-
terize this potential risk factor comparing the prevalence of positive
anti-HCV patients treated at an in-center unit versus at regular home
hemodialysis. Anti-HCV anti ClOO (ELISA "Ortho Diagnostics") was
determined in serum samples from 53 patients (31 M, 22F, aged 56.9
1.9 years) being dialyzed at an in-center set, and 20 patients (12 M, 8 F,
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aged 48.5 3.1 years) submitted to home hemodialysis. We evaluated
the known risk factors: Time on hemodialysis and number of blood
transfusions received. The prevalence of positive anti-HCV was 30.2%
among in-center patients and 40% for home patients (p NS). Time on
hemodialysis was higher in the home group (89.8 12.9 vs. 41.4 5.0
months, P < 0.0005) as well as the number of blood transfusions
received (19.5 4.5 vs. 14,8 1.9), although this difference lacked
statistical significance. In conclusion, hemodialysis therapy at in-center
units with anti-HCV seropositive patients seems not to be an additional
risk for HCV infection while maintaining the appropriate control
measures.
Predictive value of the anti-HCV anti-C 100 in the hemodialyzed (LID)
with hypertransaminasemia (LIT). M. Gorostidi, S. Aguado, E. Gómez,
M. Ona, S. Melon, E. Gago, and J. Alvarez-Grande, Services of
Nephrology and Microbiology, Hospital Covadonga, Oviedo, Spain. It
has recently been suggested that HCV is implicated in an important
proportion of community-acquired NANB hepatitis, particularly in
cases which progress to chronicity. The aim of the study was to assess
the possible predictive value of the anti-HCV anti-C 100 in HD with HT.
Seventy-three HD (43 M, 30 F) were studied. Thirty-three of them,
(45.2%), had no history of ALT elevation (NON-HT), meanwhile the
other 40 (54.8%) had it (HT). In 17 patients from the HT group (42.5%),
the enzyme alteration was acute (Ac-HT), and in 23 (57.5%) persisted
more than 6 months (Chr-HT), Serum samples were investigated for the
presence of anti-HCV anti-C 100 by an ELISA method (Ortho-Diagnos-
tics). The results are as follows:
Anti-HCV (+) Anti-HCV (-)
Group NON-HT (33)
Group HT (40)
4 (12, 1%)
20 (50%) P < 0.01
29 (87, 9%)
20 (50%)
Group Ac-HT (17)
Group Chr-HT (23)
7 (41, 2%)
13 (56, 5%) NS
10(58, 8%)
10 (43, 5%)
In conclusion, there was a significant relationship between the anti-
HCV antibody and the LIT in HD. However, anti-HCV positive
prevalence did not differ in the two evolution patterns mentioned.
Anti-HCV anti-C 100 seems to lack predictive value in HD with HT.
Essential hypertension (EH): Predictive value of the association with
total obesity. M. Gorostidi, R. Mann, F. Fernandez-Vega, E. GOmez,
and J, Alvarez-Grande, Service of Nephroiogy, Hospital Covadonga,
Oviedo, Spain. It has not been clearly defined if total obesity is a risk
factor associated with EH. The aim of the study was to assess if this
association constitutes an additional cardiovascular risk. We studied
206 patients with EH, 96 M, 119 F, aged 54.4 12.8 years. Ninety-three(45%) had a body mass index (BMI)  30, and formed the obese group.
The other 113 (55%) had a BMI < 30 and were the not obese group. We
analyzed: Associated diseases (diabetes, gout), cardiovascular compli-
cations (stroke, ischemic heart disease, left ventricular hypertrophy,
nephrosclerosis, peripheral arteriopathy), metabolic profile (glucose,
tryglicerydes, total and HDL-cholesterol, uric acid), and number of
anti-hypertensive drugs used. Both groups were similar in age and
blood pressure levels. Females predominated in the obese group (P <
0.01). When comparing the associated disease prevalence, cardiovas-
cular complication frequency, and the amount of anti-hypertensive
drugs, there were no differences between the two groups. The meta-
bolic profile showed no differences except for tryglicerydes, which were
higher in the obese group (158 104 vs. 124 58 mg/dl, P < 0.01). We
conclude that total obesity is not an additional cardiovascular risk when
associated to essential hypertension; hypertensive patients with obesity
do not constitute a worse prognosis group.
Effects of intravenous (i.v.) cyclophosphamide (cy) in proliferative
lupus glomerulonephritis (GN). M. Ramirez de Arellano, J.L. Tovar, M.
Vallés, J. Ordi, and L. Piera, Hospital General Valle de Hebrón,
Barcelona, Spain. Effects of i.v. cy in proliferative lupus GN were
retrospectively evaluated in 11 patients (pts) (8 females, mean age 39
years), who had previously received 6 monthly i.v. cy pulses of 0.7 g/m2
followed by 6 other similar doses every third month during a total
period of 2 years, together with degressive doses of prednisone ranging
from I mg/kg/day to the minimum amount required to keep pts free of
symptoms. A renal biopsy that was performed before the treatment was
started showed proliferative diffuse lesions in all pts with different rates
of sclerosis-activity index. Lupus was immunologically and clinically
active in all pts, and three of them complained of extrarenal manifes-
tations. Proteinuria was present in all pts and renal insufficiency (serum
creatinine >1.4 mg/dl) in three of them, After the first six months of
treatment, lupus was quiescent in all pts, proteinuria desappeared in
four, and renal function had normalized in two, When cy was given on
a third month schedule, an increase of proteinuria or a decline in renal
function or the appearence of extrarenal clinical manifestations of lupus
was observed in four pts, one of them consistent with cerebral vascu-
litis. Renal biopsy was performed in four pts after the last cy dose, the
histological pattern being normal in one of them who was clinically
asymptomatic, but in the other three scarce changes were seen com-
pared to the previous biopsy. Cy was commonly well tolerated although
two patients suffered from non-severe herpes zoster infections as main
treatment-related complications. In conclusion, we believe that iv. cy
could be a valuable alternative to the classic oral treatment of severe
lupus GN, permitting a substantial lower total dose of the drug.
1,25(OH)2-vitamin 1)3 intravenous and secondary uremic hyperpara-
thyroidism. C. Sanz-Moreno, E. Armada, A. Esquerda, J. Fdez-Fdez,
D. Sanz-Guajardo, E. Baamonde, and J. Botella, Hospital Puerto de
Hierro, Madrid, Spain, Using calcitriol i.v., good results have been
obtained in the control of secondary uremic hyperparathyroidism, in
patients in whom this control is not usually achieved and in very severe
cases with hgh PTHi figures (<1,000 pg/mI). Twelve patients on RDT
were treated; they had received oral treatment with calcitriol and had
high figures of PTHi (579 286.2 pg/mI). Two had a PTHi of 1130 and
1092, and another 2 had figures of 756 and 751 (pg/mI). For 6 months all
were receiving 2 meg at the end of each HD session. The Ca of the
dialysate was reduced from 3.5 to 3.0 mEq/liter. After 6 months of
treatment the PTHi had dropped 80.8 15.6% of the basal values (111.0
90.6 pg/mI, P < 0.001) in 11 of the 12 patients. Patients with basal
figures greater than 1,000 dropped to 96 and 218 pg/mI, respectively. In
the 2 cases of figures close to 700, one did not respond, and in the other
the PTHi dropped to 180 pg. It was occasionally necessary to suspend
some doses of VitD3 due to hypercalcemia. The values of P remained
stable, although it was necessary to increase the doses of Al(OH)3 in 8
patients. In conclusion, intravenous treatment with calcitriol is very
effective, even in patients with very high PTHi figures who had
previously not responded to oral administration of this drug.
A restrictive kidney pretransplant transfusion policy: Three years
experience. f.M. Gas, A. Franco, M. Perdiguero, M.C. Prados, and 1.
Olivares, Department of Nephrology, S. V.S. Hospital, Alicante, Spain.
Although the useful effect of blood transfusions (TF) in the cyclosporin
A (CsA) era has been questioned, TF continues to be the primary
inducer of sensitization in potential graft recipients. Because of this, we
decided to avoid deliberate pretransplant TF three years ago. The aim
of this study was to evaluate graft outcome of nontransfused patients
(NTP) in comparison with transfused (>0 TF) patients in our kidney
transplants. We reviewed the long-term follow up of 100 consecutive
kidney transplants, excluding 5 second transplants, 5 vascular throm-
bosis and I exitus by surgical sepsis, being 28 NTP and 61 TP. All
patients received low dose CsA (4 mg/kg/12 hr), azathioprine and
prednisone. We found no differences in age, sex, cold ischemia, HLA
A, B and DR mismatch, incidence of acute tubular necrosis and
percentage of sensitized patients (PRA >50%) between both groups.
Time on dialysis was significantly higher in TP than in NTP (42.9 31.0
vs. 20.6 13.7, P < 0.001). The incidence of graft rejection was similar
in both groups (4.5% in NTP vs. 5.6% in TP, P = NS). Graft survival
was similar in TP and NTP at 1 month (95.1% vs. 96.4%, P = NS
Mantel-Cox). This trend persisted without statistical significance
(93.1% vs. 92.9%) at long-term follow up (34 months). In our experi-
ence, graft survival in NTP seems to be similar to TP, despite the fact
that NTP remained less time on dialysis than TP.
Effect of diet and enalapril on microalbuminuria, glomerular filtrate
and renal plasma flow in diabetic patients. f.M. Mallafré, iA. Oliva, J.
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Carrió, J.M. Pou, J. Soldevila, and R. Sola, Department ofNephrol-
ogy, Hospital C. Roja, Department of Endocrinology, Sant Pau Hos-
pital, Department of Nephrology, F. Puigvert, Barcelona, Spain. The
effects of a hypoproteic diet and enalapril on 8 type I diabetic patients,
insulin-dependent (IDDM), normotensive, with normal creatinine, and
microalbuminuria values between 73 and 227 sg/ml, were studied. The
following phases were set up:
1st phase: Diet 0.7 gr/kg/day of proteins (30 days)
2nd phase: Diet 1.2 gr/kg/day of proteins (30 days)
3rd phase: 2nd phase diet and enalapril between 5—10 mg/day
At the start and end of each phase we measured: Microalbuminuria,
glomerular filtrate (EDTA-Cr-51 1), and renal plasma flow (Hippuran-I-
131). In all patients, a decrease in microalbuminuria excretion was
observed after the 1st phase (X = 63 g/ml), an increase at the end of
2nd phase (X = 53 g/ml), and another decrease at the end of the 3rd
phase (X = 58.2). In 6 patients, a rise in the GF after the first phase was
noted, with no change in the remaining. The RPF showed no difference
in the three phases. A hypoproteic diet and enalapril decrease microal-
buminuria excretion, although the latter to a lesser extent. The GF
shows a trend to increase after the 1st phase.
Late C virus seroconversion in patients on HD. J.A. Oliva, J. CarriO,
f.M. Mallafre, Department of Nephrology, Creu Roja Hospital, Bar-
celona, Spain. The presence of the C virus antibodies (HCV Ac) in
patients on hemodialysis has been demonstrated and is becoming more
prevalent. However, the elimination of transfusions since the use of
EPO and the appearance of new cases has increased expectations in the
study of contagion routes. We studied HCV Ac prevalence during three
time periods: A (12/88), B (1989), C (1990). In the first period, of 43
patients studied, 24 f and 19 m, aged 30—83 years (X = 66.3 12), Hd
time 9—109 m (X = 54.7 27.4), 13 patients were HCV Ac +(30%), and
were considered chronic C virus carriers. During the year 1989, two
patients (nos. 1 and 2) presented seroconversion 15/43 (34%), and
throughout 1990 seroconversion was observed in 7 patients (nos. 3 to 9),
mean age 75.3 years, mean Hd time 50.83. The two patients who turned
in 1989 and the seven who turned in 1990 were all considered to be
acute. Patients I and 2 had shared several of the monitors used for the
HCV Ac + chronic patients. Patient I exhibited seroconversion simul-
taneously with the maximum ALT rise peak (5 episodes, varying
between 49—128, X = 77) while patient 2 showed reconversion 11
months after the maximum ALT peak (6 episodes, varying between
50—305, X = 139 mIU/ml). We performed serological studies of the C
virus in the units transfused into these two patients; one of them had
received a unit contaminated, while with patient 2 all were negative.
During 1990, in the patients who turn HCV Ac +, a rise in ALT was
noted in 2 of them (nos. 3 and 4, 28.5%), with average values of 61.8 and
87.2, respectively in 5 measurements in the two cases. All the serocon-
verted patients had been in contact with patients 1 and 2's monitors.
The test for the C virus in the units of blood transfused into these
patients (2—57 units, X = 17.7), (2—14 units, X = 7.8) was positive in
patient 3, while the rest of the units were negative. The turn observed
during this period in patients 3 and 4 occurred 10 months after the
maximum ALT peak, when these had returned to normal. Our conclu-
sions were: (I) The negative result in the HCV Ac test for the blood
units for patients who had exhibited seroconversion in period B and C
of the study suggests other transmission sources for the C virus during
Hd. (2) The fact that the ALT failed to rise in 5 of the seven patients
who showed seroconversion during period C increases the C virus
diagnosis problems. (3) The only possible source of transmission in the
HCV Ac + patients in period B and C, apart from those who had
received contaminated blood samples, is the dialysis monitors, which in
our judgement must be considered contagion sources. (4) There is a
deferred seroconversion pattern, at 10 to 11 months in our study, from
the maximum ALT rise peak to the detection of the HCV Ac + patients.
Osmolality influence on elimination of f microglobulin and small
molecules in hemodialysis. J.J. Santos, ML. Carrasco, A. Vdzquez, P.
Abaigar, S. Pascual, and G. Torres, S. NefrologIa, Hospital Genera!
Yague, Burgos, Spain. According to the reports on hypertonic hemo-
dialysis, we have studied the elimination of /32 microglobulin (/32m) with
standard hemodialysis (HD) and sequential hypertonic hemodialysis
(SHHD). We have chosen seven anuric patients (6 males and I female),
all of whom have been treated with three seances of 180 minutes on HD
and SHHD with a polysulphone membrane (PF-60) and a wash-out
period of a week between these treatments. The sodium dialysate on
HD was 138 mEq/liter and on SHHD was changed every 45 minutes in
a sequential way (176-135-176-135) by an electronic device. Blood
samples were taken in the arterial line before and at the end of the
seance. All the dialysate fluid was stored in a container. The dialysate
flow was 500 mI/minute and blood flow was 375 mI/minute. At the end
of the SHHD sequences, a minor drop of the plasma volume and a
major extraction rate of /32m was observed. However, when the
extraction rate of f32m was corrected at the end of the seance, according
to the plasmatic volume changes, there was no significance. We did not
find differences among the extraction rate of BUN, creatinine, phos-
phorus, potassium and uric acid. There were no significant differences
predialysis among creatinine, BUN and BUN creatinine between
SHHD and HD as it has been reported. The removal of BUN,
creatinine, uric acid, /32m and phosphorus, both in HD or SHHD, was
the same.
HD SHHD
Plasma volume 17.25 9.32 11.88 6.53 (P = 0.04)
change %
Extraction f32m % 31.95 8.00 38.90 7.58 (P = 0.007)
Extraction f32m corrected 39.78 7.93 43.82 7.81 (NS)
by plasma
volume
Na postdialysis 137 1.06 140 1.68 (P = 0.007)
We think that the hyperosmolality does not have influence on the
removal of J32m nor on the small molecules.
The role of convection during simulated CAVHD. S. Cigarrán, E.
Peldez, and TA. Golper, Sección de NefrologIa, Hospital Montece!o,
Pontevedra, Spain, and University of Louisville, Louisville, Kentucky,
USA. CAVHD essentially removes solutes by diffusion; convection is
used merely to maintain fluid balance. To determine the effect of high
ultrafiltration rate (UFR) on diffusion and total clearance (Cl), we
pumped plasma containing several different molecular-sized markers
through 5 different CAVHD devices at 60 cc/mm. Dialysate flow rate
(Qdi) was 15, 30 or 60 cc/mm; UFR was 0, 5, 10 or 20 cc/mm. Each
combination of flows was studied in duplicate and devices in triplicate.
The devices performed differentely from each other, but similary
regarding the interactions between UFR and Qdi. When UFR = 20
cc/mm, raising Qdi from 15 to 60 cc/mm only increased urea (U Cl) by
23%. However, when UFR = 0, a similar increase in Qdi raised U Cl by
130%. The effects of these manipulations on tobramycin (T) Cl were
similar to those noted for U. Thus, convectively derived solute dimin-
ishes the concentration gradient and impairs the contribution of diffu-
sion to total clearance. Our studies generally confirm the original Sigler
findings that CAVHD, U Cl is Qdi limited. However, when UFR
increases, the relationship gets more complicated. For example, whenQdi = 15 cc/mm increasing UFR from 0 to 20 cc/mm raises U Cl 14
cc/mm. At Qdi = 60cc/mm, a similar increase in UFR only raises U Cl
by 10 cc/mm. Thus, diffusion lowers plasma urea concentration and this
diminishes further contributions to total Cl by convection. Despite
these interactions, the greatest clearances were noted at maximized Qdi
and UFR. As molecular size increased, this effect was much more
pronounced.
Tobramycin (T) clearance (Cl) during simulated continuous hemodi-
afiltration. S. Cigarrán, E. PelOez, M.E. Brier, and T.A. Golper,
Sección de Nefro!ogIa, Hospital Montecelo, Pontevedra, Spain, and
University of Louisville, Louisville, Kentucky, USA. We studied 5
hemofilters to test the hypothesis that T Cl was primarily due to
convection. The poorly protein bound, 468 dalton, polycationic antibi-
otic T was placed in human plasma which was pumped through
hemofilters in simulated continuous arteriovenous hemodiafiltration. At
a fixed plasma flow rate (60 cc/mm), dialysate flow rate (Qd) was 15, 30
or 60 cc/mm, and ultrafiltration rate (Qf) was 0, 5, 10, or 20 cc/mm. Each
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device was studied in triplicate and each combination of flows was
studied in duplicate. Dialysate T CI in cc/mm:
DEVICE
Qd
QfO
15
Qf5
Qd30 Qd
Qf5
60
Qf 10Qf 10 Qf5 Qf 10
HF 500 6.3 9.9 14.3 14,8 17.7 14.8 21.0
Biospal 0.3 0.6 1.4 3.2 4.0 6.1 5.3
D-30 2.4 7.2 8.9 8.3 10.8 9.3 10.9
HF 250 2.4 4.2 7.6 5.3 9.4 5.6 5.2
D-20 1.9 3.6 6.6 8.3 8.9 5.5 8.4
Multivariate analysis of variance demonstrated that T Cl was signifi-
cantly affected by Qd, Qf, and device. Of comparably sized devices, T
Cl of HF 500 > D-30 > Biospal. T appears to bind to Biospal
membrane. A 4 fold increase in Qf causes a greater increase in T CI than
a 4 fold increase in Qd. These data suggest that T is cleared predomi-
nantly by convection. For patients in acute renal failure, at low Qd and
Qf, T Cl is increased 1 to 3 fold over baseline (3 mI/mm) depending on
device. However, at high Qd and Qf, T Cl is increased 3 to 8 fold. Use
of devices with high convective flows may require dosage or dose
interval adjustment.
Effects of LGF on cultured rat mesanglal cells: Pathophiological
meaning. J. Gila, J. Diez, E. Archilla, M. Gonzalez, M. Rodriguez-
Pujol, and D. Rodriguez-Pujol, Physiology Department and Pharma-
cology Department and Nephrology Section, University of Alcala de
Henares, Spain. Liver growth factor (LGF) plasma levels have been
found enhanced in several liver diseases. The aim of the present work
was to assess the possible role of LGF in renal disorders secondary to
liver cirrhosis. In vitro experiments using cultured rat mesangial cells
(CRMC) showed a dose-dependent, time-dependent reduction in planar
cell surface area (PCSA) after incubation with LGF (PCSA, expressed
as % of basal values, after incubation of CRMC with LGF for 30 mm:
control, 102 3%; LGF: 10—10 M, 94 1%; l0- M, 91 6%; 10-8 51,
90 3%; lO M, 86 2%; 10—6 M, 68 4%; PCSA after incubation of
CRMC with 1 LGF during different intervals of time: T0: 100; T10:
91 1%; T30: 83 4%; T: 72 2%*, *D< 0.05 vs. T0). Phosphor-
ylation of myosin light chain was also increased after incubation of
CRMC with 1 ILM LGF, thus confirming the contractile nature of the
reported changes in PCSA. LGF did not induce any changes on PCSA
when sulotroban, a TXA2-receptor blocker, was added to CRMC.
Finally, when a 50 sg LGF bolus was injected to anesthetized Wistar
rats (weighing 300 25 g), there was a slight but statistically significant
reduction in glomerular filtration (—16 3%) and renal plasma flow
(—14 5%). These results suggest a possible role for LGF in renal
disorders secondary to chronic liver diseases.
Interaction between platelets and cultured mesangial cells: Possible
mediators involved. R. Martin Ambrosio, I. Arribas, C. GarcIa-Es-
cribano, D. RodrIguez-Puyol, ML. DIez Marques and M. Rodriguez-
Puyol, Department of Physiology and Pharmacology and Nephrology
Section, Alcalá de Henares University, Spain. Previous results of our
group have shown an increase in the contraction state of cultured
mesangial cells (MC) incubated with platelet-supernatants (PSN), sug-
gesting that some arachidonic acid metabolites or PAF could be
involved in the genesis of such effects. Continuing with the study of this
problem, platelets and MC were preincubated with a cyclooxygenase
inhibitor (lysin-acetylsalycilate (LAS) 10-4 M), incubating later on MC
with the PSN obtained in this way, and measuring the cellular surface
area (CSA). PSN ability to modify myosin light chain (MLC) phospho-
rilation was evaluated. TxB2 and PAF production was quantified by
RIA, in PSN and PSN-incubated MC. The effect of PSN on mesangial
cells CSA was blocked by both LAS-platelets supernatant and
LAS-MC (Control: 101 3%; PSN: 79 2%; LAS-platelets superna-
tants: 98 2%; LAS-MC: 101 3%. < 0.05 vs. C). The other
groups, N = 4; all values represent percentage of the initial surfaces, 30
mm after incubation). The amounts of TxB2 and PAF produced by
platelets and MC was: TxB2: 96.3 8.3; MC-TxB2: 1.02 0.25;
platelet-PAF: 18.4 4.3, and MC-PAF: 0.21 0.12 ng/mg. TxB2 and
PAF production did not increase significantly in cells incubated with
supernatants. PSN induced a 60 7% increase in MLC-phosphorila-
tion. These results suggest that, probably, platelets but not cell metab-
olites are the main agents responsible for the CSA changes. MLC
results confirm the contrasting nature of the morphological changes
observed.
Renal function and Fischer 344SPF oxidation patterns. P. Ruiz, M.
Gonzalez, J. Lucio, C. GarcIa-Escribano, M. Rodr(guez-Puyol and D.
RodrIguez-Puyol, Department of Physiology and Pharmacology and
Nephrology Section Alcalá de Henares University, Spain. The patho-
physiological mechanisms responsible for renal function changes on
aging are still unknown. It has been suggested that reactive oxygen
species could play a main role. Thus, renal function and some patterns
related to renaloxidation/antioxidation mechanisms in young Fischer
344 rats (a widely used experimental model of aging) were tested. C1,,
CPAH and FF values were 0.42 0.02 ml/min/l00 g; 1,84 0.25
ml/minlloo g and 28 4%, respectively (N = 15 in all the cases). These
values are similar to those found in Wistar rats. The urinary MDA
excretion was 28.7 2.1 nmol/day (N = 16). The plasmatic and
glomerular MDA values 1.67 0.71 nmol/ml (N = 20) and 4.6 0.6
nmol/g protein (N = 9) were markedly lower (P < 0.001) than in
Wistar rats: 5.75 0.37 nmol/ml (N = 18) and 21.5 3.0 nmol/sg
protein (N = 9). Finally, the glomerular and mesangial GSH determi-
nation in Fischer 344 rats yielded amounts, expressed in sg GSH/sg
protein, of 10.9 0.4 (N = 12)and 19.9 5.1 (N = 7). These results set
up a precise description of renal function and oxidation/antioxidation
systems in young Fischer 344 rats. They may become our major target
in subsequent studies.
Tumor necrosis factor (TNF) actions on cultured rat mesanglal cells
(CRMC). J. Medina, J.A. Gila, L. Baud, J. Rodriguez-Pujol, and D.
Rodriguez-Puyol, Department of Physiology and Pharmacology and
Nephrology Section Alcald de Henares University, Spain. Although it
seems that TNF may contract CRMC, some experimental evidence
does not support this fact. Thus, present experiments were designed to
analyze, with a combined morphological and biochemical approach, the
TNF ability to contract CRMC, not only in basal conditions, but in
presence of Angiotensin II (Ang H). TNF significantly reduced planar
cell surface area (PCSA) of CRMC, in a dose-dependent (C: 100 2%,
TNF 100 ng/ml: 70 l%*; TNF 10 ng/ml: 82 4%*; *< 0.05 vs. C.
Values are expressed as per cent of basal PCSA after 30 mm) and
time-dependent (TO: 100%; T 10: 87 4%*; T 20: 76 5%*; T 30: 69
5%*; 'P < 0.05 vs. 0. Values are expressed as percentage of basal
PCSA after incubation with 100 ng/ml TNF). Moreover, TNF increased
myosin light chain phosphorilation by 73% (control: 12.1 2.3 cpm/&g.
TNF: 20.9 1,5 cpm/g*. 6P < 0.05 vs. C). In addition, TNF (100
ng/ml) also increased the contraction of Ang 11(10-8 M) on PCSA of
CRMC (Ang II: 78.6 5%; Ang II + TNF: 65 2%*; *P < 0.05 vs.
Ang II. Values are percent of basal PCSA, after 60 mm of incubation.
TNF was added after 30 mm with Ang II) being unable to prevent that
contraction. These results support a contractile role of TNF on CRMC,
thus suggesting a potential role for this cytokine in the regulation of
renal function.
Utility of genetics in diagnosis of autosomal-dominant polycystic kidney
disease (ADPKD). G. de Arriba, F. Garcia-Martin, M. Sanchez, F.
Sanchez, L. Lozano, E. Martin-Escobar, B. Palomero, and M.D.
Jarillo, Hospital General Universitario, Guadalajara, and Hospital
Virgen de Ia Luz, Cuenca, Spain. We have studied 47 members of eight
kindreds with ADPKD (age 26.4 13.5, range 7—61 years) with normal
renal function (Crp < 1.5 mg/dl). Our aim was to compare carriers (C)
of the disease with healthy members (H) of the same families to detect
possible clinical and renal function differences. Genetic study in com-
plete families with DNA probes (3' HVR, pGGGI and 24-1) from
chromosome 16 allowed us to associate the pathological locus with a
defined haplotype. Renal ultrasound was performed in all, and bilateral
renal cysts were found in 20 C (9 with more than 10 cysts in every
kidney); in 4 C cysts were not found. We did not show significant
differences between C and H in age (27.7 12.9 vs. 24.9 14.2) sex,
urinary symptoms, palpable abdominal masses or incidence of high
blood pressure. There were no differences in urinary osmolality after
dehydration, urinary pH, uric acid clearance and tubular reabsorption
of phosphate. We conclude that clinical symptoms and renal function
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tests are not always reliable for ADPKD diagnosis in patients with
normal renal function. However, renal ultrasound and genetic studies
allowed us to detect asymptomatic carriers of the disease.
Relationship between high blood pressure and kidney volume in
autosomal-dominant polycystic kidney disease (ADPKD). G. de Arriba,
F. SOnchez-Ortega, F. Garcia-Martin, E. MartIn-Escobar, M. Si$n-
chez, B. Palomero, L. Lozano, J. Mayor, and M.D. Jarillo, Hospital
General Universitario, Guadalajara, and Hospital Virgen de Ia Luz,
Cuenca, Spain. We studied 41 members of eight families with ADPKD
and normal renal function (plasma Cr < 1.5 mg/dl): 20 patients had the
disease (age 26.7 12.9, range 8—52) and 21 were healthy controls (age
25.7 14.4, range 7—61). The aim was to evaluate differences in renal
volume between normotensive and hypertensive patients. We deter-
mined the mean cross-sectional area (A, cm2/l .73 m) and mean volume
(V, cm3/l .73 m2) of both kidneys using ultrasonography. Diastolic and
mean blood pressure were correlated with A (r = 0.6649) and V (r =
0.6116) in ADPKD patients but not in healthy controls. Kidney A and
V were not different between healthy normotensive members and
ADPKD patients without hypertension (A: 31.8 4.9 vs. 38.1 17; V:
121.7 29.4 vs. 145.2 84). However, ADPKD hypertensive patients
showed significative larger kidney A and V (A: 81.5 28.1, V: 559.4
317.6, P < 0.05). We conclude that blood pressure is correlated with
kidney size in ADPKD patients. Furthermore, the increase in kidney
volume is associated with hypertension in ADPKD.
Urinary excretion of microalbuminuria and N-acetyl-glucosaminidase
in autosomal-dominant polycystic kidney disease (ADPKD). M.D. Jarillo,
G. de Arriba, J.E. Martin, M. Sanchez, J. Nieto, J. Mayor, U.
Rodriguez, and F. Garcia-Martin, Hospital General Universitario,
Guadalajara, Spain. We studied 28 patients (14 females and 14 males)
from families with ADPKD to compare urinary excretion of microal-
buminuria (Mic) and N-acetyl-glucosaminidase (NAG) between pa-
tients with bilateral renal cysts (N = 16) and healthy controls of the
same families (N = 12). All were older than 20, and age was 42.9 17.5
(range 22—88 years). The incidence of high blood pressure was higher in
patients with bilateral renal cysts (68% versus 8%, P < 0.05). Plasma
creatinine was also higher in patients with ADPKD (1.7 0.3 versus I
0.1 mg/dI).
ADPKD Healthy controls
Mic mg/24 hr
NAG U/24 hr
Mic0/Cr0 x102
NAG0/Cr0 (JIg
57.9 25.1
3.29 0.70
4.53 1.90
2.66 0.64
3.70 1.30°
1.73 0.37°
0.29 0.10°
0.95 0.13°
a P < 0.05 vs. ADPKD
Serum creatinine was correlated with Mic (r = 0.7081) and with urinary
NAG (r = 0.7051). We conclude that in ADPKD, urinary excretion of
Mic and NAG is increased. The increase is related with the existence of
high blood pressure and chronic renal failure. Mic and NAG could be
considered as markers of tubular damage in ADPKD.
Treatment with angiotensin enzyme converting inhibitors and calcium
antagonists in patients with reduction of renal mass and high blood
pressure. M. Sanchez, M.D. Jarillo, J. Nieto, L. Lozano, F. GarcIa-
MartIn, G. de Arriba, F. Huguet, and J. Mayor, Hospital General
Universitario, Guadalajara, Spain. Our aim was to compare the results
of treatment in hypertensive patients with reduction of renal mass (one
kidney) with angiotensin-converting enzyme inhibitors (ACEIs) versus
calcium entry-blockers (CEBs). We studied 88 patients (58.2 17.3
years old) with reduced renal mass for 311.2 248.1 months. They
were treated with ACEIs (53%), CEBs (19%), both (4%) and other
drugs (24%). Fifty-five patients were hypertensive and 28 had moderate
chronic renal failure. The presence of proteinuria was correlated with
hypertension (r 0.33, P < 0.05) and with time of reduced renal mass(r = 0.47, P < 0.05). From 26 patients with significant proteinuria at the
start of the study, only 17 had proteinuria after treatment. We did not
find significant differences between treatment with ACEIs or CEBs with
respect to blood pressure control, plasma creatinine or proteinuria.
High blood pressure is frequently found in patients with reduced renal
mass. The presence of proteinuria was correlated with hypertension
and time with reduced renal mass. Both angiotensin-converting enzyme
inhibitors and calcium entry-blockers produced similar blood pressure
control and decrease of proteinuria in patients with reduced renal mass.
Antiphospholipid antibodies in patients with chronic renal failure on
hemodialysis (HD). F. GardIa-MartIn, G. de Arriba, M. Sanchez, J.
Nieto, and M.D. Jarillo, Hospital General de Guadalajara, and Uni-
versidad de Alcala de Henares, Spain. Antiphospholipid (aPL) antibod-
ies are autoantibodies directed against negatively-charged phospholip-
ids. Anticardiolipin antibodies (IgG-aCL) and lupus anticoagulant (LA)
are aPL antibodies clinically associated with hypercoagulability and
thrombotic phenomena. Systemic thrombosis coexists with immuno-
regulation abnormalities in uremia. The aim of the present study was to
analyze the incidence of aPL antibodies in 36 HD patients. IgG-aCL
were determined by ELISA (Rayne Institute validated), and LA by
VV-Russell, Tn and Exner methods. Ten patients (28%) had IgG-aCL
positive and eight (22%) LA; overall, thirteen patients (36%) had
IgG-aCL and/or LA. Length on HD was longer in aPL positive patients
(54 16 months vs. 42 6). No correlation was found with age, sex or
etiology of chronic renal failure. A positive correlation was found
between beta2 microglobulin and titres of IgG-aCL. Four patients met
criteria for primary atiphospholipid syndrome (APS), clinically charac-
terized by cerebrovascular accidents and/or thrombosis of vascular
access. In summary, aPL antibodies are frequently found in HD
patients, probably related with the chronic renal failure state. These
autoantibodies can be associated with thrombotic phenomena, being
part of an chronic renal failure-related APS.
Effect of progressive increasing dose of intravenous 1,25 Vit D on
calcium-phosphorous homeostasis in the chronic renal failure. J. Sanchez
Tomero, A. Diaz, V. Paraiso, C.G. CantOn, B. RincOn, C. Bernis, G.
Barn!, and J.A. Traver, S. de Nefrologia y Anal. Clin. H. de Ia
Princesa, Madrid, Spain. Seven patients on chronic hemodialysis with
secondary hyperparathyroidism (HP 2°) were treated with 1,25 Vit D
i.v. postdialysis. Initial dose was 0.5 g and gradually increased every
three months, to I and 1.5 tg. Ionized calcium (iCa), total calcium
(TCa), phosphorous (P), magnesium (Mg), alcaline phosphase (AP),
PTH and osteocalcin were determined.
Basal 0.5 1 1.5
iCa 4.5 0.3 4.7 0.5 4.8 0.4 5.1 0.4°
TCa 9.2 0.6 9.3 0.6 9.6 0.7" 9.9 0.4
P 5.1 1.3 5.5 1.9 5.0 1.6 4.6 0.9
AP 352 269 400 361 466 372 285 257°
PTH 663 131 828 132° 668 263 229
Ost 50 52±25 54±28 51±25
Mg 2.3 0.3 2.6 0.3° 2.4 0.3 2.7
a P < 0.05 from basal, b from 0.5, C from 1
Our conclusions were: (1) Treatment with 1.25 Vit D i.v. with doses
higher than 1.5 rg postdialysis decreases PTH and AP and is effective
to suppress HP 2°. (2) The decrease of PTH could be favored by the
increase of iCa, TCa and Mg. (3) The AP behaves as a more sensitive
marker than osteocalcin and decreases in parallel with PTH. (4) Doses
lower than 1.5 g are not effective to suppress HP 2°.
Bone mineral density (BMD) changes after renal transplantation (RT):
Importance of the pretransplant secondary hyperparathyroidism. D.
HernOndez, M.T. Concepción, A. Rodriguez, A.P. Rodriguez, ML.
Dominguez, f.M. González-Posada, V. Lorenzo, A. Torres, M.
Machado, and F. Toledo, Nephrology and Radiodiagnosis Sections,
University Hospital of Canary Islands, Tenerife, Spain. The determi-
nants and natural history of bone loss after RT are not well established.
We studied 21 chronic dialysis patients just before RT (basal) and 3 and
6 months thereafter. All received low dose prednisone + CsA +
azathioprine, and plasma creatinine remained < 2.2 mg/dl. In each
situation BMD was assessed by quantitative computed tomography at
the lumbar spine, and the levels of calcium (Ca), phosphorus, intact
PTH (IRMA), aluminum, and calcitriol, were also determined. A bone
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biopsy specimen was obtained during surgery, and a positive correla-
tion between BMD and trabecular bone volume (r = 0.75;P <0.01) was
found. Two distinct groups of patients were detected: Group I with
basal PTH >250 pg/mI (N = 6; 32 11 years; 5 M, I F), and Group II
with values <250 pg/mI (N = 15; 38 10, 11 M, 4 F). Basal BMD was
below age and sex matched normal values in 50% of patients of Group
land in 60% of Group II. Compared with basal values, a mean decrease
of BMD of 20.7 8.6% in Group I, and of 5, 6 13% in Group II (P
0.02), was seen after 3 months of RT. A positive correlation between
basal PTH and the % decrease of BMD was observed (r = 0.53; P =
0.02). At this time, 83% of patients of Group I and 67% of Group II
showed a low BMD. At 6 months after RT no significant changes of
BMD were detected. Post-RT Ca and PTH values remained higher in
Group! than in Group 11(10.72 + 0.86 vs. 9.71 + 0.51 mg/dl, P < 0.01;
and 112.81 + 36.7 vs. 75.3 + 19.4 pg/mI, P < 0.05, respectively, at 6
months). Age, sex, weight, accumulated steroid dose, and aluminum,
calcitriol, and cyclosporine levels had no influence on BMD changes
after RT. In summary, pretransplant secondary hyperparathyroidism is
the major determinant of the rapid bone loss seen after RT. The
maintenance of intact PTH values during chronic dialysis below the
critical value of 4 times the upper limit of normal values seems to be
important for its prevention.
Urinary concentrating defect in idiopathic hypercalciuria (III): The role
of increased prostaglandin E2 (PGE2) excretion. J. Chahin, E. Gal/ego,
M.L. Méndez, J.J. GarcIa-Perez, V. Garcia-Nieto, and A. Torres,
Nephrology Section, Hospital NS Candelaria and University Hospital,
Tenerife, Spain. An increased urinary excretion of PGE2 has been
described in IH, but its pathogenetic role in this disorder has not been
established. We studied 44 IH patients (40 II years; 14 M, 30 F;
calciuria> 0.1 mmol/kg/day). Based on the urinary calcium (Ca) and
AMPc after 10 days of Ca restricted diet, they were classified into
absorptive IH (ALH, N = 18), Renal IH (RIH, N = 19), and Undeter-
mined (UIH, N = 7). Plasma PTH levels (middle-molecule) were also
determined. Urinary concentrating ability was assessed after the nasal
administration of 20 of desmopressin (DDAVP) in all IH patients and
in 46 normal individuals (C; 32.5 8 years; 18 M, 28 F). Twenty-four
hours excretion of PGE2 (RIA preceded by extraction) was determined
in 33 IH patients (40.5 12 years; 10 M, 23 F) and 12 C (30 7.6; 4 M,
8 F). Maximal urinary osmolarity (UosmMx) was decreased in IH
patients compared to C (822 155 vs. 1035 115 mOsm/kg; P <0.01)
and 60% of them showed a concentrating defect (UosmMx <850, lower
value of C). This was more frequent in UIH than in AIH and RIH (100%
vs. 51%, P < 0.01). On the other hand, a higher PGE2 was associated
with a lower UosmMx (r =
—0.40; P = 0.023). Moreover, 32% of
patients with concentrating defect, 6% of those with normal concentra-
tion, and 0% of C, showed an urinary PGE2 >900 ng/ml (P < 0.05).
Urinary AMPc correlated negatively with both UosmMx (r =
—0.39;P
= 0.01) and POE2 (r = —0.34; P 0.05), but not with PTH. Finally, a
higher POE2 was associated to a higher calciuria (r = 0.46; P < 0.01).
In conclusion: (a) urinary concentrating defect is a common finding in
IH, (b) an increased urinary excretion of PGE2 seems to be important in
its genesis, most likely by interfering with adenylate cyclase and
decreasing vasopressin-stimulated water transport, (c) Urinary AMPc
is mainly conditioned by this derangement but not by PTH, and this test
should not be used to classify IH patients, and (d) Increased PGE2
excretion may also be important in the genesis of IH.
Adynamic bone disease (ABD) not related with aluminum in predialysis
(PD) patient. D, Herndndez, M.T. ConcepciOn, A.P. Rodriguez, J.M.
González-Posada, V. Lorenzo, and A. Torres, Nephrology Section,
University, Tenerfe, Spain. Changes in patients' demographics and
phosphate binders policy may influence the actual prevalence of the
different bone lesions in PD patients and its evolution after chronic
hemodialysis (CHD). We studied 62 consecutive PD patients (44.5 17
years, 42 M, 20 F) just before starting CHD, who underwent an iliac
crest bone biopsy. Intact PTH (IRMA) levels were also determined.
Only 2 were receiving vitamin D. All were initially treated with CaCO3,
but low dose (OH)3 Al (<1.8 g/day) was also required in 37. Bone
lesions were: mild hyperparathyroidism (MH) 13%, osteitis fibrosa (OF)
31%, osteomalacia (OM) 5%, mixed lesions (ML) 11%, and ABD (bone
formation rate < 0.03 j.tm3/m2/day) 40%, Only one patient, with
diabetes (DM) and OM, showed >10% of trabecular surface stained
with aluminum (Al). With the exception of OM, ABD patients were
older than the others (50.4 17 vs. 39.8 15 years; P = 0.01).
Although DM was rarely seen among OF and ML patients (P = 0.03),
a similar proportion of MH and ABD patients suffered DM. Cumulative
dose of phosphate binders, duration of renal failure, and levels of
calcium, phosphorus, and bicarbonate, were not different in ABD.
Seventy percent of patients with PTH <200 pg/mI showed ABD. Seven
ABD patients never received vitamin D and underwent a second biopsy
after 20 to 26 months of CHD. Six again had ABD and one evolved to
MH. Trabecular bone volume did not change significantly (22.3 6.3
vs. 20 5.7%) and none of them developed fractures. Bone surface
stained with Al remained < 5%, and plasma Al levels were 34.3 27
sg/liter (range 5—70). PTH levels decreased from 252.7 173.4 to 99.1
59 pg/mI (P = 0.08) and osteocalcin from 22.3 11.4 to 8.6 5.3
ng/ml (P < 0.05). In conclusion: (a) ABD is a common finding in
predialysis patients, especially in the elderly, (b) low PTH values are a
clue for its diagnosis, (c) aluminum intoxication does not seem to play
a role on its pathogenesis, and (d) although bone turnover rarely
improves on CHD, when aluminum overload is prevented its prognosis
does not seem to be bad.
Hepatitis B vaccination in hemodialysis (HD): A comparative study
with three schedules. R. Ortega, E. Sudrez, F. Fdez-Mora, A. Jimeno,
f.M. Onaindia, C. Suárez, and J, Gonzalez, Hospital General de
Hue/va, Seccián de NefrologIa, Sección de Digestivo, Ser. de A.
ClInico, Spain. The immune response to hepatitis B vaccine in hemo-
dialysis patients is lower than in a healthy population. In order to
evaluate if a modification of the usual vaccination schedule (40 .&g at 0,
I and 6 months) improves the immune response, three vaccination
schedules with recombinant vaccine (Engerix B, SKF) IM in deltoid
region have been compared. Seventy-seven patients (49 men, 28
women) on HD, serologically negative for virus B markers, have been
studied. The mean age was 52.9 13.1 years and the time on dialysis
48.5 36.8 months. They were randomized in three groups. Group A:
25 patients, the vaccination schedule consisted in 20 g at 0, I, 2 and 6
months; Group B: 26 patients, 40 g at 0, 1, 2 and 6 months and Group
C: 26 patients, 40 g at 0, 1 and 6 months, There was no difference in
the mean age, sex and time on dialysis between the groups. Anti-HBs
serum levels were determined at 1, 2, 3, 6 and 7 months after the initial
dose of vaccine with ELISA (BM). Seroconversion was considered if
the anti-HBs titre was higher than 10 mU/mi.
Months
Seroconversion rate Anti-HBs GMT (lU/liter)
30 60b 70C 70
Group A 28% 20% 64% 461.7
Group B 50% 58% 77% 1197.8
Group C 15% 23% 54% 890.5
a P < 0.05 B vs. C; b P <0.05 B vs. A; and C = 0.07 B/C
Patients aged less than 40 years seroconverted 100%, aged 41 to 60
years 63%, and patients more than 60 years 48%, with P < 0.05 between
the former and the latter. There was no difference in seroconversion
rate according to age, time on dialysis and the presence of anti-HCV.
Our conclusions were: (1) The vaccine schedule of 40 g at 0, 1, 2 and
6 months (group B) is more effective than the usual one, with an earlier
response (P < 0.05), a trend to higher seroconversion rate (P = 0.07)
and higher anti-HBs titres, although no statistical difference was
achieved. (2) The vaccine schedule with 20 sg (group A) had higher
seroconversion rate than the usual, without statistical significance, and
lower anti-HBs titres. (3) The seroconversion rate depends on the age
(100% in patients <40 years).
Tubular dysfunction (TD) in nephrotic syndrome (NS): Incidence and
prognostic implications. A. Andres, M. Praga, E. Hernández, C. Mon-
toyo, A. Mazuecos, C. Campy, R. Sanchez, andJ.L. Rodicio, Hospital
"12 de Octubre," Madrid, Spain. Some cases of TD associated with NS
have been reported, but no studies have evaluated the incidence and the
characteristics of such association. We have prospectively investigated
the presence of TD (renal glycosuria, aminoaciduria, renal tubular
acidosis) in 36 patients with NS. Ten patients (27.7%) (Group I) showed
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persistent renal glucosuria, ranging between 2.5—11.2 g/24 hr(x 6 2.5
g124 hr); 7 of them exhibited, in addition, renal tubular acidosis and 5 of
them aminoaciduria. There were no significant differences in sex, age,
duration of NS or histologic diagnosis between this Group I and the 26
remaining (Group LI). There were 7 membranous glomerulonephritis, 2
focal glomeruloscierosis and I membranoproliferative in Group I pa-
tients. Proteinuria and serum creatinine (Ser) were significantly higher
in Group I: 10.2 3.7 vs. 6.7 2.9g/24 hr(P <0.01) and 3.2 1.9 vs.
1.6 0.9 mgldl (P < 0.05), respectively. Uric acid levels were lower in
Group I patients: 4.8 1.7 vs. 6.6 1.9 mgldl in Group II, A renal
venography, performed in five cases of Group I, did not show renal vein
thrombosis. A renal biopsy was performed in one case of Group I,
shortly after the appearance of TD: no linear deposits were observed on
immunofluorescence at glomeruli or tubules, and anti-glomerular base-
ment membrane antibodies were negative. The appearance of TD had
coincided with an abrupt fall of renal function in most of Group I
patients; in addition, after 6 months of follow-up, Scr had increased
from 3.2 1.9 mg/dl to 4 2.9 mg/dl in this Group (P < 0.05). By
contrast, Se,. did not significantly change in Group H after the same
follow-up period (1.6 0.9 vs. 1.9 1.7 mg/dl). In conclusion, a
significant (27.7%) proportion of NS patients develop TD; the appear-
ance of such complication is associated with a rapid progression of renal
insufficiency.
Long-term beneficial effects of ACE inhibition on renal function in
patients with nephrotic proteinuria. M. Praga, E. Herndndez, C. Mon-
toyo, A. Andrés, L.M. Ruilope, J.M. Morales, T. Ortuho, J.L. Rodicio,
Hospital "12 de Octubre," Madrid, Spain. ACE inhibitors can reduce
proteinuria in several nondiabetic nephropathies. However, no studies
have demonstrated if this antiproteinuric effect modifies the progression
of renal insufficiency. We have treated 46 patients with nephrotic
proteinuria with captopril, an ACE inhibitor. Follow-up prior to capto-
pril treatment was 12 to 18 months. At the end of follow-up after
captopril introduction (24.4 7.6 months), proteinuria had decreased
from 6.3 2.5 to 3.9 3.1 g/day (P < 0.001), with a mean fall of 45
28%. The proteinuria decrease was higher in patients with refiux
nephropathy, proteinuria associated with reduction of renal mass,
inactive crescentic glomerulonephritis, nephroangioesclerosis and IgA
nephropathy, whereas patients with membranous glomerulonephritis
and idiopathic focal glomeruloescierosis showed a poorer response.
Patients were separated according to a proteinuria reduction greater
(Group A, 23 patients) or lower (Group B, 23 patients) than 45% of the
initial value. Renal function remained stable in Group A after the
introduction of captopril [creatinine clearance Ccr 52 28 to 48 31
mum, P NS], whereas it continued to deteriorate in Group B as in the
pretreatment period (Ce,. 60 29 to 44 31 mum, P < 0.01).
Proteinuria decrease did not show correlation with initial renal function,
initial proteinuria values, blood pressure variations, nor captopril
doses. Group A patients had serum total proteins significantly higher
than Group B (62 5 vs. 56 11 g/liter, P < 0.05). Serum cholesterol
significantly decreased in both Groups. In conclusion, a significant
proteinuric effect of captopril (in excess of 45%) is accompanied by an
arrest in the progression of renal failure.
Wegener's granulomatosis with initial renal involvement. C. Campo,
A. Mazuecos, M. Praga, R. Sanchez, J.R. Mosquera, J.L. Rodicio,
Hospital "12 de Octubre," Madrid, Spain. Respiratory involvement is
the most common presentation in Wegener's granulomatosis (WG).
Some patients have been described in which renal involvement was the
initial symptomatology. We have revised our experience with WG
patients in the period 1978 to 1989. Ten cases (6 females, 4 males; mean
age 59.6 9.5 years) have been diagnosed. Five out of them (Group I)
presented with renal involvement without extrarrenal symptoms. In the
other 5 cases (Group II), renal involvement coincided with respiratory
symptoms or a previous history of non-renal involvement was obtained.
In Group I patients, the clinical presentation was an acute renal failure
and the diagnosis was established because of the presence in renal
biopsies of characteristic periglomerular granulomas. In this group, 3
patients did not show any extrarrenal involvement of the disease
throughout their clinical course. However, one of them, who did not
receive immunosuppressive treatment and started on chronic hemodi-
alysis, presented Il years later with typical pulmonary nodules, nasal
involvement and ANCA positivity. Every patient but one was treated
with prednisone and cyclophosphamide. Renal function recovery was
obtained in 7 cases. Four of them remained stabilized but the other 3
patients presented a progressive decrease of their renal function and
started dialysis 2 to 4 years later. There were no differences in the
evolution between Group I and II patients: Three patients out of the 7
that recovered renal function after the treatment pertained to Group I.
The most frequent histological abnormalities on renal biopsies were
glomerular crescents (observed in 90% of specimens) and periglomer-
ular granulomas (in 70%). In conclusion, initial renal involvement in
WG is not an unusual feature in our experience; in some of these
patients, no extrarrenal involvement is observed throughout evolution
and the diagnosis should be made by the presence of characteristic
periglomerular granulomas.
Epidemiology of renal disease in Galicia during the last two decades.
Interhospital Group for Epidemiological Studies on Nephropathies in
Galicia, Spain. Renal biopsies were performed in 1,466 patients in
Galicia during the last two decades. Diagnosis, year of biopsy and age
(more or less than 15 years) were analyzed. Results were compared
with the Spanish Registry. The incidence of renal pathology (new
cases/year/million of habitants) in total population fluctuated around 30
(22—38), higher in adults (34) than in children (16). Glomerular pathology
was observed in 85% of patients. Minimal changes (16%) and IgA
nephropathy (14%) were the most common diseases among the whole
population; this order was reversed in adults. Children were more
affected by minimal changes (32%) and diffuse proliferative mesangial
GN (18%). A similar decrease of membranoproliferative GN and
increase of IgA nephropathy, membranous GN and extracapillary GN
(slightly more common in Galicia) were observed when compared with
the Spanish Registry. Within secondary renal disease in adults, lupus
(35%), amyloidosis (19%) and vasculitis (17%) predominated, while P.
Henoch (48%) was more common in children. Benign nephrosclerosis
(60%) and hemolytic uremic syndrome (24%) in adults, and the latter in
children (48%) were the vascular diseases observed. Interstitial nephrop-
athies constituted 7% of the total of biopsies, being rare in children, and
presenting with the same frequency as acute or chronic in adults. Only
1% of biopsies were diagnosed of hereditary nephropathy (9 adults, 5
children). Our conclusion is that glomerulopathies have a similar
incidence in Galicia and in Spain. Initial data on the epidemiology of
biopsy-proven vascular, interstitial and hereditary nephropathies are
reported.
Bone aluminum content in patients with advanced renal failure (ARF)
not submitted to hemodialysis. J. Bestard, D. Tordn, R. Coil, J. Gascó,
A. Morey, E. Fuentespina, and AS. Aiarcon, Nephroiogy and Bio-
chemistry Lab, Hospital S. Dureta, Palma de Maliorca, Spain. The
association between high bone aluminum content and aluminum bone
diseases is well known. Patients with advanced renal failure (ARF)
were treated with aluminum-containing compounds for phosphate con-
trol, and with a diminished renal function could accumulate aluminum
in bones. Our purpose was to investigate the total aluminum content in
these patients. Iliac bone samples obtained from 34 patients with ARF
(Ccr 24 12 mI/mm) were examined by electrothermal atomic absorp-
tion spectrophotometry using a wet digestion with nitric acid. Our
normal range from normal subjects was 5.29 + 3.5 g/g. The 34 patients
were divided into three groups: I = 20 patients with aluminum content
of 4.7 2.8 g/g (r 1.1—11.1); II = 9 patients with 19.9 4 jsg/g (r
12.3—23) and ILL = 5 patients with a content of 36.6 9 ig/g (r
29.4—51.4). We compared these groups with illness time, quantity of
aluminum prescribed, serum aluminum, bone histology with aluminum
staining, using the Stet-view statistical programs. We obtained good
correlations with the aluminum prescribed (P < 0.05), evolution time of
renal failure (P < 0.05) and bone aluminum staining (P < 0.01); no
correlations were obtained with plasma aluminum and bone histology.
In this series of patients with advanced renal failure, 40% of them had
a bone aluminum content greater than normal individuals. The alumi-
num prescribed as a phosphate binder led to a progressive accumulation
of this element in bones. These patients were not exposed to dialysis,
and for this reason they don't have the possibility of contamination with
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aluminum bath. The long term consequences of this progressive depo-
sition of aluminum in bone are probably different expressions of the
aluminum bone disease.
Evaluation of hemodialysis vascular access by digital intra-venous
arteriography substraction (DIVAS): Correlation with clinical and kinetic
assessment. F. de Alvaro, A. Mendiluce, F. Dapena, A. Macid, N.S.
Jabari, J. Bustamene, and E. Arreba, Spain. Problems associated with
vascular accesses represent the main complication in HD patients.
There is a lack of non-aggressive procedures for preventive evaluation
of the fistulas that would, otherwise, allow early treatment, saving
many vascular accesses at risk. We studied with DIVAS 36 non-
selected patients on HD, 17 M and 19 F, aged 55.7 16.1, with vascular
access for 57.6 41.3 months (range 7—152) and compared: (1) level of
recirculation; (2) difficulty to reach the prescribed flow; (3) venous
pressure at 300 and 200 mI/mm blood flow and (5) clinical evaluation of
the fistula. Findings were as follows: (a) stenosis: 83% single stenosis
[68% at the arterial anastomosis, 29% in the puncture area and 2.8% at
the distal veno-arterial anastomosis (prosthetic fistula)] and 14% multi-
ple stenosis, with levels of stenosis >50% in 58% and >75% in 33%; (b)
calcification in the puncture area in 20%, and (c) aneurismatic dilata-
tions in 22%. There were no complications associated with the proce-
dure. There were neither correlation between levels of stenosis founded
by DIVAS and levels of recirculation, venous pressure, clinical assess-
ment, nor with the usage of EPO. Incidence of stenosis was lower and
span time of fistulas higher when those were done by staff members.
Surgical restoration was carried out in 2 cases (5.6%) and later graft
thrombosis in other 2. 11 patients are waiting for surgical reconstruc-
tion. Our conclusions were: (1) Clinical and analytical methods are
slightly sensitive to detect and prevent early damage in the fistulas; (2)
DIVAS has shown to be a sensitive, specific and non-aggressive method
to demonstrate early fistula damage; (3) Surgical experience has a high
influence in the span time and complications of vascular accesses; and
(4) Other nonaggressive and more sensitive methods should be evalu-
ated.
Peritoneal dialysis adequacy: Does KT/V have the same predictive value
as in hemodialysis? A multicenter study. F. de Alvaro, F. Alvarez-Ude,
A. Bajo, A. Vigil, F. Coronel, R. Selgas, Spain. No homogeneous
criteria for CAPD prescription have been established. Using the urea
kinetic parameters applied in HD most patients on CAPD would be
underdialyzed, though there are no significant differences between both
techniques with regard to morbidity and mortality, In a first study, we
evaluated 127 non-selected patients (pts). 24% had a weekly KT/V
(KT/Vw) < 1.7; 53% between 1.7 and 2.3, and 23% KT/Vw> 1.7 and
PCRN > 1.1 g/kglday. There was a positive correlation between
KT/Vw and PCRN (r = 0.57, P <0.01), suggesting different morbidity,
hospitalization and mortality for these two groups. To corroborate that
appreciation, we followed for one year 102 non-selected pts, 48 M, 54 F,
aged 54.6 14.8, in CAPD 0—120 months (mean 24.4 23.9.8). There
was a significant drop in Kr, KT/Vw and PCRN (all P < 0.01) without
variation in serum BUN and creatinine. Serum albumin fell from 3.7
0.5 to 3.5 0.6 (P < 0.001). There was no correlation between KT/V
and PCRN and hospitalization, clinical symptoms or biochemical
findings. Patients who died had a lower KT/V and PCRN, but at the
same time they were older and had higher comorbidity, thus making
impossible to conclude if there was or it was not a correlation between
KT/V and PCRN and the exitus. Patients with KT/V < 1.7 and those
with PCRN <0.8 present higher index of symptomatology related with
dialysis inadequacy. Similar results were found in patients with PCRN
<0.8 g/kg/day. In summary, we conclude that on CAPD, in contrast to
what happens on HD, there doesn't seem to exist a clear relationship
between dialysis prescription assessed by urea kinetic analysis and
mortality, hospitalization rates and biochemical or clinical parameters.
A strict prescription of CAPD depending on KT/V values wouldn't be
justified. Further and larger studies are required in order to find more
significant factors.
Bone histomorphometry of insulin-treated diabetics in dialysis versus
non-diabetic uremics. X. Cuevas, J. Aubia, J. Bosch, L.L. Marinoso,
and S. Serrano, Nephrology and Pathology Departments, Hospital
Terrassa, H. L'Esperanca and Hospital Del Mar Barcelona, Spain.
Diabetics on dialysis have a lower rate and severity of secondary
hyperparathyroidism when compared with non-diabetic uremics. Com-
parative bone histomorphometric studies of such phenomena are scarce
and report only a short series of patients. Our aim was to describe
histomorphometric values of insulin-treated diabetics and their relation-
ships with those of uremic and normal subjects, Biochemistries (Ca, P,
alk. phosphatases, aluminemia), hormones (PTH, calcitonin-Ct) and
accumulative aluminum doses were measured in 40 diabetic patients on
dialysis who underwent transiliac bone biopsy, (23 of them after
tetracycline labeling). The control group consisted of 33 uremic non-
diabetic patients, of similar age, sex and duration of dialysis; 17 with
tetracycline labeling. Diabetics showed significantly lower values of
PTH and Ct-trabecular bone volume and formation. Resorption param-
eters were significantly lower in diabetics. Trabecular surfaces stained
by aluminum were similar in diabetics and in non-diabetics. The 30.4%
of diabetics in front of 17.4% of non-diabetics had an adynamic
behavior. In conclusion: (I) Diabetic-dialysis patients have a lower rate
of bone remodeling when compared with non-diabetic uremics. (2) In
this series, diabetics did not show any increase in aluminum trabecular
bone surfaces, compared with the amount found in control uremics.
Study of the profile lipidic and nutritional status according to the
dialytic treatment utilized in uremic patients. J. Boner, M. Borrds, J.
Bonal, J. Teixidd, F. Cofdn, R. Romero, and A. Caralps, Renal Unit,
University Hospital "Germans Trias I Pujol," Badalona, Spain. Cor-
onary heart disease (C.H.D.) is the primary cause of death in dialyzed
patients. It is known that hyperlipemia accelerates atherosclerosis, and
this has a trend towards C.H.D. The objective of the present study has
been to compare the dialytic treatments, and if they can influence the
lipid abnormality and nutritional status of the uremic patients. The
study included 18 patients on hemodialysis (HD), and 18 patients on
continuous ambulatory peritoneal dialysis (C.A.P.D.), affecting diverse
chronic nephropathies, except for the diabetics. We studied the follow-
ing parameters: Sex, age, time on dialysis, body mass index (B.M.I.)
bicipital arm circumference (B.A.C.), tricipital skinfold triglycerides
(tgldes), total-cholesterol and its fractions, atherogenic index (A.I.),
total proteins (TP), hematocrit (Hct) and parathyroidhormone (PTH).
The nutritious diets were the same in the patients on HD and CAPD.
The Student t-test and the relationship tests were used for statistical
analysis with significative value to part of one P < 0.05. There were no
objectified significative differences between the following parameters:
Age, sex, BMI, BAC, TSF, T-chol, tgldes, Hct for the Student t-test.
There were objective differences, statistically significant, for the Stu-
dent t-test in the following parameters:
LDL-chol Al PTH P
HD 2.68 1.11 3.93 2.19 178.05 150.06 <0.05
CAPD 3.63 1.57 5.66 2.07 458.05 103.52 <0.05
Moreover, we found significant relationships independently of the
dialytic treatment in the following parameters:
B.M.I. and tgldes r = 0.35 P < 0.05
B.M.I. and A.I. r = 0.33 P < 0.05
TPandHct r0,55 P<0.05
Time on dialytic treatment r = 0.47 P < 0.05
and T-chol.
Our conclusions were: (1) on CAPD there exists a bigger augment
LDL-chol, Al., and PTH in respect to HD. (2) There exists indepen-
dently of the dialytic treatment a positive and significant relationship
between BMI and tgldes, BMI and Al and TP with Hct. (3) There exists
a negative and significant relationship between the length of time on
treatment and the T-chol.
Hemorheological parameters of hemodialyzed patients treated with
erythropoietin. J.L. Miguel, C. Solis, M.J. Fernandez, E. Quevedo, F.
Borrego, J. Molano, J.M. Ara, and M.R. Codoceo, Servicios de
Nefrologia, Bioquimica and Hematologia, Hospital La Paz, Madrid,
Spain. The efficiency of recombinant human erythropoietin (rHuEPO)
Abstracts 215
in treating renal anemia has been clearly established. However, some
adverse effects have been attributed to its action, hypertension being
the most frequent of side effects. In this study we analyze the variation
with rHuEPO therapy of some hemorheological parameters which
could be implicated in these effects. Twenty-one hemodialyzed patients
with rHuEPO treatment (group 2) were studied. The period of rHuEPO
administration took over 8 months (t = 16 8 months). The same study
was carried out in 11 hemodialyzed patients without rHuEPO therapy
(group 1). A third group consisted of 12 normal individuals (group C). In
every group, hematocrit, erythrocyte deformability (filterability), eryth-
rocyte aggregation, and plasma viscosity were measured. Besides these
hemorheological parameters, erythrocyte 2-3 DPG, plasma fibrinogen
and haptoglobin were also determined, due to their influence on the
hemorheological parameters. We found that in group 1 (hematocrit =
28.5 3.5) erythrocyte deformability, haptoglobin and fibrinogen were
within the normal range. 2-3 DPG was higher than in normal group
(group C), (P < 0.01) as well as erythrocyte aggregation (P < 0.05).
Plasma viscosity was above the normal range. There were not signifi-
cant differences between groups 1 and 2, except for the increase in
erythrocyte deformability and decrease in erythrocyte aggregation.
Group 2 had a hematocrit of 34.6 4.6. From these data we deduce that
rHuEPO not only induces quantitative, but also qualitative changes in
the red cell ability to ameliorate its rheological behavior.
Heme metabolism in hemodialyzed patients after recombinant human
erythropoietin therapy. J.L. Miguel Alonso, C. So/is, F. Borrego, E.
Herrero, M.J. Fernandez, M. T. Sanchez, and f.M. Am, S. I'Jefrologia
y Bioquimica, C.S. La Paz, Madrid, Spain. The efficacy of recombinant
human erythropoietin (rHuEPO) in the treatment of anemia of end-
stage renal disease has been clearly established. However, little is
known about the cellular and molecular mechanisms that lead through
its action to a rise of hemoglobin in the treated patients. It has been
postulated that rHuEPO induces uroporphynnogen-1 synthase (URO-
S), one of the enzymes implicated in heme synthesis. In this work, we
have analyzed URO-S and ALA-dehydrase (ALA-D) erythrocyte ac-
tivities in a group of 33 hemodialyzed patients, 22 under rHuEPO
therapy and 11 without this treatment. Levels of erythrocyte protopor-
phyrin were also determined. Eight of the 22 treated patients were
followed during 12 months, with monthly controls during the first 4
months and controls at 8 and 12 months of treatment. In each control
reticulocyte counts and hemoglobin were also estimated. Besides the
txpected hemoglobin rise, we found that reticulocyte count increased
significantly up to the 3rd month of therapy. Protoporphyrin increased
in the 4th month of treatment, simultaneously with the transient
I'erropenia. URO-S activity was within normal range in hemodialyzed
patients and was not modified with the therapy. ALA-D levels were
very low, compared to normal values (P < 0.001), and did not increase
with rHuEPO therapy. The patients dialyzed with PAN membranes had
an ALA-D activity significantly higher than those dialyzed with Cu-
prophane membranes (P < 0.05). We partly attribute the low ALA-D
activity to the known disturbances that hemodialyzed patients have in
Al and Zn serum levels. As a matter of fact, we observed that in most
ases ALA-D activity turned to normal values when Zn was added in
he assay procedure. The differences of ALA-D activity found with
oth types of membranes suggest the possibility that middle molecules
:ould act as inhibitors of the enzyme.
Circadian rhythm of blood pressure in patients with chronic renal
ailure and patients on hemodialysis. C. Gámez, M. Rivera, J.L. Teruel,
1. Pascual, M. Bermejo, C. Quereda, and J. Ortuño, Department of
\Tephro/ogy, Hospital Ramón y Cajal, Madrid, Spain. Circadian
rhythm of blood pressure is present in patients with essential hyperten-
;ion (HT) and is not changed by pharmacologic therapy. However, it is
ibsent in several forms of secondary HT. We studied the blood
,ressure profile in three groups of subjects. Group A: 30 patients with
ssential HT and normal renal function; Group B: 13 hypertensive
)atients with chronic renal failure; Group C: 17 hypertensive patients
n chronic hemodialysis. The three groups had similar age, sex, and
)asal blood pressure and all patients needed antihypertensive treat-
nent. Automatic blood pressure recordings were performed for 24 hr in
iemodialysis patients the day after midweek dialysis session. Mean
:alculations of systolic, diastolic and mean BP and heart rate during
daytime (8 a.m. to 10 pm) and night time (10 p.m. to 8 am.) and the
difference between both periods (day to night) were obtained for each
patient and each group.
Daytime-night time difference mm Hg
Mean HP Heart rate
Group A 15.86 4.9 10.03 5.6
Group B 8.58 5.4 5.05 4
Group C 1.90 8.9 2.75 4.4
Daytime and night time BP values were significantly different for
subjects from groups A and B (P < 0.001), but not for group C. The
values of the daytime-nighttime difference were significantly different
among the three groups (P < 0.01) for systolic, diastolic, mean BP and
heart rate. In conclusion, chronic renal failure causes a loss of nocturnal
decline of BP and heart rate which seems to be progressive with the
evolution of renal disease.
Acute arterial occlusion (AAO) as a cause of acute renal failure (ARF):
Value of urinary parameters. C. Gámez, F. Liaño, P. Serrano, J.
Pascual, fL. Teruel, J.J. Villafruela, J. Sabater, and J. Ortuño,
Department of Nephrology, Hospital Ramon y Cajal, Madrid, Spain.
Bilateral AAO or unilateral AAO of a solitary kidney (total AAO)
represents nephrological emergencies. Even in this situation small
amounts of urine may be present, so differential diagnosis may be done
with other conditions associated with ARF and arterial pathology,
mainly if oligoanuria is present. We have analyzed initial urinary
parameters of 10 patients with total AAO (group I), 10 with unilateral
renal AAO (II) and 10 with ARF following aortic surgery (III). All
patients had arteriographic studies.
NaU K U Urea U CrU OsmU
Group I 135 6 8 1 161 29 9 3 316 8
Group II 51 11 63 16 1202 336 99 39 550 109
Group III 75 8 33 1 384 77 46 2 330 11
EFNa was 98 15, 7 3, 6 I %, respectively
X SEM, P < 0.05 vs. II, III. P < 0.05 vs. III
Interestingly, serum values in group I (Na 135, K 4.9, Urea 148, Cr 7,
Osm 310) were similar to urinary concentration. However, values in the
other groups were significantly different. These previously unreported
findings do not exclude favorable outcome if treated early. An EFNa
near 100% observed in these cases suggest abolition of aerobic kidney
metabolism. When urinary and serum parameters are similar, a total
AAO should be performed in order to start treatment.
Erythropoietin (EPO) and arterial pressure (AP): Evidence from two
patient populations. fL. Teruel, J. Pascual, C. Gámez, R. Marcén, M.
Ferrnindez, P. Serrano, and J. Ortuno, Servicio de NefrologIa, Hospi-
tal Ramón y Cajal, Madrid, Spain. Increased AP is the major secondary
effect observed after EPO treatment. However, partial correction of
anemia may also have beneficial effects on AP as cardiac output
decreases and sympathetic stimulation is ameliorated. We have studied
AP evolution in 26 hemodialysis (HD) patients (hemoglobin [Hb] 6.5
1 g/dl) treated with EPO during one year. Trying to quantitate impact of
EPO on antihypertensive treatment, we established a therapeutic index
(TI) with specific punctuation for each drug and dose. Twenty patients
on HD with invariable Hb (initial 9.6 1.9 g/dl) and without specific
treatment for anemia were also studied during a year and served as
control group. In controls, mean AP, prevalence of hypertension and TI
in the hypertensive subgroup did not change during the study period. In
EPO-treated patients, mean AP and prevalence of hypertension showed
a slow and steady decrease. However, in the subgroup of patients who
remained hypertensive, hypertension control was much more difficult:
TI precociously increased (53% at one month, when Hb increase was
minimal: 0.8 g/dl), and remained elevated during the year studied. EPO
treatment appears to have a dual effect on AP in HD patients: In a
subgroup of patients partial correction of anemia is associated with a
progressive decrease in AP. In the other subgroup, EPO induces a
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precocious worsening in AP control, observed when Hb increase is
minimal, suggesting a direct or induced vasopressor effect,
Late addition of azathioprine (AZA) to treatment with cyclosporine
prednisone (Cs-P) in renal transplantation: Long-term benefits. J. Pas-
cual, R. Marcén, L. Orofino, C. Quereda, P. Serrano, C. Gdmez, F.
Mampaso, J.J. Villafruela, and J. Ortuno, Servicio de NefrologIa,
Hospital Rarnón y Cajal, Madrid, Spain. Late deterioration of renal
function is frequent in renal transplant patients treated with Cs-P, and
definitive treatment schedules have not been developed. We have
added Aza (1—2 mg/kg/day) to 31 patients on Cs-P 11.3 9.9 months
after transplant: Group I (N = 10) had chronic renal function deterio-
ration (Se. 6 months before addition 193 79 smol/liter vs. 255 61
smol/liter at addition of Aza, P < 0.05) due to chronic rejection, Group
II (N = 11) had repeated or severe acute rejection episodes and Group
III (N = 10) had Cs toxicity despite drug tapering. In I, renal function
improved at a rate of 0.05 0.12 Sr during the entire follow-up of 25
months (P < 0.01) with stable Cs levels. In II response was worse but
the rate of declining renal function before Aza (—0.15 0.13 Sr 1) was
stopped after Aza. In HI, there was very good response, as 8 patients
improved graft function (211 52 vs. 167 26 smol/l, P < 0.05) with
significantly decreased Cs doses and levels. After 23 12 months of
follow-up post-Aza, 15 patients had improved graft function, 2 were
stable, 11 had worsened (9 on dialysis) and 3 had died (pneumonia,
myocardial infarction and brain astrocytoma). Delayed addition of Aza
to ongoing Cs-P protocol can improve chronic graft dysfunction sec-
ondary to chronic rejection or Cs toxicity, with long-term benefits in a
high proportion of patients.
Erythropoietin (EPO) induces an increase in progenitor CD34+ cells in
patients on hemodialysis (HD). J. Pascual, A. Sureda, J.L. Teruel, F.
Liaño, E. Roldán, J.A. Brieva, andJ. Ortuño, Hospital RamOn y Cajal,
Madrid, Spain. Little information is available on the effects of EPO on
circulating hemopoietic progenitor cells in HD patients. Available
studies assess variations in colony-forming units in vitro, which lack
enough reproducibility. CD34+ cells are progenitor cells capable of
restoring complete hemopoiesis in irradiated baboons. To assess the
unknown impact in vivo of EPO on progenitor cells represented by
CD34+ cells, we have studied 10 HD patients, 4 males and 6 females,
aged 38 23 years, time on HD 19 + 12 moths who began treatment
with EPO (150 U/kg/week i.v.). Peripheral blood CD34+ cells were
measured before and after starting treatment on a weekly basis with
flow cytometric analysis (Epics Profile) in patients and 7 healthy
controls. Evolution of hemoglobin, corrected reticulocyte counts and
percentage of CD34+ cells are depicted in the table.
Hb gidi Retic CD34+
Basal 7.4 0.6 0.54 0.1 0.1 0.1
I week 7.8 0.3 0.73 0.34 1.0 0.4
2 weeks 8.5 0.6a 0.88 O.21a 1.6 0.sa
3 weeks 8.8 0.4k 0.69 0.19 1.7 o.4
4 weeks 9.2 0.8a 0.65 0.20 1.3 o.4
5 weeks 9.8 0.8a 0.71 0.29 0.8 o.2
a p < 0.05 with respect to basal values (ANOVA)
We conclude that multipotent progenitor cellular compartment in bone
marrow responds to therapeutic doses of EPO in HD patients, resulting
in selective peripheral erythroid expansion.
Which is the most adequate moment to perform echocardiographic
studies in hemodialysis (lID)? Need for uniform criteria. J.L. Teruel, J.
Pascual, C. Gdmez, F. Liaño, J.L. Moya. M. Jiménez, and J. Ortuño,
Hospital Ramón y Cajal, Madrid, Spain. Cardiovascular disease is the
most important cause of mortality in HD patients. Consequently, a
great number of echocardiographic studies are undertaken in these
patients. Most of them are performed the day after a HD session and
neither the weight at that moment nor the relationship between this
weight and lean body weight are taken into account. In a group of 6
anuric HD patients we have performed echocardiographic studies in
two situations: (A) Dry weight (immediately post-HD) and (B) After 39
hours and free ingestion (weights 63.3 ii vs. 66.2 II kg, P < 0.001)
to assess the influence of volume overload on functional and anatomic
cardiac parameters. Progressive overhydration and interdialytic weight
gain produced significant increases in systolic volume (78 25 vs. 102
30 ml, 30%, P < 0.01), cardiac output (6.15 1.46 vs. 7.97 2.24
mI/mm, 29%, P < 0.01), left ventricular (LV) diastolic diameter (4.9
0.9 vs. 5.5 0.9 cm, l2%, P < 0.008), LV shortening fraction (33.5
8.6 vs. 39.1 1.7%, M7%, P <0.001) and LV mass (265 53 vs. 310
68 grams, l7%, P < 0.01) without important changes in septum and
LV posterior wall thicknesses. Volume overload in HD patients causes
per se great variations in cardiac morphology and function. Cardiologic
examinations need to be performed in identical volume load situation to
compare results reliably. The best moment could be after midweek HD
session when the patient is at theoretical lean body weight.
Erythropoietln-deficient anemia in renal transplant recipients with
preserved renal function. J.J. Plaza, G. Blum, A. Ortiz, M. Moliz, L.
Hernando, and C. Caramelo, Servicio de Nefrologia, FundaciOn
Jiménez D(az, Madrid, Spain. Successful renal transplantation corrects
uremic anemia through improved erythropoietin (EPO) synthesis, al-
though occasional patients suffer from persistent anemia. Thirty-six
patients transplanted in 1985 to 1989 had normal renal function (serum
creatinine  1.5 mg/dl and/or C. >50 mum) in October 1990. Four
(11%) of these had anemia (Hb <11 g/dl): 3 females and I male, mean
age 36 (range 30—46) years, who had received a renal graft 2 to 5 years
earlier. All had received multiple blood transfusions while on dialysis.
Normal values in the laboratory data included blood smear, serum iron,
iron binding capacity, serum and erythrocyte folates, serum Bl2 and
haptoglobin. Serum ferritin was normal or high. PTH was elevated.
Serum EPO levels (10.9 1 U/liter) were low for the degree of anemia
(Hb 10.2 0.6 g/dl). rHuEPO at an initial dose of 40 U/kg s.c. thrice a
week was begun. After three months of therapy mean Hb was 12.6
0.6 g/dl, mean rHuEPO dose was 20 3 U/kg/dose and no changes in
renal function or blood pressure were evidenced, although one patient
required antihypertensive therapy. After withdrawal of rHuEPO, Hb
returned to baseline values. In summary, EPO synthesis may be
inadequate for the degree of anemia in a subset of renal transplant
recipients with a well functioning graft, and exogenous rHuEPO cor-
rects anemia in these patients.
Hypocalciuria in early stages of kidney injury. I. Martinez, R. Sara-
cho, R. Aguiree, R. Gonzalez, andJ. Montenegro, Nefrologla, Hospi-
tal de Galdakao, Galddcano, Spain. Hypocalciuria is frequently seen in
patients with renal failure. Furthermore, it is well known that a loss of
50% of renal mass can display a normal creatinine clearance. The aim of
this paper is to establish that hypocalciuria can be a marker of renal
injury before the decrease of creatinine clearance. We selected 2
groups: (A) 37 patients with a well known renal illness, biopsy findings
of glomerular esclerosis or loss of renal mass confirmed by X-ray (IVP),
and a creatinine clearance greater than 100 mI/mm; (B) 57 normal
subjects. In both groups subjects with lithiasis or under diuretic
treatment were excluded. Ordinary tests of renal function with recol-
lection of urine during 24 hours were undertaken in both groups. Crude
analysis revealed a lesser value of calciuria in group A (125 mg/day)
than in group B (236 mg/day) P < 0.0007 (Student's t-test). Calciuria!
weight quotient showed similar results; group A: 2.34 mg/kg/day and
group B: 3.49 mg/kg/day (P = 0.0003). Using multiple linear regression
analysis we adjusted by the following variables: age, sex, natriuresis,
protein catabolic rate and proteinuria, and we observed striking differ-
ences in calciuria between both groups. We found that patients in group
A had values of calciurialweight inferior to group B in 1.28 mg/kg/day (P
= 0.00017). Values of serum ionic calcium and phosphate and RTP were
similar in both groups. Fractional excretion of calcium was 2.38% in
group A vs. 3.5% in group B, P < 0.05. Using a cut-off point of 2.5
mg/kg/day in calciuria values, we found 83% of sensitivity and 59% of
specificity for renal injury diagnosis. We conclude that hypocalciuria is
a good marker of early renal injury before creatinine clearance de-
creases.
Cytomegalovirus (CMV) in renal transplantation: serologic diagnosis
and clinical features. P. Gómez Ullate, J.J. Amenabar, R.l. Muñoz, J.
Corral, J. Ocharan, G. Garcia Erauzquin, M. Urberuaga, and I.
Lampreabe, Departments of Nephrology and Microbiology, Hospital
de Cruces, Bilbao, Spain. CMV activation was studied by 1gM antibody
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capture assay and/or antibody rise by complement fixation technique in
268 patients (pts) that received a renal graft from February 1986 to April
1991. Eighty-three pts (3 1%) had CMV activation during the studied
period. In this group we assessed several features related to CMV.
Their mean age was 39.4 years (range 8—62), 10 pts (15%) were
retransplant. Acute graft rejection occurred in 48%, in 73% of patients
receiving double immunosuppressive therapy (cyclosporine and pred-
nisone) and in 26% of those receiving triple therapy (cyclosporine,
prednisone and azathioprine). Four patients were treated with OKT3 in
corticoresistant acute graft rejection. There were no differences in these
proportions when compared to those from the control group. Graft
survival was 85% and patient survival was 91% (87 and 96%, respec-
tively, in control group, non-significant differences). In 47 patients
(70%) CMV was detected in the first six months (mean 68 days) and in
21(30%) CMV was detected later than six months (mean 481 days). As
for CMV related pathology, 35% patients had a concurrent infection,
usually mild, 3 cases were diagnosed as having pulmonary tuberculosis,
2 developed herpes zoster infection and one case had bullous pemphi-
goid. Fever appeared in 29%, liver disease in 22%, pneumonia in 8.4%
and leukopenia in 7.2%. There were no cases of gastrointestinal
hemorrhage, retinitis or tumors. One patient died as a result of CMV
complications. Our conclusions were as follows: (1) A CMV activation
occurred in 31% of patients. (2) CMV activation was detected in the first
6 months in 70% of cases. (3) Patients with CMV activation did not have
a higher incidence rate of acute graft rejection. (4) Patient and graft
survival were similar in both groups. (5) CMV related clinical findings
were more frequent in the CMV activation group, but in most cases
pathology was mild. (6) We suggest that prophylactic high-titered CMV
immune globulin should only be administered to patients susceptible to
primary CMV infection.
Late follow-up of percutaneous transluminal angioplasty in transplant
renal artery stenosis. J.J, Amenabar, P. GOmez-Ullate, S. Zarrage, G.
Garcia Erauzkin, M.A. Antoflana, F. Munoz, and I. Lampreabe,
Departments of Nephrology and Radiology, Hospital de Cruces, Spain.
Between 1985 and 1988, fifteen patients (8 males, 7 females) underwent
16 percutaneous transluminal angioplathies (PTA). All patients received
aspirin and dipyndamol for 6 months. The anastomosis of the allograft
artery to host was performed with aorta patch to the common iliac
artery in 14 cases and to the external iliac artery in 1, end to side in all
the cases. Eleven patients underwent PTA within one year of the
transplant. Prior to PTA, 10 patients showed hypertension, 4 hyperten-
sion with renal failure and 1 renal failure. The site of stenosis was: Main
renal artery 12 cases (75%), at the anastomosis 2 (12.5%) and native
iliac artery 2 (12.5%). The degree of stenosis was 75% in 5 cases, 50 to
75% in 9 and 50% in 2 stenosis. In 13 cases (8 1%) the stenosis was focal
(1 cm). In 7 patients angiography was repeated 3 to 4 years after PTA.
Dilation was immediately successful in 11 stenosis, partial in 3 and
failed in 2. Morbidity attributed to PTA included development of 3 small
infarctions, I thrombosis of a polar renal artery and 1 thrombosis of the
renal artery with graft loss. Eleven patients with hypertension pre-PTA
were evaluated at 6 months and it was noted that 2 patients were cured
(18%), 6 improved (55%) and 3 (27%) remained unchanged in their
blood pressure. Follow-up of 3 to 4 years was available in 7 patients:
HTA was cured in 4 cases (57%), improved in 2 (29%) and unchanged
in 1 (14%). The repeated angiography performed in these patients
documented recurrent stenosis in only I case. PTA is recommended as
a relatively safe and convenient procedure in the renal allograft recip-
ient with renovascular hypertension.
Variations in patient urea distribution volume (V) during hemodialysis.
F. Maduell, F. Miralles*, F. Siguenza, A. Caridad, and E. Ochoa, S.
Nefrologla y BioquImica Hospital de Xdtiva, Spain. The urea kinetic
model is used to calculate and monitor the dialysis and dietary protein
prescriptions. Because V is difficult to measure, a 58% of body weight
is usually used despite total body water, and may vary between 40 to
70% of body weight, In this study we have calculated V by a precise
method of direct quantification of urea (Barth RH Nephron 50: 191,
1988), and have validated if dialysis characteristics modified V. Ten
patients, 5 males and 5 females, with end-stage renal failure on
thrice-weekly hemodialysis (3 hour/session) without renal function
were studied. All dialysate was collected in a graduate 120-liter tank.
Urea concentration in blood and dialysate were measured hourly and V
calculated. In each patient 6 hemodialyses were performed in which
blood flow (250 or 350 mI/mn), ultrafiltration (0.5 or 1.5 l/hr), buffer
(bicarbonate or acetate) or membrane (cuprophane or AN69) were
varied. In all patients V increased progressively during hemodialysis,
43.1 7.3% of body weight during the first hour, 52.04 7.8% the
second hour and 57.3 7.5% in the third hour. V varied between 40 to
69% of body weight, but in each patient this value was practically
constant in the 6 situations studied. No differences were observed when
blood flow, ultrafiltration, buffer or membrane were changed. Our
conclusions were: (I) V is a value with individual variability and it is
constant for any patient. V increases along with the dialysis and
suggests that urea kinetic is bi- or multicompartmental.
Low molecular weight heparin (LMWH) in chronic hemodialysis (HD):
Preliminary dose study and clinical outcome. F. Siguenza, E. Grau, F.
Maduell, A. Caridad, and E. Pastor, Departments of Nephrology and
Hematology, Hospital SVS Xdtiva, Spain. In a previous study with
LMWH, Anti-Xa levels above 0.4 U/mI at the end of HD appeared to be
adequate to minimize thrombus formation in the extracorporeal circuit.
Fourteen patients received raising doses of fragmin (2500, 5000, 7500 U
anti-Xa). Each patient was injected endovenously with each dose of
Fragmin, with a 7-day period between injections and the day after HD.
Blood was drawn before e.v. injection and 3 hours after dosing and
aNTT, TT and anti-Xa were performed. The mean so anti-Xa values
at 3 hr were: 2500 U: 0.2 0.09 U/mI; 5000 U: 0.43 0.13 U/mI; 7500
U: 0.85 0.09 U/mI. All the patients from the preliminary study were
assigned to receive fragmin in a single bolus injection at the beginning
of HD (the lower dose that produced anti-Xa> 0.4 U/mI): i: 2500 U; 12:
5000 U; 1: 7500 U. 206 HD sessions under these conditions were
analyzed. The frequency of clotting events was: clot in the filter and
bubble trap 1 (0.48%), and clot in the bubble trap 3 (1.45%). No
modifications were needed in the fragmin regimen. APTT, TT and
anti-Xa were determined before and at the end (3 hr) of HD:
aPTT
Prel.
(sec)
HD Prel.
TT (sec)
HD
anti-Xa
Prel.
(U/mI)
HD
37.8 33.9 58.7 71.9 0.43 0.7
3,9 3,4 34 34.2 0.13 0,lla
a P < 0.001 between the preliminary study (prel.) and the HD
sessions.
Our conclusions were: (I) This study confirms the efficacy and toler-
ance of fragmin in a single bolus dose. (2) A dose of 5000 U is
recommended when it is first used and must be adjusted based on
anti-Xa levels. (3) Anti-Xa level at the end of HD were higher than in
the preliminary study.
Characterization of antibodies against cytoplasmic and nuclear ribonu-
cleoproteins by immunoblotting and their prognostic significance in lupus
nephropathy. f.M. LOpez-Gómez, R. Jofre, J. Lopez Longo, M. Rod-
riguez-Mahou, C. Albarracin, F. GOmez, CampderO, F. Valderrabano,
Spain. We studied the relationship between antibodies to nuclear and
cytoplasmic soluble ribonucleoproteins (anti-RNP, anti-Sm, anti-Ro
and anti-La) and the potential evolution of lupus nephropathy. Sera
from 98 patients (88 females and 10 males) with systemic lupus
erythematosus diagnosed by ARA criteria were examined by counter-
immunoelectrophoresis (CIE) and immunoblotting (IB). The age of
patients ranged between 17 to 71 years. Patients were classified in three
groups: 44 patients without nephropathy (group I), 34 patients with
clinical nephropathy (proteinuria and/or microscopic hematuria) and
normal renal function (group II) and 20 patients (group III) with renal
failure (serum creatinine higher than 1.5 mg/dl). Twenty-four patients
had at least one kidney biopsy. The immunoblotting technique recog-
nized three polypeptide components of the RNP particle (70 Kd, A and
C proteins) and two components in the anti-Sm antibodies (BB' and D
proteins). Incidence of both antibodies was significantly higher with lB
than with CIE. However, we did not find any difference between both
methods in detection of antibodies against either anti-Ro (two compo-
nents of 60 and 52 Kd) or anti-La. Antibodies against all the determined
antigens were absent in 16%, 32.3% and 70% in groups I, II and III,
respectively. Anti-RNP and anti-Sm were lesser in group III patients.
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Anti-Ro antibodies showed a negative correlation with severity of lupus
nephropathy and anti-La antibodies has a similar trend. We conclude
that lB is a more sensitive method than C1E to identify antibodies
against cytoplasmic and nuclear soluble antigens, and these antibodies
could be useful to establish the prognosis and management of lupus
nephropathy.
Relevance of glomerular filtration rate and renal plasma flow determi-
nations in the estimation of renal function. C. AlberracIn, f.M. Lopez-
GOmez, R. Jofre, A. Tejedor, P. Dominquez, M.L. Martinez, and F.
Valderrábano, Spain. Glomerular filtration rate (GFR) estimation in
patients with chronic renal insufficiency is of special importance in the
evaluation of progressive loss of renal function. In order to establish the
best routine procedure to measure GFR, we studied 56 patients (age:
19-78 years; 32 M and 39 F) and 68 normal subjects (age: 16—81; 32 M
and 39 F). We determined GFR simultaneously by 24 hours endogenous
creatinine clearance (Car), clearance of TCDTPA and creatinine
clearance estimated from the Cockcroft and Gaults equation (Ccra); and
renal plasma flow by '311-hippuran clearance. Filtration fraction (FF%)
was also calculated. Patients were classified in four groups, according
to the level of renal function measured by 9"-DTPA. The mean
difference 5D are expressed in the table:
Group TCDTFA C. CcrE Ihippuran FF %
I 17.3 7.6 35.1 13.9 28.8 8.9 136.2 50.8 13.8 6.7
II 47.6 8.4 61.5 19.9 49.7 10.4 277.5 77.5 18.9 6.7
III 92.5 8.8 85.9 22,7 70.8 15.7 395.1 77.3 21.5 4.2
IV 139.9 23 119.5 25.7 103.2 25.4 522.9 70.3 26.8 4.2
We found a significant fall in GFR of 16 ml/min/m2 decade in normal
patients older than forty years old. We conclude that both Ccr and CcrE
overestimate GFR in patients with chronic renal insufficiency because
of tubular creatinine secretion related with high serum creatinine levels.
Estimations of GFR by CCR and S9TCDTPA between 60-100 mI/mm
showed similar results. At higher GFR, TCDTPA overestimates
glomerular filtration because of increased isotope tubular secretion
related to RPF rise.
Anaphylactoid reactions in hemodialysis patients with AN69: Role of
ECA inhibitors. A. Galán, R. Perez Garcia, MS. Garcia Vinuesa, F.
Anaya, and F. ValderrObano, Hospital "Gregorio MaraflOn," Madrid,
Spain. Recently, anaphylactoid reactions (AR) have been reported in
patients receiving angiotensin converting enzyme (ACE) inhibitors
while on hemodialysis (HD) with polyacrylonitrile (AN69) dialyzers.
We have revised our experience on this topic during the last year. We
have observed AR in five out of 12 patients using AN69 dialyzer on HD.
They developed facial swelling, with eye, lip and tongue edema, and
hypotension with vomiting; symptoms occurred immediately after the
initiation of the dialytic procedure. They were shifted to polysulfone
(PSF) or cellulose-triacetate (CTA), high-flux dialyzers and no further
episodes were observed, We had 2 out of 16 patients on acetate free
biofiltration, with AN69 dialyzers, receiving ACE inhibitors and no
adverse reaction has been noticed. A single patient, who was on
hemodiafiltration (HDF) during nine months with a high-flux AN69, 1.7
m2, dialyzer and acetate as dialysate buffer, receiving an ACE inhibitor,
captopril 50 mg/day, was shifted on HD with the same dialyzer and
bicarbonate as dialysate buffer. In the first and second HD sessions she
developed an AR. She was shifted onto cuprammonium rayon, which
was sterilized with autoclave, with bicarbonate as dialysate buffer;
captopril has been continued without any further AR. In our dialysis
unit there were 54 patients on HD with polysulfone, cellulose triacetate,
duprophan, cellulose acetate, rayon cuprammonium, and all of them
were free of AR (5 with IECA). We think that this type of adverse
reaction is multifactorial, and this becomes evident when several
factors appear together: AN69, dialysate toxins, back-filtration and
ACE inhibitors. Our findings indicate that ACE inhibitors may increase
anaphylaxis during HD using AN69 membranes, probably by magnifi-
cation of back-filtration reaction, These AR can be avoided by either
shifting to hemodiafiltration or to PSF-CTA high-flux dialyzers.
Prevalence of hepatitis C in hemodialysis patients and kidney trans-
plant receptors. A. GalOn, R. Perez Garcia, M.S. Garcia Vinuesa, F.
Anaya, and F. Valderrdbano, Hospital "Gregorio MaraflOn," Madrid,
Spain. Hepatopathy is a frequent complication among kidney transplant
receptors (TR) and hemodialysis patients (HD). The aim of this study
was to evaluate the prevalence of antibodies against hepatitis C virus
(HCV) (Elisa 2, Ortho®), and hepatitis B virus (HBV), and to study the
relationship between seropositivity HCV/HBV and persistent transam-
inases elevation or clinical evidences of chronic hepatopathy. We have
studied 215 patients, 80 on HD, 135 TR. The mean age of HD patients
was 52 14 years, 57% men and 43% women, mean time on dialysis
was 7 4 years. Sixty-five percent of these patients had received < 10
transfusions, 28% > 10, and the 7% had not received any transfusion.
Fourteen had been previously transplanted. The other 135 patients were
TR, with a mean age of 38 12 years, 60% men and 40% women, a
mean time on dialysis before transplantation of 4 3 years, and a mean
time with functioning graft of 6 2 years. Seventy-two percent of
patients were immunosuppressed with azathioprine and prednisone,
and 28% with cyclosporine and prednisone. The prevalence of HBV,
HCV antibodies was significantly higher (P < 0.05) in HD than in TR
(55% vs. 38%, 32% vs. 18%, irrespectively). We have observed three
cases of HCV acute hepatitis in HD patients without transfusions. The
prevalence of HBV and HCV antibodies was associated with dialysis
permanence and number of transfusions P < —0.001. The prevalence of
persistent transaminase elevation and clinical evidence of chronic
hepatopathy was significantly higher in TR infected with HCV than in
HD patients P < 0.0001). It is concluded that HCV infection is
associated with time on dialysis and number of transfusions. It could be
transmitted by other ways than transfusions; therefore, we should
consider taking preventive measures with HVC seropositive patients.
Seventy-five percent of TR HCV seropositives had clinical evidence of
hepatopathy, and there is evidence about the detrimental effect of
severe hepatopathy on transplant evolution, We should consider if
HVC could become a potential contraindication of kidney transplanta-
tion.
Acetate-free biofiltration (AFB): More than one year follow-up. A.
Galdn, R. Perez Garcia, MS. Vinuesa Garcia, F. Anaya, and F.
ValderrObano, Hospital "Gregorio MarañOn," Madrid, Spain. The aim
of this study was to evaluate the evolution of 16 patients on AFB, a
hemodialfiltration (HDF) technique without buffer in the dialysate,
HCO3Na infusion in postdilution mode, using an AN69 filter. Seven
women and 9 men with a mean age of 51 years were included. Before
the study the mean time on dialysis was 7 5.3 years, and previous
dialysis techniques were HDF in 9 patients, bicarbonate hemodialysis
(HD) in 5 and acetate HD in 2. Membranes previously used were AN69
in 7 patients, polysulfone in 2 and cuprophan in 7. Initially, the method
was uniform in all patients, three times/week, 3 hr/session, blood flow
rate maintained at 350 mI/mm, reinfusion rate of 2 1/hr postdilution of
bicarbonate 1/6 M, polyacrilonitrile hollow fiber hemodialfilter 1.3 s.m.,
dialysis unit Monitral BSM2. Blood pressure, interdialytic weight gain,
incidence of hypotension and other intolerance symptoms, phosphate-
calcium, lipidic and nutritional metabolism, acid-base status, TAC,
PCR, KTV and B2m clearance were systematically obtained and
recorded. The follow-up was more than 12 months in all patients, mean
time 16 months. B2m was significantly reduced. The predialytic bicar-
bonate increased significantly (P < 0.005) from 21.3 23.9 2.7
mEq/liter. We have observed no significant trend to increase the
intersession weight gain. PCR increased from 0.93 0.14 to 1.04 0.29
and KTV decreased, not significantly, from 1.15 0.22 to 1.04 0.26.
We changed the dialyzer in 9 patients, deceasing KTV to a bigger one
of AN69 1.7 s.m., observing a significant increase of KTV and PCR.
The incidence of hypotension was lower in patients on AFB than in
other techniques. We conclude AFB is an adequate short dialysis
technique which improves the acidosis correction and increases the
patient comfort and stability.
Evolution of panel reactive cytotoxic antibodies (PItA) in patients on
dialysis treated with erythropoietin (EPO) R. Perez Garcia, F. Anaya,
M. Garcia de Vinuesa, A. Galan, F. Gomez Campdera, M. Gioco-
echae, and F. Valderrabano, H. General "Gregorio Marañon,"
Madrid, Spain. The aim of this study is to observe the effect of EPO and
the corresponding decrease in transfusion requirements on the rate of
PRA in presensitized patients on dialysis. We have studied PRA every
3 months during 2 years, in patients on dialysis (D) and waiting for
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transplantation (Tx), who began treatment with EPO. Forty-two pa-
tients were included, 24 women and 18 men, mean age 37 (20—58) years,
with a mean time on D of 7 3.8 (2—17) years. The follow-up period was
16.9 5 months, more than 18 months in 28 patients. Study was
stopped in 13 patients: 11 by Tx, I by moving and I by exitus. Major
blood groups of these patients were: 0(52%), A (41%), B (5%), and AB
(2%). Patients have received 18.8 18.7 transfunctions as mean.
Immunization occurred after previous Tx in 16 patients, 1 probably
during pregnancy, and after blood transfusion in 25. Peak PRA was >
75% in 8 patients. Blood transfusion (tr) requirements with EPO
treatment decreasing from a mean of 0.7 I tr/month to 0.3, 0.2, and
0 at first, second and third months after beginning. There was a
significant decline in the rate of PRA (P < 0.01) a year after EPO
initiation. PRA declined from 24.2 26.8% to 13.3 23.5%, P < 0.01.
This change was slow and became significative after 15 months.
Cytotoxic antibodies (CA) induced by transplantation declined less and
later than CA induced by transfusion. During follow-up PRA of
previous Tx patients did not decrease significantly: 35.4% prior to EPO
to 25%. Patients with monospecific CA began with lower CA levels than
bi- and multispecific CA, and declined significantly. EPO treatment of
anemia in patients on D declined PAR and increased possibilities to
receive a graft. This effect is lower in highly sensitized previous
transplanted patients.
Evolution of glomerulonephritis (GN) incidence in Spain during the
years 1989 and 1990. Spanish Registry of Glomerulonephritis (REGN).
The REGN has presented during 1991 the epidemiology of GN in Spain
for the years 1989 and 1990. Data reported to REGN included: Cases of
ON diagnosed by biopsy, clinical features that conditioned renal
biopsy, and ON diagnosed only in clinical basis. Patients were consid-
ered as "adults" when they were 15 years old and over, and "children"
if they were younger. Patients with a functioning kidney allograft were
excluded from the study. Patients were classified according to their
kidney histological features into 8 categories of primary GN (PGN) and
4 of secondary GN (SON) (Nefrologia 10, Suppl. 4:8—18, 1990). Forty-
two referring hospitals reported adult cases and 16 hospitals reported
ON in children. Adult results: The number of biopsy-patients registered
during 1989 was 529 and 582 during 1990. Clinical data were reported in
969 out of 1111 patients biopsied. The percentage PGN/all ON was 74%.
Annual ratio of membranoproliferative MP ON/PGN during 1989 to
1990(9.2%), was similar to the 1987 to 1988 ratio (8.9, 8.2%), suggesting
that the descending curve observed over the past decade is reaching a
plateau. IgA GN frequency remained without significant variation,
about 24% of PON, being the most frequent ON in Spain. Clinical
syndromes of IgA ON at time of renal biopsy have changed; macro-
scopic hematuria is decreasing and persistent urinary abnormalities
(proteinuria and microscopic hematuria) are increasing. Extracapillary
GN (EON) is more frequent in the northern region than in the rest of
Spain. Rapidly progressive GN, 12.1%, was due to EGN and 72% to
vasculitis (VAS), 7% to lupus nephritis (LES) and 5% to IgA ON.
Patients with nephrotic syndrome (NS) (39.6%) presented: 20% mem-
branous ON (MGN); 17.2% focal glomeruloscierosis (FGS); 14.6%
minimal change GN (MC); 12% LES. LES represents 37% of SON.
Systemic VAS, with 28%, is the second most frequent cause of SON.
ON associated with neoplasia were found only in 3.2% of SON.
Children results: The report included 341 children diagnosed of ON in
clinical basis and 175 of them were biopsied. Fifty-three percent of NS
were biopsied with only 23% acute nephritic syndromes. MC, with
39%, was the PON most frequently biopsied in children, IgA ON 22%,
endocapillary proliferative 14.2%, FOS 9.4%, MPGN 7.9%. VAS was
the first cause of SGN, 43.8%, (SchOnlein-Henoch purpura) and LES,
20.8%, the second cause.
Post-transplant erythrocytosis (PTE): Is spontaneous remission usual?
J.L. Rocha, M.A. Gentil, G. RodrIguez-Algarra, P. Pereira, A. Guer-
rero, L. Gil andJ. Mateos, Hospital Universitario 'Virgen del Roclo",
Sevilla, Spain. PTE appears in up to 15% of renal transplant (RT)
recipients. It is associated with thromboembolic complications, and its
usual outcome has been described as leading to spontaneous remission
after 3 to 12 months. We found PTE in 37 of 315 RT recipients; 30 males
and 7 females. Immunosuppression given was PRED + AZA in 12
patients, PRED + CsA in one patient and PRED + AZA + CsA in 24
patients. We carried out a pulmonary function study which included:
Measurement of red blood cell mass by isotope dilution using 51Cr
labeled red blood cells, an ECO-doppler to rule out renal-artery stenosis
(arteriography or DIVAS in selected cases), serum erythropoietin
(S0) levels by radio immunoassay, and neoplasia screening. Idio-
pathic PTE was diagnosed in 25 patients. The remaining 12 were
grouped as follows: 6 with acquired renal cystic disease (ARCD), 3 with
adult polycystic kidney disease, 1 with renal-artery stenosis, 1 with
hydronephrosis, and I with chronic obstructive lung disease. PTE
appeared 8.6 9.5 months after the RT, and after a follow-up period of
36.5 23.5 months it self-limited in 10 patients. We used anti-platelet
agents in all cases and phlebotomy if the hematocrit was >55%. The
rate of remission was similar in the idiopathic cases to that in the
secondary cases and unrelated to the immunosuppression. The SPO
level was higher in the ARCD group (42.9 46.1 vs. 20.48 12.71).
Thromboembolic events occurred in 8 patients: 6 AV fistula thrombosis
and 2 cerebrovascular accidents. These two had an associated disease
with high vascular risk (one severe arteriosclerosis with stroke during
dialysis, the other a dilated embolic myocardiopathy). PTE is a frequent
complication, more common in males, which tends to appear within the
first year of RT and in 2/3 of cases is idiopathic. Development of
spontaneous remission is infrequent. The most common complications
(under antiplatelet drugs and periodic phlebotomy) is thrombosis of
vascular access. In patients with other thromboembolic risk factors,
serious complications may arise. For this reason, a more aggressive
therapeutic approach is advisable in these cases.
Legionella outbreak in hemodialysis unit. R. Moll, M.J., Martin, E.
Garri gas, A. Bernat, L. Garcés, J. Villaro, J. Sanchis, and A. Perez,
Servicio Nefrologia, Hospital General Universitario, Valencia, Spain.
We report a legionella outbreak which affected our patients on hemo-
dialysis programs. Eight patients (4 men and 4 women, with an average
age of 56) out of 36 dialyzed in our unit presented with fever (more than
38°C) and productive cough in a six-day interval. All except one patient
(A) had been at the unit 4 days before. The roentgenogram showed
unilateral alveolar infiltrate, which affected a single lobe in six cases; in
two cases the infiltrate was bilateral. There were no pleural effusions or
cavitations in any case. Only one patient developed hypoxemia (P 0260
mm Hg). Two patients died. In only two cases there was antibody
seroconversion for legionella pneumophila serotypes (1—4) with indirect
immunofluorescence. Blood and sputum cultures and urine determina-
tion of legionella antigens were negative. All the patients, except A,
were dialyzed in the same room, at different hours, and with the same
air-conditioning system. Legionella pseumophila was isolated in oxygen
humidifiers (only used by patient A), and in one of the hot water pipes.
Ten days before, garden work was performed near the unit. No
simultaneous legionella outbreaks were detected anywhere in the
hospital. We want to emphasize the poor serologic response of these
patients.
Mesangial glomerulonephritis and IgA defiCiency. A. Bernat, Mi.
Martin, M. Gimenez, S. Kortebi, and A. Perez, Servicio de Nefrologia,
Hospital General Universitario de Valencia, Spain. We report 3 cases
of mesangial glomerulonephritis and IgA deficiency, a very rare clinical
and pathological entity, which has scarcely been reported in current
literature. The series reported with 3 cases by French and colleagues in
1987 is the most important. Four patients, 1 women and two men,
whose ages were between 26 and 56, and a girl of 12 (the daughter of one
of the male patients) were sent to our unit for study. One of the patients
was first studied for hypertension, with microscopic hematuria and mild
proteinuria and serum level of LgA=0 mg/dl in repeated determinations,
as well as in saliva. His daughter was found to have partial IgA
deficiency, without pathologic findings in urine, and normal renal
function parameters. The other two patients were sent for gross
hematuria in one case and microscopic in the other, with serum IgA
levels of 6 and 29 mg/dl, respectively. In all patients, the rest of the
immunologic parameters were normal. Only the hypertensive patient
developed moderately high BUN levels, and only his daughter had an
enhanced susceptibility to upper respiratory tract infections. In the 3
adult patients, renal biopsy showed a pattern compatible with mesangial
glomerulonephritis, with granular deposition of 1gM and/or C3, without
interstitial or tubular pathologic changes, and with mild vascular
hyalinosis only in the hypertensive patient. Our findings in these three
patients are similar to those reported in literature. We raise the question
220 Abstracts
of whether we are not facing a new characteristic entity, though we
think further reports and studies must be done.
Primary hemostasia in uremic patients without severe anemia and
uremic patients treated with recombinant human erythropoietin
(rI4uEPO): A comparative study. J. Martin, A, Cervero, J, Sanchis, A.
Bernat, E. Garrigos, E. Parra, and A. Perez, Servicio Nefrologia y
Hematologia, Hospital General Universitario, Valencia, Spain. Treat-
ment with rHuEPO enhances primary hemostasia in chronic uremic
patients. This effect has been related to anemia improvement, although
other direct actions of rHuEPO have not been discarded. We have
studied platelet function in 29 patients with severe anemia (hemoglobin
levels: 6 1.1) before starting with rHuEPO therapy and when they
reached hemoglobin levels between 9 and 12 g/dl (10.3 1.1). The same
study was also performed in 11 uremic patients, whose hemoglobin
levels, without rHuEPO therapy, were similar to those reached by the
first group after rHuEPO therapy.
Pre-rHuEPO Post-rHuEPO Sin rHuEPO Control
Hb 6.8 1.1 10.3 1.1 10.6 0.7 13 1.5
TH 16.5 6.8 9.2 5.3 11 6 4 I
RC 215 25 236 54 240 57 228 38
VPM 7.3 0.7 7 0.7 7.1 0.9 10.1 2
IRPV 15.3 13.1 55.4 25.3 61.6 23.6 89 6.2
AA 1.4 30.5 19.6 49.2 20.4 62.2 22.7 75 19
AA 0.7 31.7 21.3 46.4 22.2 56.5 28.3 75 7.6
COL 34.4 20.7 45 23.3 60 21.3 70 15
ADP 2 27.4 16.7 33.3 19.2 45.8 13 64 14
ADP 4 36.2 16 54.2 15.5 62.2 12.1 61 9.3
Rt 1.2 31.4 23.6 60.7 12.4 72.6 12.5 82 6.7
Rt 0.8 21.8 22.2 38.8 27.8 47.2 22.5 52 6.8
MDA 1.4 14.8 8.9 22.4 15.3 13.8 9.9 21.2 3
MDA 0.7 9.1 5.9 15.2 9.4 7.3 4.4 12 1.8
Abbreviations are: Hemoglobin (Hb), hemorrhage time (HT), platelet
count (PC), average platelet volume (APV), platelet adhesiveness (PA 6
IRPV), platelet clustering arachidonic acid-induced (AA), collagen
induced (COL), adenosine-diphosphate (ADP) induced, and ristocetin
induced (RE), malonil-dialdehide (MDA) generation stimulated with
AA.
HT, adhesiveness, platelet clustering and MDA release significantly
improved after rHuEPO administration. Levels reached in HT, platelet
adhesiveness and clustering were similar to those found in uremic
patients without severe anemia, though in any case they reached the
levels of the control group. HDA release was significantly greater in
patients treated with rHuEPO in comparison to uremics without severe
anemia, and reached the same levels of the control group.
Prognostic significance of HLA sensitization in renal allograft recipients
treated with cyclosporine. L.M. Pa!lardó, N. Puig, J. Sanchez, J.
Garcia, P. Sanchez, J.L. Górriz, and J.M. Cruz, Servicio de Nefrolo-
gIa, Hospital General La Fe, Valencia, Spain. In 308 patients trans-
planted during a period of five years, treated with a protocol including
prednisone, cyclosporine and during the first two months with azathi-
oprine, we have analyzed the clinical data and the evolution of the 61
transplants (20%) performed in presence of HLA sensitization. Eigh-
teen patients (6%) showed reactivity against more than 50% of the
panel. The crossmatch was positive with B lymphocytes in three
patients. The 247 nonsensitized patients were analyzed as a control
group. Patients in the study group were characterized by a longer stay
on dialysis (P = 0.0000), more pretransplant blood transfusions (P =
0.0000), and predominance of females (P = 0.0004). HLA A+B
compatibility was higher (P = 0.0075), but HLA DR compatibility was
lower (P = 0.012) than in the control group. Post-transplant acute renal
failure was higher in the sensitized group (P = 0.0049). The incidence of
acute rejection episodes was similar in both groups (25%), but they
were more severe in the study group (rejection episodes/patient, P =
0.016); however, there were not significant differences in graft (P =
0.29) and patient survivals (P = 0.21) between both groups. In conclu-
sion, HLA sensitization was followed by a longer waiting period in
dialysis before transplantation, but it did not negatively influence graft
and patient survival.
Analysis of factors that influenced the early and late renal ailograft
survivals. L.M. Pallardó, J. Garcia, J. Sanchez, P. Sanchez, J.L.
GOrriz, E. Orero, I. Beneyto, and f.M. Cruz, Servicio de Nefrologia,
Hospital La Fe, Valencia, Spain. In 474 kidney transplants performed
in the period of February 1980 to January 1991, with at least three
months follow-up, we have analyzed the factors that have influenced
the early (first three months, 58 failures —12.2%) and the late losses
(after the third month posttransplant, 63 failures —13.3%). Early graft
survival was correlated with immunosuppression (better with cyclos-
porine) (P = 0.0005), with the acute rejection episodes (P = 0.0001), the
precocity of rejection episodes (P = 0.045), the vascular suture time (P
= 0.13), and CMV disease (P = 0.0000). In the 308 patients treated with
cyclosporine, the early graft survival was correlated with the age of the
patient (P = 0.010), the sex (P = 0.0023) and the type of nephropathy
with the type of immunosuppression (0.0000), with the acute rejection
episodes in the early posttransplant period (0.0001), with the HLA
DR+B identities (0.021), and with the general evaluation of the patients
at transplantation (0.017). In conclusion, the knowledge of the charac-
teristics that have influenced graft survival in our series has been useful
to modify the selection criteria of recipients for renal transplantation.
Renal retransplantation: Characteristics and evolution with a triple
drug protocol. L.M. PallardO, J. Sanchez, J. Garcia, P. Sanchez, J.L.
Górriz, E. Orero, and f.M. Cruz, Servicio de Nefrologia, Hospital La
Fe, Valencia, Spain. We have analyzed the characteristics and the
evolution of the 34 retransplants (11%) from a series of 308 kidney
transplants performed in the period from December 1985 to January
1991, and treated with triple drug protocol including cyclosporine,
prednisone and during the first two months azathioprine. As a control
group we have analyzed the 274 first transplants. The group of retrans-
plants had received more blood transfusions (P = 0.0000), had remained
longer on chronic dialysis (P = 0.0009), and the cold ischemia time was
shorter (P = 0.037) than in the cold group. HLA A+B compatibilities
were higher in the study group (P = 0.019),but there were no significant
differences in the HLA DR locus matching (P = 0.10). In the retrans-
plants the crossmatch with donor T and B lymphocytes were required
to be negative, but three primary transplants were performed with a
positive B lymphocytes crossmatch. The incidence of both acute renal
failure immediately posttransplant and acute rejection episodes were
similar in both groups, (P = 0.43) and (P = 0.48), respectively.
Infectious diseases in the three months posttransplant were more
frequent in the study group (P = 0.0029), but there were not significant
differences in actuarial graft (P = 0.38) and patient (P 0.85) survivals.
In conclusion, in kidney retransplants it is possible to obtain with the
present immunosuppressive protocols similar results to those in the first
transplants.
Control of high blood pressure by angiotensin converting enzyme
inhibitors. L.M. Pallardó, P. Sanchez, J.L. Górriz, M.J. Martin, E.
Orero, J. Sanchez, F. Ros, and f.M. Cruz, Servicio de Nefrologla
Hospital La Fe, Valencia, Spain. High blood pressure (HBP) is a
common finding in renal transplant recipients that can contribute to
glomerular hyperfiltration and to the deterioration of allograft function.
Angiotensin converting enzyme inhibitors (ACEI) are the ideal drugs,
as they can ameliorate both. We have treated 40 kidney transplanted
patients with ACEI during a mean period of 26.4 10.4 months, It was
given to patients with HBP, no suspicion of renal artery stenosis, and a
serum creatinine (Scr) < 2.5 mg/dl. In three cases it was administered as
the sole antihypertensive drug, and in the rest it was added to other
drugs because of an inadequate control of HBP. ACE! reduce both
systolic (pre-ACEI 167.5 15.4 mm Hg, post-ACE! 147.4 3.7 mm
Hg; P < 0.001) and diastolic blood pressures (pre-ACEI 100. 3 5.9
mm Hg, post-ACE! 86.4 8.5 mm Hg; P < 0.001). Sr and proteinura
did not change significantly (pre-ACEI 1.7 0.5 mg/dl and 0.58 1.6
g/24 hours, post-ACE! 1.8 0.7 mg/dl and 0.33 0.80 g/24 hours,
respectively; P = NS). In conclusion, ACE! were safe and effective
drugs in controlling HBP and preventing the deterioration of renal
allograft function.
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Study of the risk factors associated with aseptic bone necrosis in renal
transplantation. J.L. Górriz, M. Ba/lester, P. Sanchez, E. Orero, L.M.
Pallardó, J. Sanchez, I. Beneyto, and J.M. Cruz, Servicio de Nefrolo-
gia, Hospital La Fe, Valencia, Spain. We have analyzed the prevalence
of aseptic bone necrosis (ABN) in the series of 410 kidney transplants
performed in our hospital in the period from February 1980 to January
1990. The immunosuppressive treatment included azathioprine and
prednisone for the first 166 transplants (40%), and triple therapy
(cyclosporine, prednisone, and for the first two months azathioprine) in
the other 244 transplants (60%). Seventeen patients (4%) showed ABN
11.5 10.1 months postranspiant. The 394 patients that did not show
ABN were analzyed as a control group. ABN was correlated with the
cumulative prednisone dose in the first month and during the six months
postranspiant (< 0.05), with the daily prednisone dose at one month (<
0.05), with hepatic disease at transplantation (< 0.05), and one year
posttransplant (0.05). There were no significant differences between
both groups in the age, sex, type of nephropathy, hyperparathyroidism,
type of donor, retranspiants, and biochemistry (serum creatinine,
calcium, phosphate, alkaline phosphatases, serum proteins, choles-
terol, triglycerides and serum glucose along the first two years post-
transplant. In conclusion, the cumulative doses of prednisone in the
first six months posttransplant, and the presence of hepatic disease in
the first year were the risk factors of ABN identified in our series.
Magnetic resonance imaging versus subtraction gammagraphy in the
diagnosis of hyperparathyrodism. P. Sanchez, E. Orero, E. Caballero,
J.L. Gorriz, 1. Beneyto, F. Ros, L. Mar11, L. Martin, and J.M. Cruz,
Hospital La Fe, Hospital Dr. Peset, Valencia, Spain. This prospective
study was done in 28 patients diagnosed with hyperparathyroidism, TI
and T2-weighted Magnetic Resonance Imaging scans (MR) and Tecne-
tium-Talium Subtraction Gammagraphy (Tc-TI) of the neck were per-
formed on every patient and blindly interpreted. There was a clinical
suspicion of primary hyperparathyroidism in twelve patients; nine had
secondary hyperparathyroydism and seven patients were kidney al-
lograft recipients with sustained hypercalcemia two years after trans-
plantation. Twenty-one patients were parathyroidectomized. The his-
tologic diagnosis was of adenoma in ten patients and hyperplasia of the
four glands in eleven. The diagnosis obtained by Tc-TI was correct in all
the cases of adenoma and ten of the eleven cases of hyperplasia. RM
diagnosed accurately seven of the ten adenomas, but only three of the
cases of hyperplasia. The diagnosis was coincidental between the two
methods in three of the seven patients who didn't undergo a surgical
procedure: In two cases, both MR and Tc-TI were negative, and the
third one was a patient with primary hyperparathyroidism; MR and
Tc-TI revealed an adenoma, but the patient refused surgery. In four
patients MR was negative, but Tc-TI showed adenoma in two cases and
hyperplasia in other two. We conclude that, in our experience, Tc-TL is
a more sensitive procedure than MR in the diagnosis of hyperparathy-
roidism, especially in detecting glandular hyperplasia.
Utility of Doppler in the evaluation of acute kidney allograft dysfunc-
tion. P. Sanchez, E. Orero, J.L. Gorriz, J. Sanchez, A. Ba/lesta, I.
Beneyto, L. Pallardó, andJ.M. Cruz, Hospital La Fe, Valencia, Spain.
The purpose of this study is to evaluate the usefulness of duplex-
Doppler sonography in the diagnosis of the various causes of acute
allograft dysfunction. We have prospectively obtained, by means of
duplex-Doppler ultrasonography, 189 studies of the Resistance Index
(RI) and Pusatility Index (P1) in the arcuate arteries of 68 kidney
allografts, transplanted between January 1990 and February 1991. The
measurements were systematically performed within ten days of trans-
plantation, between 3rd and 5th week, and subsequently before 20th
week, and whenever there was an acute deterioration of renal function
histologically confirmed. The initial RI obtained among the 34 primary
functioning grafts was significantly higher than the mean RI obtained
between the 3rd to 5th week (0.71 0.10 vs. 0.66 0.11; P <0.001).
There was no significant difference between the mean RI determined
within 3rd and 5th week and the mean RI in the third period. The
comparative analysis for P1 did not show statistical differences among
the three periods of study. Nineteen grafts were initially nonfunctioning
because of oliguric acute tubular necrosis. The highest levels of RI and
P1 were obtained in this group, with significant difference from the
primary functioning allogralts (RI = 0.81 0.14, P1 = 2.11 0.91, P <
0.05). With the exception of oliguric acute tubular necrosis, the values
of RI and p1 were not able to discriminate among the various functional
conditions of the graft (stable renal function, acute rejection, obstruc-
tion, cyclosporine toxicity and non-oliguric acute tubular necrosis).
Mean RI and P1 in acute rejection were not significantly different from
the mean values obtained in cyclosporine toxicity. The wide range of RI
and P1 levels obtained in the different conditions determines the
sensibility and specificity of duplex-Doppler ultrasonography to be
insufficient in the etiologic diagnosis of acute transplant dysfunction.
Direct action of cyclosporine on proximal tubules in the pig: Modifica-
tions of energetic metabolism. A. Tejedor, A. Martinez, A. Galán, and F.
Gómez, Hospital General "Gregorio Marañón," Madrid, Spain. Cy-
closporine (CsA) causes structural and functional lesions on proximal
tubules, probably by vasoconstriction and renal ischemia. However,
other processes inducing renal ischemia don't show the same kind of
lesions. The objective of this study is to determine if CsA directly
modifies the energetic metabolism of isolated proximal tubules in
suspension. The suspension of proximal tubules (80% purity) was
obtained from renal cortex of minipigs by digestion with collagenase at
37°C for 45 on Krebs solution minutes (A. Tejedor. Can. J. Physiol.
Pharmacol. 66:997, 1988). Oxygen consumption (Q02) was determined
polarographically. Metabolites and intracellular ATP determinations
were obtained by UV spectrophotometry. CsA at low concentrations (1
ng/ml) induces a significant increase in the ouabain sensitive Q02. The
reserve capacity of the pump is decreased, suggesting a basal activation
of the pump or an increase in Na permeability. Higher concentrations of
CsA produce no changes in the oxidative or the phosphorylative
capacity of the tubule, nor in the intracellular concentration of ATP.
After incubation for 30 minutes in the presence of lactate 10 mM!
pyruvate 1 mt, CsA decreases lactate consumption and increases the
use of endogenous substrates (lipids) with reduction in the respiratory
quotient. CsA seems to directly modify the Na transport, ATP turnover
and intermediary metabolism of isolated proximal tubules.
ATP turnover in the porcine kidney: In vivo and in vitro studies. A.
Martinez, A. Tejedor, E. Junco, F. Valderrdbano, R. Perez, M. Renge/
and R. Jofre, Hospital 'Gregorio Maraflón," Madrid, Spain. Tubule
suspensions allow better control than 'in vivo" conditions in the study
of renal metabolism. However, absence of glomeruli and free access of
apical and basolateral membranes to assay media may determine basal
conditions very different from the physiologic ones. We have studied
Na transport, ATP turnover and energetic pathways in the kidney of
isogenic minipigs (in vivo) and in tubule suspensions from the same
animals (in vitro), all under basal conditions. Oxygen consumption in
vivo was 69 tmol/g hour, 86% of it derived for Na transport. In vitro
oxygen consumption was 175 molIg hour, with 41% derived for active
Na transport. Na reabsorption in vivo was 1682 mEq/g hour, requiring
an ATP consumption of 365 tmolIg hour. In vitro, Na transport was
1296 mEq/g hour, requiring 432 .tmol/g hour (in the absence of
apical-basal gradient there is no passive transport). In the presence of
the usual substrate mixture in "in vivo" conditions (in mM: lactate 1.87,
pyruvate 0.09, aspartate 0.02, glutamine 0.11, glutamate 0.12, alanine
0.29, citrate 0.05), porcine kidney obtains a 69% of the ATP from
pyr/lac oxidation, and a 31% from glutamine/glutamate. In vitro, this
situation was modified by incubating tubule suspensions in presence of
high lactate and pyruvate concentrations (10 and 1 mM), obtaining 100%
of ATP from these substrates. Both in vivo and in vitro conditions
showed that part of the pyruvate pool was not oxidized to CO2, being
derived to biosynthetic pathways. We could not show net glucose
production in vitro. Glutaminase activity was detected. In summary,
tubule suspensions are an useful and versatile tool in the study of the
energetic and intermediary renal metabolism. However, peculiarities in
the Na transport and oxygen consumption make it advisable to interpret
cautiously those results.
Mitochondria.transport ATPases relationship: Channeling of ADP? A.
Tejedor, A. Martinez, C. Albarracin, F. Valderrábano, f.M. Lopez
GOmez, Hospital Gregorio Marañón," Madrid, Spain. Under condi-
tions of oxidation-phosphorylation coupling, cell oxygen consumption(Q02) depends directly on intracellular ADP concentration. In the
proximal tubule cell, the main source of ADP is transport ATPases, and
Na transport is the major determinant of Q02 along the nephron. In a
suspension of tubules obtained by enzymatic digestion from pig renal
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cortex, intracellular ADP availability can be modified by varying Na
transport. Changes in ADP production induce changes in Q02 that can
be registered polarographically in a chamber designed for such a
purpose. Basal Q02 of tubules in an isotonic milieu similar to extracel-
lular fluid is 127.2 4.4 rmol 02/g hour. ATP or ADP addition to the
extracellular medium does not modify Q02 because nucleotides do not
permeate cell membrane: 111.8 3.8 jmol 02/g hour. Na pump
inhibition with ouabain reduced Q02 to 90.4 13.2 moI 02/g hour, but
stimulation with ionophore nystatine increases it to 184.2 9.6 tmol
02/g hour, as expected. In the absence of Na, tubules consume 75.7
1.4 mo1 021g hour. In order to directly induce changes in ADP
intracellular concentration, cell membrane was permeabilized with 0.1
mM digitonine (mitochondria membrane results unaffected at this con-
centration). Basal Q02 dropped to 67.3 16.2 tmol 02/g hour when
intracellular ADP diffused out of the cell. Surprisingly, ADP addition to
the permeabilized tubules did not result in significant increases in Q02
(64.3 16.2 mol 021g hour). However, ATP addition raised Q02 to
125,4 2.2 .tmol 02/g hour. This effect could only be explained in terms
of ATP hydrolysis by membrane ATPases to ADP and direct access of
the last one to mitochondria. These findings suggest that ADP obtained
in situ from ATP hydrolysis but not exogenous ADP is accessible to the
mitochondrial phosphorylative sites, even if cell membrane has seen
previously permeabilized. This ADP "compartimentation" or "chan-
neling" between ATP hydrolysis and synthesis sites could play a
relevant role in the tight coupling existing between Na active transport
and oxidative phosphorylation in the tubule.
Ten years experience in the treatment of the acute vascular rejection
with plasmapheresis. F. Anaya, A. Tejedor, F. Niembro, R. Perez, J.
Lu,io, F. ValderrObano, Hospital 'Gregorio Marañdn," Madrid,
Spain. We present our experience in the treatment of kidney acute
vascular rejection (AVR) with plasmapheresis since 1982. Inclusion
conditions were: (I) clinical or biochemical suspicion of rejection. (2) no
responsiveness to a standard metyiprednisolone (MP) cycle (0.5—1
g/day). (3) biopsy compatible with AVR. The AVR was classified in
types I, II, HI, and IV depending on the degree of vascular affection. In
every case, 6 plasmaphereses following a second biopsy were per-
formed. We practiced 360 plasmaphereses in 60 patients of the 468
grafted between 1982 and 1990: 28 had VAR type I, 16 type II, 11 type
III and 5 type IV. The results were compared with a group of 14 patients
with VAR type I treated solely with MP, prior to 1982 (historic control).
Sex distribution was irrelevant. More severe VAR were observed in
patients grafted later and with less identities. Probability of being
heterogroup was significantly higher in group III than in group I. Renal
biopsy was in general performed later in patients with type II and III
VAR. Plasmapheresis was useful in decreasing plasma creatinine levels
in types I and II but not in III and IV. Post-plasmapheresis biopsy
showed complete or partial reversion of vascular lesions in 96% of type
I VAR, 50% of type II and 0% of types III and IV. Graft survival after
six months of the procedure was 81.6% in type I, 24.8% in type II and
9.1% in type III. Graft survival in the historic control group was always
less than I month. None of the grafts with type II, III or IV VAR was
functioning 1 year after plasmapheresis. Surprisingly, lesions diagnosed
of type I VAR in cyclosporine treated patients did worse than type I
without cyclosporine: 45% survival after 6 months and 18% after 5
years. Plasmapheresis is an effective treatment in the reversion of the
acute vascular rejection, significantly increasing graft survival. Proce-
dure is limited by older age at the time of diagnosis, heterogroup graft,
three or more HLA incompatibilities, late diagnosis and cyclosporine
treatment.
Immunoadsorption: Preliminary clinical experience. F. Anaya, J.L.
Muboz, A. Galán, M. Rengel, R. Garcia Perez, MS. GarcIa Vinuesa,
A. Tejedor, F. Gdmez, F. Valderrábano, Hospital "Gregorio Mara-
ñón," Madrid, Spain. Immunoadsorption (lADS) is a novel technique
that allows removal of immunoglobulins (lgG) and circulant antibodies
from the bloodstream. It seems to be more effective than plasmapher-
esis for certain entities because of the higher specificity. We present our
experience of 110 lADS under different clinical settings: HLA hyper-
sensitivity in patients on a waiting list for transplant (64 sessions in 3
patients), Myasthenia gravis (30 sessions in 5 patients), systemic lupus
(10 sessions in 2 patients) and multiple conductive blockade neuropathy
(6 session in 1 patient). In every lADS session, three liters of plasma are
removed with a plasma filter (OPT5L) and immunoadsorbed through
tryptophan or phenylalanine columns. Before and after every lADS we
analyzed rate and title of antiHLA antibodies, IgG, complement,
coagulation parameters and circulant antibodies. A clinical evolution
was performed in every case, Results showed a decrease in IgG,
complement and anti HLA title but not rate, Specific clinical tests used
(Osserman, Oosterhois, Functional Scale) showed no amelioration in all
cases. Transient hypofibrinogenemy was the only registered complica-
tion, but in any case prevented total completion of treatment. In
summary, lADS is a new technique, with preliminary good and prom-
ising results, and no major complications described yet.
Influence of HD on the antioxidant capacity of uremic erythrocytes. A.
Pedraza, M. Candel, E. Mahiques, V. Valls, P. MunIz, and G.T. Saez,
Hospital Santa Lucia Alcira, Hospital Clinico Universitario Valencia,
Departmento de Bioquimica y Biologla Molecular Valencia, Spain.
Superoxide dismutases (SOD) are a group of enzymes that play a very
important role as a specific scavenger against superoxide radicals
generated during aerobic metabolism. It is considered the most impor-
tant antioxidant mechanism of the aerobic living cells. To know the
effect of dialysis membranes on the SOD activity, we have measured
the levels of this enzyme in blood from 5 patients submitted to
hemodialysis using two types of membranes: Cuprophan (CU) and
cellulose acetate (CA). These values have been correlated with those
found in the clearance and similar UF. None of the patients used in this
study were transfused or received erythropoietin. We found significant
differences of SOD activity when comparing hemodialysis with CU or
CA after 30, 180 and 240 minutes of treatment. However, there was no
significant difference when these values were compared with the global
ones. CU fiber membrane appear to reduce the antioxidant capacity of
uremic red cells during hemodialysis as indicated by a lower SOD
activity of these patients.
Intracellular levels of SOD in renal failure. A Pedraza, M. Candel, E.
Mahiques, V. Valls, P. MuñIz, and G.T. Saez, Hospital Santa Lucia
Alcira, Hospital ClInico Universitario Valencia, Departamento de
Bioquimica y Biologia Molecular, Universidad de Valencia, Spain.
Superoxide dismutase (SOD) activity in freshly hemodialyzed blood is
an indication of the antioxidant capacity of red cells since SOD is the
most important superxoide radical scavenger. We have studied the
possible role of oxygen free radicals in the renal failure (RF) syndrome
induced anemia by measuring blood SOD activity of volunteers under
three different situations: Normal subjects (0-I N = 6); in preterminal
RF with, Cr 15 mI/mm (0-Il N = 7); and in TRF with hemodialysis
program (G-IH N = 17). SOD activity was measured in freshly
hemodialyzed blood samples by the modified method of Stock-Nor-
mandy. Proper clinical analysis together with the study of the KtIV in
G-IIl has been also performed. There is a significant difference in SOD
activity between the G-I and G-II groups. SOD activity in 0-Ill is
recovered when compared with the G-II group, although no significant
differences are observed. There is no correlation between enzyme
activity and the rest of the parameters tested with the exception of
hemoglobin (Hb) levels (r = 0.4905) in the G-III. No changes or
correlation were found between smokers and non-smoker subjects, nor
with those patients consuming scavengers with the diet, The patients
with preterminal RF (G-II) show a blood SOD activity which is higher
compared with normal subjects (0-I). P < 0.05, This value decreases
with the instauration of HD, and there is no correlation with other
clinical parameters.
Active cytomegalovirus infection in acute dysfunction of renal allograft:
Analysis by i situ hybridization. P. Lardelli, N. Navarro, A. Montes,
M.T. Medina Cano, M.M. Biechy, J.M. Osorio, R. Cisterna, S. Cerezo,
C. Assensio, and R. Garcia del Moral, Departments of Pathology and
Nephrology, University Hospital, Granada, Department of Nephrol-
ogy, Virgen de las Nieves Hospital, Granada, Department of Microbi-
ology, Civil Hospital, Bilbao, Spain. Since the introduction of mono-
clonal antibodies to analyze the leucocyte subsets involved in renal
graft rejection, a frequent association between an acute form of
glomerulopathy, mediated by CD8+ cells, and high levels of antibodies
to cytomegalovirus (CMV) has been described. Moreover, the active
phase of the viral infection has been related with certain types of
irreversible rejection. We have studied the rate of CMV infection by in
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situ hybridization, on 44 post-transplant renal biopsies; samples were
obtained from two groups of 22 patients each immunosuppressed with
azathiopnne (AZA) + prednisone and cyclosporin A (CsA) + GAL +
prednisone, respectively. In every case, the renal sample was obtained
during acute or subacute dysfunction of the allograft, clinically suspi-
cious of rejection. In addition, the leucocyte subsets of the inflamma-
tory infiltrates present in renal biopsies were studied by immunohisto-
chemical techniques (ABC), using the following MoAb: CD45, CD3,
CD4, CD8, CDI5, CDI6, CD25, CD57, UCHL-l, L-26 and macro-
phages. Our results showed that: (1) Active infection by CMV is more
frequent in patients treated with CsA + GAL that in those treated with
AZA (9 vs. 3, P < 0.05, Fisher). (2) The number of lymphocytes T
(CD3+) and B (CD22+) present in glomeruli is lower in those cases
with positive hybridization (1.8 vs. 4.6 cel/glomerular section, P < 0.01,
t-test) and (0.3 vs. 1.5 cel/glom., P < 0.05, t-test), respectively. (3)
Negative cases showed a higher number of CD8+ cells in the inflam-
matory infiltrates as well as a greater rate of irreversible rejection
reactions. (4) No significant differences were observed between the two
groups with respect to the level of creatinine at the end of the follow-up,
seric titre of anti-CMV antibodies and presence of the virus in urine. We
concluded that: (A) Active infection by CMV, evaluated by in situ
hybridization, is more frequent in patients immunosuppressed with CsA
+ GAL than in those treated with AZA. (B) CMV infection is not
related with acute glomerulopathy mediated by CD8+ lymphocytes
and, therefore, does not influence the clinical evolution of acute
dysfunction of the renal graft.
Determination of nephrotoxicity by immunohistochemical detection of
cyclosporin A and P.170 glycoprotein in posttransplant renal biopsy. R.
Garcia del Moral, M. Gómez-Morales, M.J. Quesada, F. O'Valle, T.
Caballero, J. Alonso, M.D. Caracuel, D. Aguilar, and J. Aneiros,
Department of Pathology, University Hospital of Granada, Spain.
Since the use of cyclosporin A (CsA) as the most important immuno-
suppressive drug in renal transplant, the classic rejection reactions have
been substituted by subtler clinical and morphological manifestations,
generally in the form of chronic tubulointerstitial lesions, at times
similar to those produced by the nephrotoxic effect of CsA; this fact
makes the differential diagnosis between both situations difficult. Seric
control of CsA was, until now, the only method to regulate the dosage
of the drug. Sensitivity to CsA, as in the case of some aminoglucosids
and antineoplastic drugs, seems to be linked to the functional activity of
a membrane glycoprotein (GP-170), expressed by the apical edge of
renal tubular cells; this molecule acts by expelling, from the cellular
cytoplasm, certain potentially toxic substances. The aim of this study is
to present an immunohistochemical method for the determination of
CsA and GP-170 in renal tissue, as well as the results of its application
on a series of 35 post-transplant renal biopsies. The alkalyne phos-
phatase anti-alkalyne phosphatase technique was performed using the
monoclonal antibodies anti-GP-l70 and anti-CsA (given by Sandoz
Farma SAE). Our results show that: (1) Strong positivity for CsA is
associated with tubular overexpression of GP-170. (2) The conjunction
of heavy immunostaining for CsA and GP-170 is statistically related
with a low rate of inflammatory cells in the glomeruli and the intersti-
tium (Kruskal-Wallis, P < 0.05). (3) The absence of CsA immunostain-
ing is observed in cases of severe rejection and is associated with excess
of CD25 positive cells in the inflammatory infiltrate. (4) The intensity of
in situ CsA deposits is not related with seric level of the drug. We
conclude that: (I) The immunohistochemical determination of both CsA
and GP-170 can be useful in (a) the differential diagnosis between graft
rejection and nephrotoxicity, and (b) to evaluate the acute rejection
produced by deficiency in pharmacological immunosuppression. (2)
The immunohistochemical analysis of CsA and GP-170 in renal needle
aspiration cytology could be of help in the clinical follow-up of
transplanted patients.
Clinicopathological study and digital image analysis of gingival hyper-
plasia induced by cyclosporin A in 30 kidney transplanted patients. R.
Garcia del Moral, F. O'Valle, J.J. Lopez Caballero, F. Mesa, A.
Montes, M. Gonzalez Jaranay, F. Medina, M.D. Caracue/, and J.
Aneiros, Departments of Pathology and Dentistry, University Hospital
of Granada, Spain. Gingival hyperplasia (GH) is one of the main
complications of prolonged uptake of cyclosporin A (CsA) and carries
an important peridontal problem for patients under this therapy. The
relationship between the development of GH and the degree of oral
hygiene is at present very controversial. On the other hand, the correct
estimation of the degree of GH as an indicator of the sensitivity to CsA
is incorrectly estimated by nephrologists and orthodontists as they use
merely subjective criteria for the follow-up of the lesions. The aim of
this work is to present a comparative study of the clinical evaluation
and of the image analysis on digitalized photographs, using the infor-
mative back-up developed by Noesis (software Visilog), of a series of 30
kidney transplanted patients with GH of variable degrees. We propose
the use of new indicators which will allow the evaluation of patients'
sensitivity to CsA more objectively. The parameters studied are: (1)
The level of CAOD oral hygiene, bacterian plaque and gingival bleed-
ing; (2) the total area of gingival surface (GHTA) which includes the
hyperplastic gingival mucose of both anterior dental arcades; (3) the
total dental area (TDA) which includes the uncovered dental surface of
the incisors; (4) the dental papillar area (DPA), or surface located
between the free gingival edges and gingival groove and (5) the index of
gingival hyperplasia (GHI), obtained from the ratio GHTA/TDA. The
main results obtained were (a) An index GHI > 1.10 indicates the start
of GH. (b) The degree of GH is significantly related to the degrees of
bacterian plaque and gingival bleeding (Kruskal-Wallis, P < 0.05) and
(c) Low levels of GH have a GHI index lower than 1.5; in those cases
with intense GH the index is higher than 2, and a GHI index between
1.5 and 2 is related with GH of moderate intensity. We conclude that:
(I) The GH secondary to treatment with CsA can be accentuated by
deficient oral hygiene. (2) The morphometric evaluation of the lesions
facilitates the clinical follow-up of gingival enlargement and allows a
higher precision in the evaluation of the individual sensitivity to CsA.
Elective steroid treatment versus OKT-3 therapy in patients with renal
graft rejection. A. Montes, M.T. Medina, N. Navarro, P. Galindo, M.
Bustos, J. Bravo, P. Lardelli, A. Osuna, C. Asencio, andR. Garcia del
Moral, Department of Pathology. University Hospital of Granada,
Spain. At present, the diagnosis of rejection in post-transplant renal
biopsy is based on the analysis of the leucocyte subsets in frozen
sections. The presence of glomerulointerstitial infiltrates with very high
proportion of lymphocytes T CD8+ has been associated with irrevers-
ible rejection. We have analyzed the glomerulointerstitial infiltrates
from 33 post-transplant renal biopsies using an immunoperoxidase
technique and the following monoclonal antibodies: CD45, CD3, CD4,
CD8, CDI5, CDI6, CD25, CD57, UCHL-l, L26 and macrophages.
Patients were treated with steroids or with the monoclonal antibody
OKT-3, depending upon the leucocytes subsets incriminated in the
rejection. The indication of steroid treatment was made when the total
CD4/CD8 ratio (TCD)—mean value between the CD4/CD8 ratio in
glomeruli and interstitium—was greater than 1 .5 (predominance of
macrophages and CD4+ lymphocytes in the infiltrate); treatment with
OKT-3 was carried out when TCD was less than 1.5 (predominance of
CD8+ lymphocytes). Of the 33 patients, 22 received prednisone and 8
OKT-3; 2 patients had chronic rejection and were not treated; the
remaining histological diagnoses were: Vascular-interstitial rejection (7
cases), glomerulointerstitial (20 cases) and pure interstitial rejection (4
cases). In the group treated with steroids, whose average TCD was 5.0,
acute rejection remitted after steroid therapy in 11 patients, another II
cases needed to be rescued with OKT-3; rejection became irreversible
in one patient. Of the 11 cases rescued with OKT-3, another patient lost
his graft. In the group of 8 patients treated initially with OKT-3 (average
TCD 1.06), a complete remission was obtained in 7 cases. On studying
comparatively the group treated with steroids and that treated with
OKT-3, a significant difference was observed in the number of CD8+
lymphocytes at the glomerular level (1.17 vs. 3.6 cells per glomerular
section; P < 0.05, t-test). Differences were also significant when TCD
values were compared (7.66 vs. 1.07 P < 0.05, Mann-Withney). Our
conclusions were (I) The immunohistochemical determination of leu-
cocyte subsets in the post-transplant renal biopsy can be useful for the
establishment of an elective treatment with OKT-3 MoAb in graft
rejection predominantly mediated by CD8+ cells. (2) The presence of a
heavy glomerular infiltrate by CD8+ lymphocytes in certain corticore-
sistant cases explains the effectiveness of an additional treatment with
OKT-3 MoAb in these patients.
Immunohistochemical study of leucocyte subsets in 32 cases of IGA
mesangial proliferative glomerulonephritis. R. Garcia del Moral, V.
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Cortés, A. Navas, M. Gomez Morales, J. Lopez Caballero, M. Garcia
Cortes, A. Montes, C. Asensio, S. Cerezo, Department of Pathology,
University Hospital of Granada, Granada, Spain. IgA mesangial pro-
liferative glomerulonephritis (MGNIgA) shows a diffuse proliferation of
mesangial cells and capillomesangial fixation of IgA and IgG in clinical
association with an incomplete nephritic syndrome or recurrent hema-
tuna. At present, and owing to the transcendence that the tubulointer-
stitial lesions have for the evolution of the disease, it has been suggested
that some mechanisms dependent on cellular immunity play a role in the
genesis of the lesions, We present an analysis of the glomerulointersti-
tial leucocyte subsets present in 32 cases of MpGNIgA studied with
MoAb (CD45, CD3, CD4, CD8, CD11b, CDI5, CDI6, CD25, CD35,
CD57, L-26 and UCHL-l) on cryostat sections. Results are expressed
as mean of inflammatory cells per glomerular section and per mm2 of
interstitium. In every case studied there was an important interstitial
infiltrate by macrophages and CD4+ lymphocytes when compared with
control samples (263 35.66 vs. 106 18.84 and 217 64.46 vs. 42
14,62, P < 0.01 t-test); CD4/CD8 ratio was of 3.7. The glomerular
infiltrates were scarcely relevant. The statistical study showed a direct
relationship between the level of creatinine at the end of the clinical
follow-up and the number of interstitial inflammatory cells—sum of
CD45, CD4 and CD8 positive cells—(multiple regression, r squared =
0.99, P < 0.01). We concluded that in the MpGNIgA there exists a
notable interstitial inflammatory infiltration by macrophages and T
CD4+ lymphocytes and that the intensity of the infiltration of both
types of cells along with the presence of a nephrotic type of proteinuria
are the two most important factors in evaluating the progression to renal
insufficiency.
Significance of glomerulointerstitial infiltration by natural killer cells in
the renal graft rejection reaction. M. Bustos, M. Andzijar, M. Gómez
Morales, A, Montes, 1. Ruiz Avila, Mi. Quesada, D. Aguilar, C.
Asensio, and R. Garcia del Moral, Department of Pathology, Univer-
sity Hospital of Granada, Spain. Antibody dependent cellular cytotox-
icity (ADCC), mediated by NK cells, increases during renal graft acute
reaction. In addition, NK cells as well as lymphocytes T CD8-t- are
related to irreversible glomerulointerstitial rejection. The aim of this
study is to analyze the NK cells activity in the inflammatory infiltrate
present in renal graft rejection, in order to evaluate its role in the
genesis of the histological lesions observed in rejection and its relation-
ship with other leucocyte subpopulations present in graft rejection. We
have performed an immunohistochemical study in 35 post-transplant
renal biopsies using the monoclonal antibodies CDI6 (Leu-l Ic) and
CD57 (Leu-7); all renal samples were obtained during acute graft
rejection. Immunohistochemical data were correlated with the most
important histological lesions observed in graft rejection, as well as with
the response to treatment (steroids and steroids plus the MoAb OKT3,
when this last was indicated). Our results showed that: (1) In patients
with poor therapeutic response the average of interstitial NK cells per
mm2 was greater than in those with a favorable response (174 vs. 96
cells. P < 0.05 t-test); (2) The number of interstitial NK cells was also
significantly different when cases with severe interstitial fibrosis and
indirect signs of vascular rejection (myointimal fibrosis and hialine
arteriopathy) were compared with those samples showing interstitial
rejection, (3) No correlation was observed when the number of NK
cells and lymphocytes CD8+ were compared. We conclude that the
cellular subset with ADCC activity probably contributes to the loss of
function of the allograft; the in situ evaluation of these cells in renal
aspirative suction or post-transplant biopsy would allow the identifica-
tion of those cases in which a good therapeutic response could be
expected.
Immunohistochemical analysis of leucocyte subsets in the idiopathic
nephrotic syndrome. M. Andujar, M.L. Aguayo, F. O'Valle, A. Navas,
M. Montes, D. Aguilar, J. Aneiros, S. Cerezo, and R. Garcia del
Moral, Department of Pathology and Nephrology, University Hospital
of Granada, Service of Nephrology, Virgen de las Nieves Hospital,
Granada, Spain. At present, the analysis of leucocyte subsets with
monoclonal antibodies (MoAb) in diverse glomerulonephrites is gaining
a greater importance in evaluating the progression of the disease and
understanding the pathogenesis of the histological lesions observed in
this disease. In fact, an increased number of intraglomerular leuco-
cytes, along with the presence of interstitial inflammatory infiltrate, are
considered important factors in the genesis of lesions associated with
the idiopathic nephrotic syndrome (INS). In this study, we have
analyzed the inflammatory infiltrate present in 110 cases of INS, using
MoAb on cryostat sections (CD45, CD3, CD4, CD8, Cdllb, CDI5,
CD16, CD25, CD35, CDS7, L-26 and UCHL-1). Cases were classified
as follows: Minimal change glomerulopathy 19 (MC); focal and segmen-
tal hyalinosis 16 (SF11); membranous glomerulonephritis 25 (MGN),
mesangiocapillary glomerulonephritis 22 (MCGN), 1gM proliferative
glomerulonephritis 23 (IgMPMGN), and immunonegative mesangial
proliferative glomerulonephritis 5. The results obtained were: (1) With
the exception of T CD3 + lymphocytes in MC and SFH (Kruskal-
Wallis, P < 0.05), neutrophilic granulocytes in SFH (Anova, P < 0.05),
and macrophages in MCGN (Anova, P < 0.01), the glomerular infil-
trates are scarcely relevant; these facts support the hypothesis that
glomerular sclerosis is the consequence of a reparative process origi-
nated by a local liberation of inflammatory mediators; (2) the number of
inflammatory cells in the interstitium is very high in all the groups
studied when compared with a control group, and particularly and in
decreasing order for SF11, MCGN, MON and IgMPMGN (Anova, P <
0.01); (3) The macrophagic interstitial infiltrate is maximum in MCGN
and relatively scarce in LgMPMGN and MC (Anova, P < 0.01); (4) The
number of inflammatory cells per mm2 along with the presence of
glomerular sclerosis is the most important prognostic factor in predict-
ing the evolution to renal insufficiency (multiple regression, P < 0.01).
HLA typing on peripheral blood lymphocytes (PBL) from cadaver
donors before kidney removal. C. Muñoz, f.M. Gas, A. Franco, M.L.
De Ia Sen, MC. Prados, M. Perdiguero, and J. Olivares, Departments
of Immunology and Nephrology, S.V.S. Hospital, Alicante, Spain.
Several studies have reported that prolonged cold ischemia (CI) in-
creases the frequency of acute tubular necrosis, which could reduce
graft survival rates. In the potential cadaver donor (CD), HLA typing
with PBL using nylon wool to separate B cells and NIH technique can
be difficult. Thus, it is advisable to type, for HLA DR at least, using
spleen or lymph node cells (LNC), but it results in a prolonged CI. The
validity of HLA typing using cells selected by immunomagnetic (IM)
isolation as compared to conventional NIH technique has been estab-
lished. The aim of the study was to evaluate this alternative technique
where HLA typing is obtained from PBL by positive immunospecific
isolation, employing IM monodisperse microspheres (DYNABEADS)
coated with monoclonal antibodies specific for CD8 or HLA class II
monomorphic epitopes. The study was performed using the same lots of
antisera, complement and fluorochromes. PBL and LNC were obtained
simultaneously from 31 CD and we compared identified antigens on
PBL with those obtained on LNC. The results were 100% specificity
and 98.4% sensitivity for HLA DR typing, being 100% and 96% for
HLA A+B typing. The IM HLA typing technique permits rapid HLA
class I and II typing to be performed on PBL from CD, reducing CI.
Insulin resistance and vascular risk factors in arterial hypertension
(HTA). M. Bermejo, L. Orte, C. Quereda, M. Rivera, J. Sabater, J.J.
Villafruela, A. Gonzalo, and J. Ortuño, Hospital Ramon y Cajal,
Madrid, Spain. Hyperinsulinism is considered a vascular risk factor in
HTA. Nevertheless, its relation and extent of association with those
classically known, has not been studied much in our health influence
area. We earned out a prospective study on 117 essential hypertensives
and non-diabetics, without other selection criteria. We analyzed glyce-
mia and insulin (I) with a 75 grs oral overload test of glucosa (basal, 30',
60', 90', 120'), glyosylated hemoglobin, ARP, Aldosterone, lipid profile,
PTH and ECG. Eighty-nine percent of HTA population had more than
one risk factor associated with HTA. The most prevalent risk factors
were: Obesity (77%), glucose intolerance (IHC) (54%), LDL >150(54%), total cholesterol >250 (34%), hyperinsulinism (32%),
tabaquisme (31%), left ventricular hypertrophy (18%) and HDL <35
(9%). Some 35% meet 3 risk factors in addition to HTA. Insulin (basal,
120' and increment) was significatively related with glycemia (basal,
120' and increment), cholesterollHDL, LDL/HDL and cholesteroll
triglycerides. Hypertensive patients with IHC had higher serum levels
of I (basal, 120' and increment; P < 0.001), cholesterol (P < 0.05),
CholesterollHDL (P < 0.01) and LDL/HDL (P < 0.05). Lipid profile
changes, hyperinsulinism and glucose intolerance were also detected in
the non-obese HTA group, and these findings were independent of the
current antihypertensive treatment. Insulin resistance and classically
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known vascular risk factors are frequently associated with HTA. Global
risk factor control approach is needed to decrease vascular morbimor-
tality of HTA.
New metabolic tolerance spectrum to the medical treatment of essential
hypertension. L. Orte, C. Quereda, M. Bermejo, M. Rivera, A.
Gonzalo, J. Sabater, J.J. Villafruela, andJ. Ortuño, Hospital RamOny
Gala!, Madrid, Spain. Antihypertensive medical treatment (MT), asso-
ciated with classical secondary metabolic effects, is well known and
now its influence on insulin resistance is well known. We studied 117
consecutive HTAE (excluded were those with fasting glucose greater
than 110 mgr/dl), the possible relationship between MT and insulin
(RIA), glycemia and glycosylated hemoglobin, fasting and after a 75 grs
oral glucose overload; likewise, we analyzed the correlation of these
modifications with simultaneous changes in serum K, lipid profile, uric
acid and renal function. Diuretics (D) induce a greater insulin resistance
(120' = 88 44 vs. 64.5 45 sU/ml; P <0.001) and glucose intolerance
(glucemia at 120' = 152 48 vs. 121 100 mgr/dl, P < 0.001). With
calcium channel antagonists, only the glucose increment was significa-
tive (Basal, 120' = 100 44 vs. 28.6; P < 0.05). These parameters were
not modified with betablockers or CE!, given alone or associated with
diuretics. Insulin and glucose changes are independent to other de-
tected significative secondary metabolic effects of MT: Lower levels of
Ks with D (3.64 0.4 vs. 3.92 0.4 mEq/liter; P < 0.001) or HDL with
B (49.5 12 vs. 59.5 31 mgs/dl; P < 0.05). Diuretics induce insulin
resistance and glucose intolerance in HTAE; secondary effects that
disappear with their association to B or CE!. The long-term role of
these changes on global vascular risk remains to be discerned.
Hypercalciuria and insulin resistance in essential arterial hypertension
(HTAE). C. Quereda, L. Orte, M. Bermejo, T. Vita, J. Sabater, M.
Rivera, and J. Ortuño, Hospital Ramon y Gala!, Madrid, Spain. The
epidemiological relationship between calcium (Ca) and HTAE is a
matter of controversy. It has been described that Ca-rich diets may
have a protective effect in HTAE, but there has also been found a high
prevalence of hypercalciuria in HTAE patients. We have prospectively
studied the prevalence of hypercalciuria and urolitiasis in 117 consec-
utive HTAE patients. We analyzed its relation with PTH, glucose and
insulin (I) values after oral glucose overload (75 gr), serum Ca,
potassium (K), sodium (Na), chloride (Cl), uric acid (Ua); creatinine
(Cr) clearance and the urinary (U) excretion and fractional excretion
(FE) of Na, K, P and Ua. UCa/Uc. was higher in HTA than in controls
(0.13 0.09 vs. 0.08 0.03; P < 0.001). 42% of not treated HTA had
UCa/Ucr> 0.15 (controls 4%; P < 0.001) and in 22% UCa/Ucr > 0.20(controls 0%; P < 0.00!). Global lithiasis incidence was 30% (45% if
Ua/Ucr > 0.20). PTH showed a significant positive correlation with
basal I (r = 0.43; P < 0.01), but there were no significant differences in
PTH values of normo- or hyper-calciuric patients. In untreated HTAE
there was an inverse significant correlation between UCa and serum Ua
(r = 0.45; P <0.01) and a direct one between UCa and FE Ua (r = 0.32;
P < 0.05) but not with the U or FE Na, K, Cl. We conclude that in
HTAE there is a relationship between PTH values and basal hyperin-
sulinism and a high prevalence of hypercalciuria and lithiasis. Never-
theless, hypercalciuria seems not to be related to hyperparathyroidism,
but to disturbances of tubular Ca management.
Antiphospholipid antibodies in glomerulopathies: A prospective study.
C. Quereda, G. Garcia-Otero, A. Gonzalo, M. Rivera, L. One, J.
Pascual, and J. Ortuno, Department of Nephrology, H. Ramón y
Cajal, Madrid, Spain. Lupus anticoagulant (LA) and anticardiolipin(AC) antibodies have been found in the serum of patients with SLE
vasculitis or thrombotic microangiopathy and in healthy subjects.
However, incidence and clinical significance of the association of these
antibodies with glomerular diseases are unknown. We have prospec-
tively studied the presence of Al and AC in 120 patients with biopsy-
proven parenchymatous renal diseases: SLE (N = 28), chronic glomer-
ulonephritis (GN) (N = 63) and other nephropathies (N = 29). The
presence of AL was established by positivity of TIT (Schneider) and
Russel test. AC and AL serotype were determined by ELISA. In 11
SLE cases (39%), AL was positive (9 IgG, 2 IgG-IgM), with AC also
positive in 10 of them (9 IgG, I !gG-IgM). Five chronic GN (7%)
showed antibodies: 3 membranous GN (20% of all tested, AL and AC
were IgG in 2 and 1gM in I case). I mesangial GN (AL-AC 1gM), 1
FSGN (AL IgG-IgM, AC IgG). All were Ana+, DNA—, ENA— and
had normal complement. Miscellaneous group showed 7 positivities
(24%), all with acute nephropathies: Necrotizing vasculitis, 1 staph.
GN, 1 acute proliferative GN, 2 interstitial (1 drug, 1 salmonellosis), 1
scierodermic crisis). We conclude that the incidence of AL and AC in
chronic GN is similar to that in the general population. However,
incidence is high in membranous GN. Some cases could be atypical
SLE forms. Positivity in acute and systemic nephropathies is frequent,
probably in relation with intense and transient autoimmune activity.
Anthropometric parameters and insulin (I) resistance in essential
arterial hypertension (HTAE). C. Quereda, M. Bermejo, L. Orte, G.
Otero, J. Sabater, J. Villafruela, and J. Ortuflo, Hospital Ramon y
Gala!, Madrid, Spain. To analyze the prevalence of anthropometric
abnormalities and its relation with I resistance, we have prospectively
studied in 117 consecutive HTAE the following anthropometric param-
eters: Body mass index (BMI), ideal weight deviation (IWD), tricipital
fold (TF) and muscular arm circumference (MAC). Correlation studies
of these parameters with glucose (G) and insulin (I) values after glucose
oral overload (75 gr), glycosylated hemoglobin (HGb), and serum lipids
were performed. According to BMI, 80% of patients were obese (in 36%
grade II or more) without significant differences regarding age or sex.
There was a variable correlation between weight and adiposity param-
eters: BMI-IWD (r = 0.96); BMI-TF (r = 0.63); BMI-MAC (r = 0.42);
IWD-TF (r = 0.65); IWD-MAC (r = 0.48); TF-MAc (r = 0.33). BMI and
IWD, but not TF or MAC, showed a significant positive correlation
with basal and 120! values and with diastolic blood pressure. Obese (0)
and not obese (nO) HTA patients had higher basal G values than
healthy controls and glucose intolerance criteria in 59% and 25% of the
cases. G and I (basal and 120 mm, P < 0.001), GHb (P < 0.05) and the
cholesterol/triglyceride index (P < 0.05) were higher in 0 than in nO
and healthy controls. I (basal, 120 mm) showed a significant positive
correlation with G values (basal, 120 mi G increment). We conclude
that the prevalence of obesity in HTAE is very high resulting in higher
hyperinsulinism, glucose intolerance and lipid abnormalities. Neverthe-
less, there is a 25% of nO HTAE showing glucose intolerance with high
I levels.
Distal urinary acidification impairment in patients treated with low-
dose cyclosporine (Cs). C Quereda, J. Sabater, N. Gallego, C. Sorio, L.
Orte, M. Bermejo, L. Orofino, and J. Ortuño, Hospital Ramon y CaIn!,
Madrid, Spain. Cs may induce nephrotoxicity even when low-dose
regimens are used. Among disturbances described, there is acidemic
tendency and alterations in renal handling of potassium and sodium.
Nevertheless, little information is available regarding renal acidification
processes in non-transplant patients treated with Cs. We have assessed
renal acidification capacity induced by furosemide (80 mg) (F) in 29
patients with psoriasis and normal renal function, treated with Cs
(initial dose 5 mg/kg subsequently tapered until complete withdrawal
after 6 months). In 5 cases on Cs, urinary pH was always over 5.3, the
alteration persisting in 2 patients 1 month after treatment stoped.
Sequential studies (basal, 3 m and post-treatment) were performed in 9
patients showing impaired acidification in Cs-treated group: Minimal
urinary pH reached after F was higher on Cs (4.59 0.06 vs. 4.86
0.33, P 0.01) whereas ammonium, tritable acid and net acid excretion
were significantly lower. Serum creatinine, urea and uric acid were
higher during Cs and total CO2 and phosphate tubular resorption were
lower. No differences were seen in fractional excretion of Na, K or Cl.
We conclude that F test discloses subclinical anomalies in distal
acidification, even in patients treated during short periods and with low
Cs doses, probably related to a drug-induced proton-pump defect.
Acute cerebrovascular attacks (ACVA) in autosomal polycystic kidney
disease (APKD). M. Rivera, A. Gonzalo, J.M. Gobernado, L. Orte, C.
Quereda, andJ. Ortuño, Nephrology and Neurology services, Hospital
Ramón y Cajal, Madrid, Spain. There has been described a high
incidence of ACVA in patients with APKD. In addition, polycystic
patients are thought to have a higher incidence of berry aneurysms than
the general population. We have retrospectively reviewed 142 APKD
patients. Fourteen (9.8%) had 19 episodes of ACVA at a mean age of 55
years. (range 17—70). Ten were male and 4 female. Three patients (2.1%)
had an intraparenchymal hemorrhage, 3 had confirmed ruptured aneu-
rysms (2.1%). and 8 had ischemic events (5 cerebral infarction and 3
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transient ischemic attacks). The mean age of the patients was not
significantly different for each type of stroke. Renal function at ACVA
was as follows: Chronic renal failure (Cr 1.3 mg/dl) in 11 episodes,
terminal renal failure (Cr 10 mg/dl or Ccr 15 mI/mm) in 3, and unknown
in 5 episodes. It is worth noting that in seven patients (50%) the first
clinical symptom of APKD was a cerebral complication. The outcome
of the patients after ACVA was as follows: 2 patients totally recovered,
5 had moderate neurological deficit and 3 had to be excluded from
dialysis because of dementia. Transient ischemic attacks have been
excluded from this analysis because, by definition, patients always
recover. Therefore, cerebral complications are an important cause of
morbidity and mortality in APKD patients and these portend a disabling
outcome before and after dialysis and transplantation.
Does hepatitis C improve after kidney transplantation? C. Gdmez, R.
Marcén, P. Serrano, M.L. Mateos, L. Orofino, J. Pascual, and J.
Ortuño, Department of Nephrology and Microbiology, Hospital
Ramdn y Cajal, Madrid, Spain. We have investigated the prevalence of
antibodies to hepatitis C virus (anti-HCV) by an enzyme-linked im-
munosorbent assay (ELISA) in 227 renal transplant recipients: 145
patients were on cyclosporin (CsA) and 82 on azatioprine (Aza).
Positivity was confirmed by a recombinant immunoblot assay (4 RIBA).
Serum samples were obtained at the time of transplantation (186) and
between 6 and 144 months after the procedure. Thirty-three patients
were definitively anti-HCV positive before transplantation; 16 patients
(48%) remained positive thereafter (ELISA and RIBA positive), and in
another 7 patients positivity was only detected by RIBA, 3 patients
were RIBA indeterminate, and 7 patients (2 1%) became negative. After
transplantation 3 negative patients (1.5%) seroconverted. The anti-
HCV positivity before transplantation was related to a longer stay on
dialysis, transfusions and previous liver disease, mainly non-A non-B
hepatitis. Abnormalities on liver function test persisted throughout the
follow-up in 16 seropositive patients (61%). The remaining 7 seroposi-
tive patients and those who seroconverted never had any liver abnor-
mality. Liver biopsy was performed on 6 seropositive patients: 3 had
chronic active hepatitis and 3 chronic persistent hepatitis. In conclu-
sion: The prevalence of anti-HCV decreased after transplantation, and
the presence of anti-HCV was associated in up to 60% of cases with
chronic liver disease. The ELISA test can underestimate the prevalence
of positivity.
Cyclosporine (CsA) can induce clinical remission of dialysis-acquired
chronic lIver disease (CLD). C. Campo, J.M. Morales, G. Castellano, F.
Colina, A. Andres, G. Fernandez-Zatarain, C. Garcia Canton, R.
Sanchez, and J.L. Rodicio, Nephrology Department, Hospital 12 de
Octubre, Madrid, Spain. CsA has been considered as a potential
hepatotoxic drug. However, it has been reported that CsA could be
beneficial in some autoimmune liver diseases. The aim of the present
study was to analyze the effect of CsA on clinical course after RT of
CLD (abnormal liver tests for longer than six months) acquired before
transplantation. From 200 renal transplants functioning more than one
year we selected 26 (13%) that had CLD before RT and were treated
with CsA plus steroids: 6 were AgHbs positive, 18 were anti-HCV
positive (second generation test) and 5 were seronegative. After RT 9 of
26 (34.6%; 6 anti-HCV positive and 3 seronegative) showed a clinical
remission of CLD (normalization of liver tests) after 1 to 4 months (X 2.
1 months) maintained for a mean of 42.1 20 months. Biopsies were
available of three patients before RT: 2 of them, anti-HCV positive,
showed siderosis degree III with fibrosis. They were treated with
deferoxamine but enzyme values were normal only after RT. A new
biopsy of one patient at five years after RT showed a persistent chronic
hepatitis, The remaining patient was seronegative and he had active
chronic hepatitis (ACH). New biopsies at 12 and 48 months after
clinical remission show persistence of the histological pattern with the
same Knodell index. The remaining 17 patients showed abnormal liver
tests and although none developed severe clinical CLD, CsA therapy
did not impede the development of a severe histopathological pattern in
5 patients, in whom iterative biopsies were available: 4 developed ACH
and one of them cirrhosis (all anti-HCV positive). CsA was well
tolerated except in two patients because of colostasis. In conclusion,
our data suggest that CsA could be useful in patients with pretransplant
CLD due to hepatitis C or non-A non-B. So, CsA can induce clinical
remission in 34% of these patients and perhaps could slow the progres-
sion of liver disease. In patients without clinical remission CsA did not
impede the evolution to severe histopathological patterns.
Cyclosporine (CsA) alone as therapy of maintenance in renal transplant
patients over fifty years old. A prospective study. J.M. Morales, M.A.
Munoz Cepeda, S. Sancho, A. Andres, f.M. Alcazar, C. Campo, G.
Fernandez, C. Garcia Cantdn, and J.L. Rodicio, Hospital 12 de
Octubre, Madrid, Spain. It has been reported that cyclosporine (C5A)
monotherapy can be an effective treatment in old renal transplant
patients. Prospectively in 18 patients, group I, aged 56.6 6 years, with
at least one year of graft functioning, a slow steroid withdrawal was
performed while maintaining low CsA doses. The clinical results in the
first 15 months after steroid interruption were compared with those of a
group of 20 patients, group II, age 54.3 2.2 years old maintained with
low steroids and CsA doses. Both groups were comparable in the time
of graft functioning (group 120.9 11.5 vs. group 1124.6 12 months,
P = NS), acute rejection and transitory CsA nephrotoxicity incidence,
number of second grafts, frequency of hyperimmunized and degree of
renal function, Two patients of Group I developed an episode of late
acute rejection (11.1% vs. 25%, P = NS), one was controlled with
steroids and the other was steroid and OKT3 resistent. In the remaining
16 (87.7%) group I patients the clinical course was excellent, maintain-
ing a stable renal function during the follow-up (Se. 1.22 0.40 mg/dl)
with low CsA doses 2.78 0.88 mg/kg/day. The incidence of transitory
CsA nephrotoxicity and the association of azathioprine were similar to
group II. Graft survival in group I was 94.5% vs. 90% group II, P = NS,
and patient survival was 100% in both groups at 15 months. Also, a
tendency to present fever infections and readmissions together with a
diminution of cholesterol and triglicerydes was evident in the group I,
while in the group II there was no changes. In conclusion, our results
suggest that in patients over 50 years old with a functioning graft of
more than one year, CsA monotherapy can be a useful immunosup-
pressive maintenance protocol that can avoid the undesirable effects of
steroids.
Treatment of erectile impotence In renal transplant patients with
intracavernosal vasoactive drugs. A. Rodriguez, f.M. Morales, T.
Fernandez, A. Andres, R. Diaz Gonzalez, M. Pamplona, L. Calahorra,
and E. Alvarez, Urology and Nephrology Departments, Hospital 12 de
Octubre, Madrid, Spain. Erectile impotence is an important problem of
males who are in dialysis and after renal transplantation. Also, its
treatment is difficult and not well established. From September 1976 to
December 1989 in our hospital 431 renal transplants (RTs) were
performed. From 250 males we studied 11 RTs (4.4%) that presented
erectile impotence. Age was 46.7 10 years (range 25 to 56) and the
previous time on dialysis was 60 18 months (range 24 to 116). Time
after transplantation was 22.7 10 months (range 10 to 42). At the
moment of the study graft function was normal in 7 and renal insuffi-
ciency in the remaining 4. Eight patients related an erectile impotence
history before transplantation. Vascular anastomosis was to external
iliac artery in 9 cases and to internal iliac artery in 2 cases. Penile blood
pressure determined by a Doppler Technique showed in 7 cases an
index of penile braquial >0.70, corresponding to 2 of 4 pathologic index
(<0.60) in patients with anastomosis end-to-end with internal iliac
artery. In 5 patients hormonal alterations were seen showing low
testosterone levels together with FSH-LH elevations. Six patients, all
with normal vascular index, were treated with intracavernous drugs: 4
received papaverine. The evolution was excellent in three (all are on
treatment at home), and in the remaining patient the treatment was
unsuccessful probably due to fibrosis at cavernose corps, because this
patient was operated by priapism on dialysis. In two patients the
treatment was PGEI, and the results were excellent without any
side-effects. Another patient was treated with testosterone and the
response was good. One patient improved only with the suppression of
cimetidine, and the last one improved after implantation of an inte-
grated penile prosthesis. In summary, when there is a good vascular
perfusion, the treatment with intracavernosal vasoactive drugs, papav-
erine and most recently PGEI, show a great efficacy in renal transplant
patients with impotence.
Incrusted pyelltis (IP) and cystitis (IC) by corinebacterium group 02
(CGD2): A new severe complication following renal transplantation. f.M.
Morales, J. Aguado, R. Diaz Gonzalez, E. Salto, A. Andres, and J.L.
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Rodicio, Hospital 12 Octubre, Madrid, Spain. CGD2 may produce
deposits of struvite on the vesical wall leading to IC. IP is a similar
process not previously described affecting the renal pelvis. From 500
renal transplants (RT), 9 patients (PTS) (1.8%) (6 M, 3 F) developed IP
(7 pt) and IC (2 pts) during the last five years. CGD2 (>10 cfu/ml) was
isolated from 4 pts with IP (urine 3, blood 1) and from I pt with IC
(urine). CGD2 could not be isolated from 2 formerly evaluated pts who
had lost their grafts due to an obstructive uropathy (OU) secondary to
IP. Two other previously studied RT pts (IP 1, IC I) were lost for
microbiological re-evaluation. Alkaline urines with struvite crystals,
microscopic hematuria, and sterile conventional urine cultures were
present in all our cases. All IP pts developed OU with worsening of
renal function and pyelonephritis (4 pts) or renal abscesses (2 pts).
Chronic urinary discomfort (CUD) and macroscopic hematuria were
present in the 2 pts with IC. A "pig-tail" ureteral catheter was present
in all IP pts but in no pt with IP. In spite of the antibiotic treatment, all
the pts with IP required a derivative procedure, and a cystoscopic
resection of the incrustations was necessary in the 2 pts with IC. We
conclude that IP and IC should be investigated in RT pts who develop
an UO or CUD if they presented alkaline urine, struvite stones and
sterile conventional urine. CGD2 could have a pathogenic role in these
recalcitrant complications.
Impact of hepatitis C after renal transplantation: A clinico-pathological
study. f.M. Morales, C. Campo, G. Castellanos, F. Co/ma, A. Blanco,
A. Andres, and J.L. Rodicio, Hospital 12 de Octubre, Madrid, Spain.
Hepatitis C is an emergent problem in renal transplant patients (RT). To
know the clinical importance of hepatitis C we performed a clinico-
pathological study in 200 long-functioning RTS (38 17 months after
transplantation). In 66 of them (33%) 58 on CsA and 8 on Aza,
anti-HCV was repeatedly positive (immunoenzyme assay Elisa-Ortho)
and 44 of these (66.6%) exhibited chronic liver disease (CLD) (persist-
ent abnormal liver tests for longer than 6 months), while the remaining
22 had normal liver tests. Pathological liver studies performed in 27
RTS (37 biopsies) with CLD demonstrated that 14 exhibited a severe
diagnosis: cirrhosis in 5 and active chronic hepatitis (ACH) in 9
(especially in Aza therapy). Persistent chronic hepatitis was seen in 6,
siderosis inS and other diagnosis in 2. Iterative biopsies performed in 10
patients showed in 8 a progressive worsening of liver disease, and 3 of
them needed a combined liver (LT) and kidney transplantation. In two
liver transplant patients between 3 and 4 post-transplant months a
relapse of hepatitis C was seen, developing a picture of ACH with
fibrosis between 7 and 17 months, respectively. In summary, in
long-functioning RTs, hepatitis C can be a serious problem: 66% of
patients had CLD, and more than 50% of CLD biopsied patients
exhibited a severe diagnosis of cirrhosis or ACH that in some cases
needed an LT. Also, after LT an early relapse of hepatitis C can appear,
developing rapid ACH with fibrosis.
Clinical importance of acute renal failure on liver transplantation using
cyclosporine. C. Garcia Canton, J.M. Morales, G. Fernandez Zatarain,
A. Andrés, R. Sanchez, I. Farias, C. Loinaz, R. Gomez, M. Marcello,
I. Garcia, E. Moreno, and fL. Rodicio, Hospital 12 de Octubre,
Madrid, Spain. The aim of this study was to know the incidence,
characteristics and clinical course of the acute renal failure on liver
transplanted patients treated with cyclosporine. We studied 163 ortho-
topic liver transplants in 143 adult patients, performed in our hospital
between March 1986 and February 1991. Acute renal failure was
defined when serum creatinine was more than 3 mg/dl or an increment
of 50% of its previous values when renal failure was previously present.
Acute renal failure was seen in 27 cases (16.4%). The etilogy was
multifactorial in 24 (89%) and the main etiologic factors were: arterial
hypotension (80%), poor liver function or rejection (48%), cyclosporine
nephrotoxicity (55%), sepsis (37%) and the administration of potential
nephrotoxic drugs (29%). Impairment of renal function usually ap-
peared early, in the first week post-transplant in 74% of the cases.
Eighteen cases showed oliguria and 9 were nonoliguric. In 62.9% of the
cases dialysis and/or ultrafiltration were necessary. Cyclosporine neph-
rotoxicity was an important etiologic factor (55% of the cases). In this
way, fractional excretion of sodium and cyclosporine blood levels were
of great utility for its diagnosis. Ten patients died during the episode of
acute renal failure. In the remaining patients, renal function recovery
was observed between 5 years and 24 days. Survival rate in patients
with renal failure was a little bit lower than patients without renal
impairment (59% vs. 75%; P < 0.01). In summary, acute renal failure is
a frequent and severe complication after liver transplantation. The
etiology usually is multifactorial and frequently appears in the clinical
context of liver failure, sepsis or hemodynamic alterations. Also it is
important to make a careful diagnosis of cyclosporine nephrotoxicity,
another potential complication that can explain renal dysfunction easily
reversible after the cyclosporine dose is adjusted.
Organ procurement in a general hospital. A. Andres, f.M. Morales,
M. Praga, T. Ortuño, S. Vazquez, M.P. Cebrian, J.A. Sanchez
Izquierdo, and C. Garcia, Spain. We prospectively analyzed the
influence of several factors of organ procurement in the Hospital 12 de
Octubre. In 1990, 69 patients were diagnosed with cerebral death: 38
(55%) by cerebral trauma, 19 (27.5%) because of non-traumatic hemor-
ragic stroke, 2 (2.8%) after surgery, 8 (11.6%) due to encephalopathy
postanoxic and the remaining 2 by other causes. Their ages ranged from
I month to 66 years (mean 29.5 17). From 69 patients with cerebral
deaths, 7 (10.1%) showed a clear contraindication to organ donation:
sepsis in 4, renal disease in 2 and the last one was a man with a history
of intravenous drug abuse. In 6 patients (8.6%) it was impossible to
maintain hemodynamics, and in 18 (26%) the family refused organ
donation. From 38 effective donors, 62 kidneys from 76 possible donors
were obtained, and also 20 livers (52.6%) and 10 hearts (26.3%) (14
kidneys were excluded: 5 by trauma, 5 by senile sclerosis, and 4 by
other causes). Mean age of effective donors was 32.7 17 years. In
conclusion, brain nontraumatic hemorrage and postanoxic encephalop-
athy are frequent causes of cerebral death, and these patients are
potential organ donors. Families negative to donation are an important
limitating factor in order to obtain organs for transplantation. In our
experience the number of non-useful organs extracted is significant,
probably due to the fact that there is little contraindication to organ
extraction, as a consequence of more flexible criteria.
